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Introduction 
The gastrointestinal (gi) tract is the source of a large number of signals and 
mechanisms that play a role in satiety and (cessation of) food intake. This renders the 
GI tract an obvious physiological target of strategies aimed at weigh management and 
weight loss1. In the gastrointestinal tract, the signals that influence satiety and food 
intake, the so-called satiety signals, are generated by various types of stimuli. These 
stimuli are either mechanical or chemical. Mechanical stimulation is provided by 
distension of the luminal wall. Chemical stimulation is provided by the presence of 
nutrients in the small intestine. These stimuli then result in release of gut peptides or 
activation of local vagal afferents.  
Within the small intestine, differences exist with regard to the satiety signals that are 
released. When the proximal small intestine is exposed to nutrients, this leads to 
secretion of cholecystokinin (CCK), a gut peptide that is known to reduce food intake 
and increase satiety. The enteroendocrine cells that are responsible for the secretion 
of CCK are found predominantly in the duodenum and jejunum, although the 
presence of these cells has also been demonstrated in the terminal ileum2. In the 
distal small intestine, the dominant enteroendocrine cell is the L-cell, that produces a 
number of peptides, including peptide YY (PYY), Glucagon-like peptide-1 and -2 
(GLP-1, GLP-2) and oxyntomodulin. Secretion of gut peptides, when combined with 
neural signals from the stomach and small intestine during and after meal ingestion, 
leads to meal termination, a process which is called satiation. These signals also 
influence between-meal hunger, which is called satiety. 
In this thesis, we will focus on the effects of ileal brake activation on satiety and food 
intake. The term ‘Ileal Brake’ was first used to describe the phenomenon that gastric 
and small intestinal motility and transit are inhibited by ileal infusion of nutrients3,4, 
but later studies have also demonstrated that infusion of nutrients into the ileum 
reduces hunger and food intake5,6.  
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Aims and outlines of the thesis 
In Chapter 2, we will review the current knowledge on the different mechanisms and 
signals, emanating from the gastrointestinal tract, that influence satiety and food 
intake, and in Chapter 3, we will focus in detail on the effects of ileal brake activation 
on gastrointestinal function, and the role of the ileal brake in gastrointestinal 
physiology. The effects of ileal brake activation on food intake and satiety will be 
discussed, both in animals and in humans. In that chapter we also discuss the 
potential clinical relevance of ileal brake activation for weight loss. 
 
Previous studies examined the effects of ileal infusion of large amounts of fat on 
satiety. Whether infusion of small amounts of fat, infused at rates that mimic the 
physiological fat delivery after meal ingestion also could affect satiety, was not known. 
In the study described in Chapter 4, we examined the effects of 3 and 10 g of fat, 
infused in the ileum, on satiety and gut peptide secretion. In that way we were able to 
explore whether the effects on the ileal brake are dose-dependent.  
  
When fat is infused in the duodenum, it is well known that the physicochemical 
properties of the fat influence the effects on satiety and food intake and on gut 
function7-9. Recently, it has been demonstrated that the droplet size of a fat emulsion 
affects its emptying from the stomach10. As the rate of gastric emptying may have 
pronounced effects on satiety and food intake11, we have examined the effects of the 
droplet size of a fat emulsion on satiety and food intake, and how this effect may 
differ between duodenum and ileum (Chapter 5). In Chapter 6, we tested another 
physicochemical property of fat, the degree of triacylglycerol fatty acid saturation on 
satiety, food intake and peptide secretion. The degree of triacylglycerol fatty acid 
saturation has been shown to affect food intake when the fat is infused into the 
duodenum 7. 
 
In the previous studies, described in chapters 4-6, we scheduled the fat ileal infusion 
at the time point during which the physiological postprandial exposure of the ileum to 
nutrients is supposed to be at its maximum. In the study described in Chapter 7, we 
examined whether the timing of the ileal infusion, relative to a preceding meal, also 
affects the effects on satiety and food intake. In addition, we compared these results 
to duodenal infusions.  
 
As we learned from the study described in chapter 7 that the effects on an ileal fat 
infusion are more pronounced in the early postprandial period, we scheduled all 
infusions in this study at an earlier time point during the test day. It is known from 
animal studies that, apart from exposing the ileum to nutrients, increasing the small 
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intestinal surface area exposed to nutrients also increases the anorectic effects. In the 
study described in Chapter 8, we compared oral fat ingestion to fat infusion in the 
ileum, and to infusions that resulted in a larger exposed area of small intestine. 
 
Studies in which the fat was directly infused into the small intestine have 
demonstrated that lipids do induce satiety. It is, however, unclear to which extent 
gastric lipid processing influences satiety. In the study described in Chapter 9, we have 
tested whether the effects of intragastric lipid on fat absorption, gastric emptying CCK 
secretion and satiety scores can be modulated by controlling intragastric lipid 
distribution. 
 
The results of the various studies described in this thesis have been summarized and 
discussed in Chapter 10. We will discuss our findings in relation to data from the 
recent literature. In addition, we will highlight several items for further research in 
this area. In Chapter 11 we will summarize the results in Dutch. 
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Abstract  
Background 
The gastrointestinal tract elicits numerous signals regulating food intake and satiety, and recently many 
studies have been performed in order to elucidate the mechanisms regulating these signals. 
 
Aim 
To describe the effects of the gastrointestinal tract on satiety, satiation and food intake. 
 
Method 
A PubMed search was performed to identify and select relevant literature using search terms including 
‘gastric satiety, intestine + satiety, satiation, cholecystokinin, ghrelin, PYY, GLP-1, ileal brake’. 
 
Results 
Satiation, satiety and food intake result, among other factors, from signals originating in the stomach 
caused by distension and signals from the small intestine. These intestinal signals result from nutrient 
sensing in the gut and activate neural and humoral pathways.  
Activation of the distal part of the gut, the so called ileal brake, leads to reduction in hunger and food 
intake, and models of chronic ileal brake activation lead to massive weight loss. 
 
Conclusion 
Gastrointestinal signals are crucial for the regulation of food intake, satiety and satiation. The ileal brake 
deserves special attention, as both ileal intubation studies and surgical studies demonstrate that activation 
of the ileal brake reduces food intake. In the surgical models weight loss occurs without adaptation to the 
anorectic effects of ileal brake activation. 
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Background/Aim 
The gastrointestinal tract elicits numerous signals regulating food intake and satiety1. 
Both in the stomach and in the small intestine, the presence of nutrients, through 
distension of the stomach or by chemical interactions between nutrients and the 
luminal wall induces the release of satiety signals2-4. These signals contribute to the 
inhibition of food intake. Distension of the stomach by a volume load is able to 
significantly reduce food intake2,3. Exposing the small intestine to nutrients leads to 
release of gut peptides and neurotransmitters that induce a reduction in hunger levels 
and food intake4-7.  
During the process of meal ingestion, some nutrients will already have entered the 
small intestine and gastric and intestinal satiety signals interact in order to limit meal 
size5,8, to increase satiation and to increase satiety between meals. 
In this review, we will discus the satiety signals from the stomach and the small 
intestine (with a special focus on the ileum), how both interact to satiation, satiety 
and food intake and the underlying neuro-endocrine regulation of these signals.  
We use ‘satiation’ to refer to processes that act to reduce or terminate eating within a 
meal and the (acute) feeling state associated with this. ‘Satiety’ refers to processes 
that act to inhibit early post-prandially and/or redue intake at later meals, and the 
associated feeling state (hunger suppression). 
Methods 
Relevant studies were identified by a PubMed search using search terms including 
‘gastric satiety, intestine satiety, CCK, cholecystokinin, ghrelin, PYY, peptide YY, GLP-1, 
glucagon-like peptide 1, ileal brake’. Original articles and reviews were selected, and 
references in these papers were also examined for relevant papers. Where possible, 
emphasis was given to human studies, but when data was lacking, animal studies 
were used. 
Gastric satiety signals 
Instillation of a volume load in the stomach induces distension of the stomach wall. 
The satiating effect of distension of the stomach has repeatedly been demonstrated: 
Feinle et al. used an inflated barostat balloon to demonstrate that a gastric distension 
increases fullness9 and Rigaud et al. and Nieben et al. found that the presence of an 
inflated gastric balloon in the stomach, as a treatment for obesity, reduced food 
intake and hunger10,11. Geliebter et al. showed that the threshold volume for a gastric 
balloon to reduce food intake is around 400 ml 12. These results suggests that a 
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volume load by itself is sufficient to induce a gastric satiety signal and reduce food 
intake and hunger9-12. The role of nutrient composition of a gastric volume load in the 
reduction of food intake and hunger has been studied extensively in rats: Phillips et al. 
infused either saline or different nutrient solutions into the rat stomach and found 
that equivalent volumes produce equivalent reductions in food intake, without any 
effect of the nutritive value of the gastric load2,3. However, when this load was 
allowed to exit the stomach, the nutrient infusions inhibited food intake more 
potently than the saline infusions2. In humans, Goetze et al. found that postprandial 
hunger and satiety were correlated to postprandial gastric volumes, without 
significant effects of the nutrient composition of the meal13. From these studies one 
may conclude that gastric satiety is volume-dependent. Although the stomach is able 
to sense some aspects of the nutrient content of the stomach (for example, to 
regulate gastrin release), this does not seem to play a role in gastric satiety14. Up to 
40% of a meal may have emptied from the stomach into the intestine before the end 
of meal ingestion occurs8 and interaction occurs between gastric and postgastric 
signals in physiological conditions. Many small intestinal satiety signals induce a delay 
in gastric emptying, and it is often thought that this inhibition is relevant for 
prolonging gastric distension15.  
The role of the vagus nerve in gastric satiety has been studied in rats. Rats with pyloric 
cuffs underwent either sham vagotomy or total subdiaphragmatic vagotomy. After 
surgery, rats in both groups were fed 0, 5 or 10 ml meals, and the effect of these 
premeals on food intake was assessed. In the sham-operated group, the 5 ml meal 
reduced food intake by 60% compared to the 0 ml meal, and by 80% in the 10 ml 
group. In the vagotomy-group, both 5 ml and 10 ml meals reduced food intake by 20% 
in either group, demonstrating a central role for the vagal nerve for gastric volumetric 
satiety3. From this and other studies it follows that gastric satiety is predominantly 
mediated by neural pathways16-18. 
Intestinal satiety signals 
Exposure of the small intestine to nutrients increases satiety and limits food intake4,6,9. 
This increase in satiety occurs within seconds after the start of the intestinal nutrient 
infusion, suggesting that at least some of the intestinal satiety signals arise directly 
from the gut, rather than from post-absorptive nutrient processing14. French et al. 
demonstrated that infusion of certain long chain fat emulsions into the duodenum 
reduced food intake significantly compared to a saline infusion4 and this has also been 
demonstrated for carbohydrates and protein20. In the study by French et al., a 180 
kcal infusion of intralipid reduced food intake by over 200 kcal, demonstrating that 
intestinal nutrient infusion is capable of releasing potent satiety signals4. 
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Gastric emptying of already a small part of a meal will activate duodenal nutritive 
signals, and from there, gastric volumetric and intestinal nutritive signals cooperate. In 
rats, gastric infusions of saline reduced food intake, whereas an equal infusion in the 
duodenum had no effect on food intake3. An equivalent volume of 2.5-10% glucose 
did reduce food intake when infused into the duodenum, and this reduction in food 
intake could be enhanced by concomitant infusion of saline into the stomach, showing 
that combination of gastric and duodenal signals produced an additive inhibition of 
food intake3. In humans, Oesch et al. combined a 300 ml gastric distension prior to a 
meal with a duodenal infusion of either fat or saline. The distension combined with 
the saline infusion did not affect hunger, maybe due to a sub threshold volume load12, 
but when this distension was combined with a duodenal fat infusion, a decrease in 
hunger was observed. Food intake is significantly reduced by fat infusion, independent 
of the presence or absence of a distension21. A gastric distension up to 600 ml was 
necessary in order to reduce hunger without fat infusion, while the fat infusion 
lowered the distension threshold profoundly.  
Similarly, Feinle et al. have shown that gastric distension-induced satiety scores were 
increased by a concomitant duodenal nutrient infusions9,22, and subjects stated that 
adding a 20% lipid or maltodextrose infusion to the distension made the satiety 
sensation more meal-like22. These studies are examples of how the stomach and the 
small intestine interact in order to limit food intake and reduce hunger feelings21. 
While gastric satiety is of mechanical origin (volume-dependent), intestinal satiety is 
typically nutrient-dependent: the satiety signals are released upon interaction 
between the gut wall and nutrients3. Exposure of the small intestine to nutrients 
increases vagal afferent firing, and it is suggested that this is the case in intestine-
mediated satiety23-25. Intestinal nutrient exposure induces release of 5HT, a 
neurotransmitter, and Ondansetron, a 5HT3 receptor antagonist, has been shown to 
attenuate the inhibitory effects of intraduodenal Intralipid on food intake in rats7. 
Direct vagal activation by intestinal nutrients may therefore be mediated by 5HT3. 
Exposure of the intestinal mucosa to nutrients also induces release of many gut 
peptides and after release, these peptides either enter the bloodstream to function as 
a hormone, or they activate neural pathways14. Many of these gut peptides delay 
gastric emptying, thereby contributing to prolonged distension of the stomach, satiety 
and subsequently to meal termination. Regional differences exist in the release of gut 
peptides (Figure 2.1, Table 2.1): in the duodenum and jejunum, exposure of the gut 
wall to fat and protein results in the release of CCK, whereas in the distal small 
intestine, the presence of nutrients induces the release of GLP-1, oxyntomodulin and 
PYY14.  
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Figure 2.1 Principal site of secretion of gut peptides involved in regulation of eating behaviour. 
 
 
Table 2.1 Gut peptides involved in satiety. 
Peptide Location of release Food intake 
Cholecystokinin Proximal intestine, I-cells ↓ 
Glucagon-like peptide 1 Distal intestine, L-cells ↓ 
Peptide YY Distal intestine, L-cells ↓ 
Oxyntomodulin Distal intestine, L-cells ↓ 
Enterostatin Exocrine pancreas ↓ 
Apolipoprotein A-IV Intestinal epithelium ↓ 
Pancreatic peptide Pancreatic F-cells ↓ 
Amylin Pancreatic b-cells ↓ 
GRP, NMB Gastric myenteric plexus ↓ 
Leptin Gastric chief and P cells ↓ 
Ghrelin Gastric X⁄A like cells ↑ 
GRP, gastrin-releasing peptide; NMB, neuromedin B. 
 
Proximal small intestine: Cholecystokinin (CCK) 
CCK has been widely studied as satiety signal1,26,27. CCK is released from intestinal I-
cells in the duodenal and jejunal mucosa in response to the intraluminal presence of 
digestion products of fat and protein in the small intestine. Various biological forms of 
CCK exist, classified according to the number of amino acids they contain28,29. In 
humans, the main circulating forms are CCK-8, CCK-22, CCK-33 and CCK-5830. Two 
types of CCK receptors have been identified: The alimentary CCK-1 receptor (CCK1R) 
mediates gall bladder contraction, relaxation of the sphincter of Oddi, pancreatic 
growth and enzyme secretion, delay of gastric emptying and inhibition of gastric acid 
secretion31. The CCK-2 receptor (CCK2R) is the predominant CCK receptor in the brain, 
although the CCK1R has also been demonstrated in the hindbrain and the 
hypothalamus31.  
Stomach: Ghrelin,
Leptin, GRP
Pancreas: PP, Glucagon, 
Insulin, Enterostatin
Small intestine:
Proximal: CCK,
Apo A-IV 
Distal: GLP-1, PYY, Oxyntmodulin
Colon: GLP-1, PYY, 
Oxyntomodulin
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Gibbs et al. demonstrated in rats that administration of CCK-8 induced a dose-
dependent reduction in both the size and duration of a meal27. In humans, Kissileff et 
al. were the first to demonstrate that intravenous administration of CCK-8 reduces 
food intake and hunger in humans32. Following a 216 kcal preload, intravenous 
infusion of CCK-8 reduced ad libitum food intake by 19% when compared to a saline 
infusion32. These results have been confirmed by several investigators33-36. Lieverse et 
al. demonstrated a decrease of 19% in food intake after intravenous infusion of CCK-
33 37. However, the effect of CCK-infusion on food intake is short-lasting: when the 
interval between the infusion and the start of the test meal is over 30 minutes, no 
anorexic effect will be observed14.  
 
The role of endogenous CCK in the regulation of food intake has been studied with the 
specific CCK-1 receptor (CCK1R) antagonist loxiglumide. Intravenous infusion of 
loxiglumide attenuated the inhibitory effects of an intraduodenal fat infusion on 
subsequent energy intake38 and reduced satiety in humans39, whereas a CCK-2 
receptor antagonist did not40.  
After release, CCK activates CCK1R on gastric and duodenal vagal afferents. These 
vagal afferents transmit the signal to the nucleus of the solitary tract (NTS) and area 
postrema (AP) in the hindbrain, from where it is relayed to the hypothalamus31. 
Vagotomy has been shown to attenuate the anorexic effects of peripheral CCK-
administration41, demonstrating a crucial vagal pathway for CCK-mediated satiation.  
Gastric and intestinal satiety signals interact to reduce hunger. Regarding CCK, an 
intestinal satiety signal, it has been shown that the satiating effect of intravenous CCK 
infusion is enhanced by concomitant gastric distension. Intravenous CCK-infusion 
combined with a 300 ml gastric balloon distension resulted in a stronger reduction in 
food intake compared to either CCK or distension alone36. Furthermore, the CCK 
induced dorsal vagal complex (DVC) activity was increased by concomitant gastric 
distension, indicating a stronger anorexic effect42,43.  
Proximal small intestine: Ghrelin 
Ghrelin, an acylated peptide hormone was first discovered by Kojima et al.44. 
Two/thirds of circulating ghrelin is produced by X/A-like cells in the gastric oxyntic 
mucosa, and most of the remainder originates in X/A-like cells of the small intestine. 
Gastrectomy results in a decrease in plasma ghrelin concentrations of 75%45. Ghrelin 
is also produced in other organs, such as pancreas, thyroid, adrenal, pituitary, 
hypothalamus, kidney, heart, lung and etc., but in much lower amounts than in the 
stomach46.  
In humans, energy intake was increased by 28%, and hunger increased significantly in 
response to the ghrelin infusion47. Administration of ghrelin stimulates gastric 
emptying and small bowel transit.  
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Ghrelin plasma concentrations peak before a meal and decrease postprandially, in 
response to nutrient ingestion48. The pre-meal increase in ghrelin-concentrations 
implicates a role for ghrelin in mealtime hunger and meal initiation, as a signal for 
energy depletion48. However, a recent study by Drazen et al. showed that when rats 
were forced to eat larger meals, this resulted in an increase in the pre-prandial ghrelin 
peak. These findings demonstrate that conditioning, and not just energy depletion, 
plays a role in pre-meal increases in ghrelin concentrations49. In line with other 
observations, during a 24h fast, ghrelin concentrations increased before and 
decreased after the time points of customary meals, pointing to a conditioned 
pattern50. It is therefore uncertain whether these pre-prandial increases reflect the 
need for food by the body, resulting in increased hunger and ingestion, or that these 
increases are not related to pre-meal hunger but reflect a preparatory response in 
order to facilitate the subsequent digestion, absorption and metabolism of the 
upcoming meal51. 
 
At least two mechanisms have been proposed to explain the decrease in ghrelin 
concentrations. First, as mentioned above, when fasting, ghrelin concentrations 
decreased in the absence of a meal, and this is probably mediated by cephalic neural 
mechanisms52. Second, the postprandial decrease in ghrelin concentrations is related 
to the ingested caloric load53, with fat being less potent than either carbohydrates or 
proteins51,54. However, the mechanism regulating this decrease in ghrelin 
concentrations is not fully understood. While the majority two/thirds of circulating 
ghrelin is produced in the stomach46, stomach content does not play a role in the 
regulation of ghrelin concentrations, since intestinal infusion of nutrients also results 
in a decrease in plasma ghrelin concentrations54, while inhibition of intestinal 
exposure by a pylorus-occluding cuff in rats did not affect ghrelin levels55. Whether 
small intestinal exposure to nutrients has a direct effect , as suggested by Caixas et 
al.56, or influences ghrelin concentrations via insulin release57-59 remains to be 
determined.  
Several gut peptides, such as PYY, GIP, GLP-1, Somatostatin, CCK but also the vagal 
nerve influence plasma ghrelin concentrations, and may therefore have a role in the 
physiological regulation of ghrelin concentrations52. 
The orexogenic effect of ghrelin requires an intact vagal nerve: patients who 
underwent vagotomy did not demonstrate an increase in energy intake after 
intravenous administration of ghrelin60.  
Distal small intestine: GLP-1 
GLP-1 is released from enteroendocrine L-cells in the distal small intestine, in 
response to exposure of the gut wall to especially fat and carbohydrates61. Secretion 
not only occurs when nutrients are present in the lumen of the distal small intestine, 
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but also from the duodenum by an indirect neurohumoral pathway involving the 
autonomous nervous system, Gastrin Releasing Peptide and acetylcholine62.  
Infusion of GLP-1 results in a dose-dependent reduction in food intake and elicits 
satiety in normal weight, obese and diabetic humans63. Apart from the effects on food 
intake, GLP-1 increases glucose-dependent insulin-secretion, reduces glucagon-
secretion and increases pancreatic β-cell growth61. GLP-1 mimetics are therefore 
being developed for the treatment of diabetes. Diabetic patients treated with GLP-1 
or the GLP-1 receptor agonist exenatide experienced progressive weight loss in trials 
lasting up to two years14,64. A 14 week trial with a long-acting GLP-1 analogue resulted 
in significant weight loss compared to placebo65, and this might be due to a decrease 
in appetite64. A recent meta-analysis showed that administration of GLP-1 resulted in 
a reduction of food intake by an average 11%63. 
Degen et al. demonstrated that the anorexic effect of GLP-1 could be increased by a 
400 ml (225 kcal) protein drink, but not by 400 ml water administered 20 minutes 
prior to the test meal66. As the authors did not measure gastric distension or gastric 
emptying, it is impossible to determine whether this reduced appetite is due to a 
nutrient-specific effect of gastric distension or due to duodenal exposure to nutrients. 
Since gastric satiety signals are considered to be mechanical rather than nutritive, an 
additional duodenal signal is more likely to explain the additional anorectic effect. This 
study clearly demonstrated that GLP-1 interacts with gastric or duodenal satiety 
signals to increase satiety and reduce food intake66.  
The mechanisms resulting in the anorexic effect of GLP-1 are not fully understood. A 
crucial ole for the vagus nerve was demonstrated in rodents, where vagotomy 
abolished the anorexic effect of peripheral GLP-1 administration67. Reduction of food 
intake by GLP-1 is mediated by the GLP-1 receptor (GLP1R), as a GLP1R knock-out 
mouse did not demonstrate a reduction in food intake68. This receptor can be found in 
the gut, pancreas, brainstem, hypothalamus and vagal-afferent nerves61. 
As long-term administration of GLP-1 reduces food intake and hunger, and improves 
glucose control, increasing endogenous GLP-1-release by specific food products is 
therefore an interesting target. 
Distal small intestine:PYY 
PYY is co-secreted with GLP-1 by enteroendocrine L-cells in the distal small intestine. It 
is released postprandially in proportion to the amount of ingested calories, with fat 
being the most potent macronutrient, followed by carbohydrates, followed by 
proteins69. Direct exposure of the distal small intestine to nutrients will release PYY, 
but an indirect neurohumoral pathway from the proximal small intestine to the distal 
small intestine also exists70,71. PYY is released as PYY1-36, and rapidly cleaved by DPP4 
into the active form of PYY, PYY3-36 
69.  
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Batterham et al. demonstrated that intravenous infusion of PYY3-36 significantly 
reduced energy intake by 33% over a 24h period72. Degen et al. have questioned the 
role of PYY as a physiological mediator of satiety. These investigators found that 
during infusion, PYY3-36 was able to reduce energy intake, but only at PYY-levels that 
were higher than they observed after a 1500 kcal meal, and therefore should be 
considered as supraphysiological73. One study even failed to demonstrate any 
anorexic effect of PYY administration74. In humans, a significant reduction in food 
intake is observed only at supraphysiological plasma PYY concentrations, and adverse 
events that may influence food intake such as nausea and abdominal discomfort are 
frequently observed73,75. For instance, in a recent study, five of nine participants failed 
to complete the PYY3-36 infusion protocol, due to severe malaise
75. These results have 
prompted some pharmaceutical companies to stop the clinical development of 
intranasal PYY3–36 because of insufficient efficacy14. 
We have previously conducted a study in which we compared the effects of intestinal 
fat infusion to intravenous PYY infusion. At PYY-concentrations that were similar after 
intravenous infusion and after intestinal fat, the effects on satiety after the intestinal 
fat infusion were much more pronounced19.  
Batterham et al. have demonstrated a reduction in energy intake and resulted weight 
loss in mice72. Although several investigators have not been able to reproduce and 
confirm these results74,76, the current consensus is that in rodents, PYY is a potent 
anorexic agent and long-term administration leads to significant weight loss77,78. 
 
The anorectic effects of PYY3-36 are thought to be mediated by the Y2-receptor in the 
hypothalamic arcuate nucleus, and this receptor may be directly accessible via the 
bloodstream14. However, vagotomy abolished the anorectic effects of peripheral PYY 
administration, suggesting a role for the vagus nerve67,79.  
Ileal brake and satiety  
Studies in animals have clearly demonstrated that the reduction in food intake is 
larger when the distal in stead of the proximal half of the small intestine is exposed to 
nutrients80. In the ileum, exposure of the gut mucosa to especially fat and 
carbohydrates activates the ileal brake40,81,82. The ileal brake is a negative feedback 
mechanism that potently inhibits gastric emptying and small intestinal transit (Figure 
2.2)83. Furthermore, activation of the ileal brake results in a reduction in gastric acid-
secretion, pancreatic enzyme secretion, and bile acid secretion84-86.  
Welch et al. were the first to demonstrate the potent anorexic effects of ileal brake 
activation in humans87,87-89. Perfusing the ileum with 370 kcal corn oil emulsion 
resulted in a 575 kcal reduction in energy intake, demonstrating a net reduction of 
205 kcal (88). In a subsequent study, they compared an ileal and a jejunal fat infusion 
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to a control infusion, and found that the jejunal infusion induced the largest reduction 
in energy intake87. It should be noticed that these infusions were at high 
supraphysiological rates. During the jejunal infusion, fat may also have activated ileal 
receptors, thereby explaining the increased potency of the jejunal infusion to reduce 
food intake87. Our group recently conducted a study comparing the effects of 
duodenal and ileal infusion of fat on satiety levels, and found that the reduction in 
hunger levels was significantly larger after the ileal compared to the duodenal fat 
infusion90.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Effects of ileal brake activation. 
 
 
These studies have employed ileal intubation techniques in order to expose the ileum 
to increased amounts of nutrients, resulting in ileal brake activation. However, 
surgical techniques provide excellent examples of the effects of chronic ileal brake 
activation on food intake and satiety. The jejuno-ileal bypass (JIB) is a procedure in 
which the proximal part of the jejunum is anastomosed to the distal part of the 
ileum91. This surgical procedure has been introduced as a treatment for massive 
obesity92. First, the mechanism resulting in weight loss was thought to be 
malabsorption. Condon et al. demonstrated that malabsorption could only account 
for 22% of weight loss, therefore other mechanisms must be involved93-95. Jejuno-ileal 
bypass results in rapid transit of nutrients to the distal intestine, with increased 
exposure of the ileum to nutrients96. Postoperatively, ad libitum food intake 
decreases94,95;97. Bray et al. found that, compared to presurgical energy intake, energy 
intake was decreased with 80% at 1 month and with 45% at 12 months after jejuno-
ileal bypass95. Naslund et al found a decrease of 13% nine months after jejuno-ileal 
bypass97. As jejuno-ileal bypass can lead to diarrhoea, psychological factors have also 
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been suggested as an additional cause for this reduction in food intake98, but more 
importantly, both GLP-1 and PYY levels are increased after jejuno-ileal bypass 
compared to pre- jejuno-ileal bypass levels99. The chronically increased PYY and GLP-1 
concentration may account for the reduction in food intake and weight loss99. 
 
Which neural or hormonal mechanisms mediate the ileal brake is not exactly known. 
As the effects of an ileal infusion on pancreatic enzyme secretion could be abolished 
by infusion of a specific GLP1R-antagonist, GLP-1 is thought to play an important role 
in the ileal brake100. Pironi et al. and Spiller et al. found that PYY correlated with 
changes in gastrointestinal motility, indicating a role for PYY in the ileal brake82,101. 
Therefore, PYY and GLP-1 are both considered mediatory peptides for ileal brake-
activation61,102. Furthermore, Lin et al. have demonstrated that different neural 
mechanisms are involved in mediating the different effects of ileal brake-
activation71,83,103,104. 
The results from these surgical models demonstrate that no compensating behaviors 
on intake occur in response to the anorectic effects of chronic ileal brake activation. 
Therefore, we consider the ileal brake to be an excellent and promising target for the 
development of food products aimed a reducing food intake and hunger feelings.  
Conclusion 
The satiety signals that are derived from the stomach and the small intestine have 
been reviewed with special emphasis on their interaction in the reduction in hunger 
and food intake. Activation of the ileal brake significantly increases satiation and 
satiety, and reduces food intake. Surgical procedures that lead to increased exposure 
of the ileum to ingested nutrients confirm these results and indicate that adaptation 
to the anorectic effects of ileal brake activation does not occur, not even in the long 
term follow up..  
The gastrointestinal tract is host to many signals that affect satiety and food intake. 
The ileal brake is considered an interesting target when designing products or 
procedures able to reduce food intake and produce weight loss. Not only  studies  
using ileal delivery of nutrients via oro-ileal but also from studies on surgical models  it 
has become apparent  that activation of the ileal brake leads to a reduction in food 
intake, weight loss, without long term adaptation to these anorectic effects. 
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Abstract  
With the rising prevalence of obesity and related health problems, there is increased interest in the 
gastrointestinal system as a possible target for pharmacological or food-based approaches to weight 
management. Recent studies have shown that under normal physiological situations undigested nutrients 
can reach the ileum, and induce activation of the so-called “ileac brake”, a combination of effects 
influencing digestive process and ingestive behaviour. The relevance of the ileal brake as a potential target 
for weight management is based on several findings: First, activation of the ileal brake has been shown to 
reduce food intake and increase satiety levels. Second, surgical procedures that increase exposure of the 
ileum to nutrients produce weight loss and improved glycaemic control. Third, the appetite-reducing effect 
of chronic ileal brake activation appears to be maintained over time. Together, this evidence suggests that 
activation of the ileal brake is an excellent long-term target to achieve sustainable reductions in food intake. 
This review addresses the role of the ileal brake in gut function, and considers the possible involvement of 
several peptide hormone mediators. Attention is given to the ability of macronutrients to activate the ileal 
brake, and particularly variation attributable to the physicochemical properties of fats. The emphasis is on 
implications of ileal brake stimulation on food intake and satiety, accompanied by evidence of effects on 
glycaemic control and weight loss. 
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Introduction 
Obesity is seen a growing world-wide threat to health and prosperity. Reduced-energy 
diets are a widely-recommended, non-invasive primary treatment strategy for 
overweight and obesity. However, it is difficult for obese individuals to maintain the 
desired regime of dietary control in part because of the associated effects including 
feelings of hunger and food cravings. Compliance with weight control diet 
programmes could be improved, or at least less burdensome, if the associated hunger 
feelings were less pronounced. Because the gastrointestinal tract is host to various 
signals that regulate hunger, food intake and satiety1, it is an obvious physiological 
target for developing food products and ingredients aimed at improving dietary 
compliance with a reduced energy intake. The relevant gastrointestinal signals are 
generated by various types of stimuli, such as distension of the luminal wall, presence 
of nutrients in the lumen or changes in pH, and lead to the activation of vagal 
afferents or release of gut peptides2. For example, entry of nutrients, especially fat 
and proteins, into the duodenum and jejunum results in release of cholecystokinin 
(CCK), a peptide that induces satiety and inhibits food intake3,4.  
The entry of nutrients into the duodenum and jejunum activates the so-called 
duodenal and jejunal “brakes”: negative feedback mechanisms that influence the 
function of more proximal parts of the gastrointestinal tract. Activation of both of 
these feedback mechanisms results in reduction of food intake and inhibition of 
hunger, probably partly by inhibition of gastric emptying (thus contributing to 
enhanced and prolonged gastric distension)5-9. More distal in the GI tract, the ileal 
brake is a feedback mechanism that results in inhibition of proximal gastrointestinal 
motility and secretion. Animal and human studies show that activation of the ileal 
brake by local perfusion with nutrients increases feelings of satiety and reduces ad 
libitum food intake10-12. These results all point to a potential role of the ileal brake in 
the regulation of digestion, with direct or indirect impact upon eating behaviour and 
satiety.  
This review considers 1) the role of the ileal brake in the regulation of gut function, 
including its physiological role and comparison to other intestinal braking 
mechanisms; 2) the mechanisms and mediators involved in activation of the ileal 
brake; 3) the effects of dietary components on ileal brake; and 4) the effects of ileal 
brake stimulation on eating behaviour. The paper focuses on data from research in 
humans, with data from animal models discussed where adequate human data are 
lacking. 
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Ileal brake and gut function 
The ileal brake can be defined as a distal to proximal feedback mechanism to control 
transit of a meal through the gastrointestinal tract in order to optimise nutrient 
digestion and absorption13. While the original finding of ileal brake was confined to 
effects on jejunal motility and intestinal transit, since then the feedback concept was 
broadened to effects on gastric emptying, and pancreatic and biliary secretion. Spiller 
et al.14 and Read et al.15 were the first to describe such a transit control mechanism, 
and named it the “ileal brake”. Spiller et al.14 demonstrated that ileal infusion of fat 
reduces jejunal motility, and this has since been confirmed by other studies16,17. Read 
et al., as well as others, demonstrated that gastrointestinal transit of a test meal is 
delayed when the distal part of the small intestine is perfused with a lipid emulsion 
(e.g.15,18,19). Activation of the ileal brake results in a dose-dependent delay in gastric 
emptying and small intestinal transit both for solid and liquid meals20-22.  
Ileal brake activation leads to a decrease in the frequency of antral and duodenal 
peristaltic pressure waves, a decrease in propagated antro-pyloro-duodenal pressure 
waves and induces an increase in pyloric sphincter pressure23 and these factors 
correlated with and contributed to the delay in gastric emptying23.  
Activation of the ileal brake by nutrients in a meal also leads to a decrease in the 
frequency of jejunal contractions, the percentage of jejunal contractions involved in 
propagation, and the distance of propagation16, whereas ileal and16 duodenal16 
motility remain unchanged, although others have found changes in duodenal motility 
in response to ileal fat infusion23. Together, these effects result in an increased small 
intestinal transit time.  
Apart from the inhibition of gastrointestinal motility leading to a delay in 
gastrointestinal transit, other processes contributing to nutrient digestion are also 
affected by activation of the ileal brake. First, activation of the ileal brake by ileal 
perfusion of nutrients has been shown to strongly reduce meal-stimulated secretion 
of pancreatic enzymes (over 80% reduction)24. Second, ileal fat perfusion reduces bile 
acid output in a dose-dependent fashion25. Third, activation of the ileal brake inhibits 
both basal and endogenously stimulated gastric acid secretion26,27. This clearly shows 
the distal to proximal negative feedback: infusion of nutrients into the ileum affects 
motility in the stomach, duodenum and jejunum and reduces gastric and pancreatic 
secretion. However, as there is very limited information on the actual nutrient 
concentrations in the ileum, studies using an ileal catheter to perfuse the ileum with 
nutrients may have used supraphysiological concentrations of nutrients in the ileum 
(postprandial concentrations between 3.6 and 10 mg/ml have been measured28-30, 
and meal conditions greatly affect these results31), although several studies (see 
below) show that relatively high nutrient concentrations do occur in the ileum. An 
additional problem is that, as demonstrated by Feltrin et al., effects of nutrients are 
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not concentration, but load dependent32. This suggests that, when discussing whether 
nutrient infusions are (supra-) physiological, the concentration of nutrients found in 
the ileum may be less important than the total amount of nutrients entering the 
ileum. 
Physiological role of the ileal brake 
It is uncertain whether the ileal brake plays an important role in the regulation of gut 
function under physiological conditions. The percentage of nutrients reaching the 
ileum after meal ingestion is dependent on the caloric load of the meal, the meal 
composition and the rate of gastric emptying, i.e. entry into the duodenum. Lin et al., 
for instance, have demonstrated in dogs that 7% of a 15-g fat emulsion administered 
in the stomach reached the ileum (i.e., was not absorbed proximally) and of a 60-g fat 
emulsion, 30% reached the ileum31. The same group has demonstrated that after a 
protein load, 7-11% will reach the ileum in dogs, and 27-33% in rats, irrespective of 
the load given33,34. Meyer et al. demonstrated in rats that intragastric fatty acids 
would spread to the distal third of the small bowel, and the amount of fatty acids in 
the ileum was highest after the highest intragastric dose35.  
In humans, small amounts of nutrients will reach the ileum in response to a normal 
size meal28,36 (Keller et al.36 found 50j/ml of ileal content after a low-energy meal (300 
kcal)). Layer and colleagues studied the effect of the entry of nutrients in the ileum on 
proximal intestinal motor and secretory function in healthy volunteers36,37. They 
demonstrated that increased nutrient concentrations in the ileum correlated to the 
transition from a fed to a fasted pattern of gastrointestinal motor and secretory 
function36. Taken together, these studies provide convincing evidence that biologically 
relevant amounts of nutrients can reach the ileum and that the ileal brake mechanism 
contributes to the regulation of gastrointestinal motility and secretion under 
physiological conditions. 
Ileal brake versus other intestinal brakes 
Few studies have compared the inhibitory effects of duodenal and/or jejunal vs ileal 
infusion of nutrients on gastrointestinal motility. Our group has demonstrated that 
gastric emptying of a liquid meal was significantly delayed after ileal fat perfusion 
compared to an equicaloric duodenal infusion (gastric emptying half time: 207 vs. 138 
min, small bowel transit time: 144 vs. 85 min, both p<0.05)19. In dogs, the inhibition of 
both gastric emptying and intestinal transit was found to be significantly stronger 
after ileal perfusion of a carbohydrate and a fat infusion compared to proximal 
intestinal perfusions18,38. In rats, Giralt et al. found no difference in inhibition of antral, 
duodenal or jejunal motility after an ileal or duodenal infusion of a protein 
hydrolysate39. However, inhibition of motility after duodenal infusion occurred only 
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when the perfusate was allowed to pass to the rest of the intestine; blocking this 
passage abolished the inhibition in motility. This suggests that access to the distal 
intestine is necessary for the most potent inhibition of intestinal motility. In addition, 
the length of intestine exposed to nutrients influences the effect size of a given 
nutrient infusion40-42. 
Ileocolonic brake? 
Whether (signals arising from) the colon add to the ileal brake effect is uncertain. PYY 
and GLP-1 secreting cells are abundant in the colon, and colonic infusions of nutrients 
have been shown to release both peptides43,44. In animals, colonic nutrient infusion 
resulted in a prolongation of the cycle length of duodenal MMCs, an inhibition in ileal 
motility43 and a reduction in pancreatic secretion45,46. In humans however, Read et 
al.15 demonstrated that infusion of nutrients in the colon did not affect small bowel 
transit time at a dose that gave a significant reduction when infused into the ileum. 
However, colonic infusion of nutrients reduced biliary and pancreatic secretion47.  
The effects of colonic nutrient infusion on food intake has never been studied in 
humans, but in rats, cecal nutrient infusion significantly reduced food intake, and this 
reduction in food intake was larger than the reduction observed after ileal infusion12. 
This suggests that in rats, the colon may very well contribute to the anorectic effect of 
ileal brake activation. As the colon is capable of secreting PYY and GLP-1, the weight 
loss, increased satiety and improvements in glucose homeostasis after bariatric 
surgery may, apart from the effects of increased ileal exposure to nutrients, also have 
a colonic component. However, in humans, this has never been specifically studied. 
Mediators of the ileal brake 
The satiety signals that are derived from the stomach and the small intestine have 
been reviewed with special emphasis on their interaction in the reduction in hunger 
and food intake. Activation of the ileal brake significantly increases satiation and 
satiety, and reduces food intake. Surgical procedures that lead to increased exposure 
of the ileum to ingested nutrients confirm these results and indicate that adaptation 
to the anorectic effects of ileal brake activation does not occur, not even in the long 
term follow up.  
The gastrointestinal tract is host to many signals that affect satiety and food intake. 
The ileal brake is considered an interesting target when designing products or 
procedures able to reduce food intake and produce weight loss. Not only studies using 
ileal delivery of nutrients via oro-ileal but also from studies on surgical models  it has 
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become apparent  that activation of the ileal brake leads to a reduction in food intake, 
weight loss, without long term adaptation to these anorectic effects. 
There is not yet a clear consensus on the physiological factors mediating the actions of 
the ileal brake. In general, nutrients in the small intestine influence gut function as 
well as satiety and food intake via activation of neural afferents or the release of gut 
peptides3,48-51. Of the gut peptides, Proglucagon-derived peptides (PGDP) and 
neurotensin have initially been proposed as hormonal mediators of the ileal 
brake14,15,20. Indeed, intravenous (iv) administration of neurotensin has been shown to 
delay gastric emptying52, change antroduodenal motility to a post-prandial pattern53, 
reduce gastric acid secretion54,55 and reduce gall bladder emptying56. Neurotensin is 
secreted by N-cells in response to oral ingestion of a mixed meal57. However, Pironi et 
al. and Read et al. found that ileal perfusions of oleic acid or Intralipid® caused a delay 
in gastric emptying or small intestinal transit without changes in plasma neurotensin 
levels15,20. This seemingly excluded a role for neurotensin as the circulating peptide 
primarily responsible for activation of the ileal brake, and little further attention has 
been given to neurotensin as a mediator of the ileal brake.  
The following sections consider evidence for Peptide YY (PYY) and Glucagon-like 
peptide-1 (GLP-1) as the most likely putative mediators of the ileal brake, and for 
oxyntomodulin as a possible additional candidate for which more evidence is needed. 
Peptide YY 
Attention has recently focused on PYY13 and two products of the proglucagon gene, 
GLP-1 and oxyntomodulin58,59. PYY is a 36 amino-acid peptide, secreted by L-cells in 
the ileum and colon. It is released into the circulation following food intake, 
influenced by meal energy content and composition. Higher plasma concentrations 
are seen after fat-rich compared to protein- or carbohydrate-rich meals. An 
association between a delay in small intestinal transit and PYY release triggered by 
ileal fat perfusion has been repeatedly demonstrated17,20. Furthermore, in dogs, 
immunoneutralization of PYY was shown to abolish the delay in small intestinal transit 
caused by ileal fat60. The inhibitory effects of PYY on gastrointestinal motility have also 
been confirmed by intravenous infusion studies in humans and animals61.  
 
From these observations it can be concluded that PYY is involved in distal-to-proximal 
intestinal feedback, and that PYY is a candidate mediator of the effects of the ileal 
brake. However, Vu et al. showed that intravenous perfusions of PYY equivalent to the 
levels reached during ileal fat perfusion was unable to reproduce the effects of 
intestinal fat-perfusion on satiety and gastric relaxation62. 
The discrepancy between the associations of local ileal brake activity with endogenous 
PYY and the apparent lack of effect of exogenous PYY may be a consequence of the 
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possibility that PYY acts more as a paracrine or neurocrine agent than as an endocrine 
agent, suggesting that plasma levels may not reflect the local effects of PYY63,64. This 
follows from studies demonstrating that a reduction in food intake after peripheral 
administration of PYY (and GLP-1) could be abolished by vagotomy63,64. Similarly, it 
was demonstrated that vagotomy also abolished PYY-induced activation of feeding 
neurones in the hypothalamic arcuate nucleus64. These data suggest that the effect of 
PYY on food intake is paracrine, affecting local vagal afferents, rather than endocrine.  
Furthermore, the inhibitory effect of PYY on food intake, as originally reported by 
Batterham et al.65,66 has been a subject of intense debate67,68. Batterham et al. 
demonstrated in humans that intravenous infusions replicating postprandial PYY3-36 
concentrations lessened hunger and decreased ad libitum food intake by 36%, 
without causing nausea, affecting food palatability or altering fluid intake65,66. Several 
laboratories reported difficulties in reproducing these anorectic effect of PYY-
administration in animals, despite using numerous different rodent models, 
experimental procedures and chemically validated PYY3-36 preparations
67,69. However, 
recent studies have shown that stress, the habituation of the animals and the timing 
of the injections all influence the effects of the PYY-infusions69, and this might explain 
the discrepancies70.  
Most recently, the anorectic effect of PYY3-36-infusion has been confirmed in humans, 
but only at supraphysiological concentrations68. Until these issues are resolved, the 
(physiological) role of PYY as primary humoral mediator of the ileal brake, or perhaps 
the particular conditions in which its effects dominate, remains unsettled. 
GLP-1 
Another candidate mediator of the ileal brake is GLP-1 58. GLP-1 is secreted by L-cells 
in the distal small intestine and colon, predominantly in response to carbohydrates 
and fat. GLP-1 inhibits gastroduodenal motility71, relaxes the proximal stomach72, 
stimulates phasic and tonic motility of the pylorus71 and inhibits gastric acid73,74 and 
exocrine pancreatic secretion71. Furthermore, the averaged result from several studies 
of intravenous infusion of physiological amounts of GLP-1 in humans is an 11% 
reduction in food intake75. In rats, the GLP-1 receptor antagonist Exendin(9-39)amide 
was found to reduce the inhibitory effect of ileal nutrients on gastropancreatic 
secretion by 50%76. In rats, the inhibition seen in antral, duodenal and jejunal motility 
in response to intraileal perfusion of a protein hydrolysate was abolished after 
infusion of a GLP-1 receptor antagonist39. Since effects of the ileal brake can be 
mimicked by intravenous perfusion of GLP-1, and these ileal brake effects can partially 
be blocked by a specific GLP-1 receptor antagonist, it is assumed that GLP-1 secretion 
is essential for activation of the ileal brake76. However, the potency of Exendin (9-39) 
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amide to reduce the effects of ileal nutrients on gastrointestinal motility and food 
intake has not been evaluated in humans.  
Both PYY and GLP-1 are therefore presently considered as key candidate mediators of 
the ileal brake. There is also evidence that the two peptides may act synergistically. 
They are co-secreted by intestinal L-cells, and the effects of simultaneous perfusion of 
both peptides on food intake and inhibition of gastric acid secretion in humans is 
larger than the sum of the individual contributions73,77. In addition, Keller et al. 
demonstrated that both GLP-1 and PYY were inversely correlated to the decreases in 
trypsin and bile acid secretions seen after intraileal perfusions of fat25. 
Oxyntomodulin 
Oxyntomodulin (OXM) is co-secreted with PYY and GLP-1 by L-cells. Intravenous 
infusion of oxyntomodulin has been shown to reduce gastric acid secretion and inhibit 
gastric emptying and duodenal postprandial motility in humans59. In rats, OXM 
reduces pancreatic exocrine secretions78 by a vagal-mediated indirect pathway79. The 
anorexic effects of OXM in normal weight humans were recently studied by Cohen et 
al., who reported a 19.3% decrease in energy intake from a buffet meal, and an 11% 
decrease in energy intake in the 12 h post-infusion period80. Given its effects on 
gastrointestinal motility, satiety and food intake, OXM should be considered a 
candidate mediator peptide for the ileal brake. However, to date there are no studies 
focusing specifically on the role of OXM in the ileal brake. 
Neural mediators 
Brown et al. demonstrated the involvement on neural pathways in the ileal brake 
when they showed that administration of 5HT3- 81,82, adrenergic- 83 or opioid receptor 
antagonists84 were able to abolish the inhibitory effect of ileal fat infusion on small 
bowel transit. This latter observation has been confirmed in humans85. 
Lin and colleagues considered the ileal brake a reflex, in which nutrients were sensed 
in the distal small intestine (efferent limb) and this induced inhibition of small 
intestinal transit in the proximal small intestine (afferent limb)86-89. Using a fistulated 
animal model that compartmentalized the distal and proximal small bowel, they and 
others demonstrated that that these neural pathways were located on the efferent 
limb of the ileal brake reflex86-90. Furthermore, by showing that immunoneutralization 
of PYY abolished the inhibition of small bowel transit after ileal fat infusion, they 
demonstrated that the afferent limb depended on PYY60, and furthermore, that the 
effects of PYY could be blocked by the same receptor antagonists87,88. Extrinsic 
denervation of the jejunoileum also abolished the inhibitory effects of ileal fat on 
gastric emptying91. This data demonstrates that neural pathways are involved in the 
inhibition of small bowel transit and gastric emptying after activation of the ileal 
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brake. Similarly, vagotomy reduced or abolished the inhibitory effects of PYY on 
pancreatic secretion92 and food intake63,64 and of GLP-1 on gastric acid secretion93 and 
food intake64. This suggests that neural and humoral mechanisms interact to produce 
the inhibitory effects of ileal brake activation. 
Effect of dietary components on ileal brake 
To date, studies in humans evaluating effects of ileal brake on food intake have 
employed only fat infusions. In order to asses the ability of different nutrient types to 
activate the ileal brake, it is necessary to refer to studies that used motility, transit 
and upper gut secretion as parameters.  
Studies in animals indicate that all three macronutrients induce activation the ileal 
brake94. In humans, studies comparing the relative effects of macronutrients are 
limited in number and scope. For instance, Spiller et al.17 compared isotonic infusions 
of 10 g fat, 7 g protein and 10 g carbohydrates. In this study, the fat infusion reduced 
jejunal motility, whereas the protein and carbohydrate infusion did not affect jejunal 
motility. As the intestine may recognize calories, studies using isotonic in stead of 
isocaloric infusion do not allow for direct comparison of the relative potencies of 
different macronutrients to activate the ileal brake. However, in this same study by 
Spiller et al.17, a higher dose of 15 g of carbohydrates did reduce jejunal motility, but 
this dosage was not pursued further due to nausea. Read et al. demonstrated that 
infusion of protein induced a significant delay in small intestinal transit15. From these 
studies, we can therefore conclude that both fat and carbohydrates, as measured by a 
reduction in jejunal motility, and protein, as measured by in increase in small 
intestinal transit time, activate the ileal brake (Table 3.1). However, as fat is the most 
extensively studied macronutrient for ileal brake activation, this review will primarily 
focus on fat as the stimulus. 
 
Table 3.1 Effects of different nutrients on ileal brake activation and hormone release. 
Infused 
nutrient 
Gastric 
emptying 
Intestinal 
transit/motility 
Pancreatic 
secretion 
Bile acid 
secretion 
Gastric acid 
secretion 
Food 
intake 
PYY GLP-1 
↓ (22, 95) ↓ (15, 17, 22)  ↓ (24, 25)  ↓ (25)  ↓ (27)  ↓ (10,11) ↑ (20,25) ↑ (25, 27) Fat 
 = (25)       
↓ (21) ↓ (17) ↓ (24, 116) = (21) ↓ (27)  - ↑ (21) ↑ (27) CH 
= (95)  = (21)    = (27)  
= (95) ↓ (15) - - = (27) - = (27) = (27) Protein 
 = (17)       
Effects of different nutrients on ileal brake activation and hormone release. When characters are present in 
the second row per nutrient, this denotes that studies have yielded mixed results. = denotes that the 
perfusion did not induce a change in the given parameter, - denotes that this parameter has not been 
studied for this nutrient. 
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Fat 
Perfusion of fat into the ileum inhibits small intestinal transit, gastric emptying, 
pancreaticobiliary, gastric acid secretion and food intake in humans10,15,16,22,25,27. 
The subsequent sections therefore focus on the role of physicochemical properties of 
fat in the activation of the ileal brake.    
Fatty acids vs. triacylglycerols 
In food, fat is by large extent present in the form of triacylglycerols (TAG). The lipase-
mediated hydrolysis of TAG to monoacylglycerols and fatty acids (FA) is a necessary 
step for fat digestion and absorption. Spiller et al. investigated whether hydrolysis of 
TAG is required in order for fat to be able to activate the ileal brake17. These authors 
compared the effects of ileal perfusion of FA versus TAG or glycerol on jejunal 
motility. Thirty minutes after the perfusion, the inhibition of jejunal motility seen with 
FA was significantly greater than with TAG, and there was no effect of glycerol. Welch 
et al. found that 5 g FA and 12 g TAG had equivalent inhibitory effects on gastric 
emptying95. Although a direct comparison between these different doses is difficult to 
make, this study suggests a more potent effect of FA than TAG, possibly due to a 
relatively low lipase activity in the ileum. In rats, a difference between FA and TAG has 
been clearly demonstrated: vagal afferent activity, as measured by multi-unit recoding 
of the number of electronic discharges per second was much higher after perfusion of 
FFA vs. perfusion of TAG or Intralipid® emulsions96. Thus, it seems that hydrolysis of 
dietary TAG is important in activation of the ileal brake, as has been demonstrated for 
signals influencing satiety and gastrointestinal motility arising from the 
duodenum50,97,98. More definite are results from a study by Meyer et al.12 in rats, that 
demonstrated that the satiating effect of an oral corn oil load was completely 
abolished by addition of orlistat to the oil. In the same paper, they demonstrate that 
ingestion of this preload led to spreading of a large amount of FFA to the ileum. 
However, as orlistat almost completely blocked lipolysis, no or very little FFA, but 
large amounts of TAG will have entered the ileum12. These data demonstrated that 
FFA, and not TAG activate the ileal brake.  
Furthermore, given that monolein (a MAG) was also able to inhibit gastric emptying, 
this suggests that both lipolytic products of TAG, but not TAG itself, are able to 
activate the ileal brake41. 
Release of GLP-1 was nearly completely blocked by addition of orlistat to a duodenal 
fat load, suggesting the necessity of the presence of FFA for the L-cell to release 
GLP-199. One could argue that the low lipase activity in the ileum100 may limit 
hydrolysis of food TAG, favouring the use of (or even requirement for) FFA vs. TAG as 
the source material for lipid-derived ileal brake stimulation. Furthermore, Randich et 
al. suggest that the pH gradients in the distal small intestine may further inhibit 
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enzymatic hydrolysis96. However, Holtman et al. found that, in the presence of 
nutrients (especially carbohydrates) lipase activity decreased 75% during duodenoileal 
transit, which leaves sufficient lipase activity for hydrolysis to FFA101. This has been 
confirmed in canine models, where Meyer et al. showed that as little as 2% of normal 
lipase secretion may suffice for normal fat hydrolysis and absorption when gastric 
emptying of fat is held below 5 grams per hour102. It is therefore unclear whether the 
enzymatic conditions favour the use of FFA over TAG as a food source for ileal brake 
stimulation.  
Chain length of fatty acids 
It is generally accepted that medium chain TAG (MCT) are hydrolyzed and absorbed 
more rapidly than long-chain TAG (LCT). FA with chain length under C10 diffuse from 
the enterocytes and pass predominantly into portal blood, bound to albumin, whereas 
FA with chain length above C10 proceed from the enterocyte via chylomicron 
formation into the lymphatic system103. When infused in the duodenum, lipids 
containing FA with chain length over C10 inhibit gastric emptying more than lipids 
containing FA with chain length below C10 104,105. Beyond chain length C14, no further 
increase in inhibition of transit is observed106. Feltrin et al. demonstrated that 
intraduodenal C12 but not C10 decreased appetite and energy intake107. Spiller et al. 
demonstrated that intraileal perfusion of MCT (trioctanoin (C8), tridecanoin (C10)) 
activated the ileal brake and increased plasma PYY concentrations17. No differences 
were seen with between MCT and LCT in their potency to inhibit jejunal motility. 
However, the inhibition was more rapid in response to the MCT perfusion, and the 
recovery of activity was also more rapid17. PYY concentrations were higher after 
triolein (C16) compared to MCT17. Brown et al. found no differences between fatty 
acids of different chain lengths (C14, C18 and C22) in their ability to delay transit time 
in rats106, and in pigs intraileal perfusion of short-chain FA (SCFA, e.g. C6 or smaller)) 
induced an inhibition in gastric motility108.  
Overall, the evidence indicates that both MCT and LCT can both induce activation of 
the ileal brake in humans, and that activation of the ileal brake occurs more rapidly 
after MCT than LCT17. However, the comparative effects on satiety and food intake 
have not been studied, and when infused in the duodenum, fat with a chain length 
below C12 does not directly affect satiety and food intake107, although anorectic 
effects of MCT ingestion have been demonstrated (for a review, see109). As MCT are 
rapidly absorbed, their satiating effect may be due to conversion in the liver110. Fats 
with a chain length >C12 affect satiety and food intake by their action on the mucosa, 
as their effects occur before the entry into the systemic circulation, immediately upon 
application to the mucosa.  
In animals, activation of the ileal brake has also been demonstrated after perfusion of 
SCFA in pigs108 and very long-chain TAG in rats106. Food intake was not assessed in 
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these studies, but after mid-intestinal infusions in sham-feeding rats a reduction in 
food ingestion was observed only from fats with chain length >C10 12.  
Degree of saturation of fatty acids 
Several studies have evaluated the effect of degree of FA saturation on food intake in 
humans. Findings from these studies suggest that differences in the degree of 
saturation of orally ingested fat usually only marginally affects satiety or food 
intake111. However, French et al. reported that when fat was infused directly into the 
duodenum (bypassing the mouth and stomach), di-unsaturated fats significantly 
inhibited food intake (but not satiety), whereas monounsaturated fat had no effect112. 
We have recently conducted a human study on the effects of degree of fat saturation 
on satiety when the fat was delivered directly into the ileum113. The satiating effects 
of mono- and di-unsaturated fats, but not a saturated fat source, were significantly 
larger than the saline control113. In rats, no differences were found between FA with 
different degrees of saturation perfused in the ileum in their ability to delay small 
intestinal transit106. Together this literature indicates that when infused directly in 
duodenum and ileum, the satiating effect of unsaturated fats is probably larger than 
saturated fatty acids, but the issue is not fully resolved. 
Quantity of fat  
Pironi et al. observed a significant delay in gastric emptying after just 480 mg oleic 
acid when infused into the ileum20, and 1200 mg of oleic acid delivered to the jejunum 
and/or ileum have been shown to slow both gastric emptying and small intestinal 
transit in humans114. A dose-dependent decrease in pancreatic and biliary secretion 
has been demonstrated in response to doses of fat of 0, 50 or 100 mg/min perfused 
into the ileum25. In that study, however, no differences were seen in GLP-1 and PYY 
concentrations between the high and low dose of fat.  
In general, it appears that relatively low doses are able to induce ileal brake effects on 
gut function. However, the effect on satiety of these low fat doses has been 
addressed in one study. We have shown that 3 or 9 g of fat infused in the ileum 
delayed small intestinal transit, and both amounts of fat induced reductions in hunger 
and food intake as compared to oral fat consumption115. 
Proteins 
Read et al. found that perfusion of protein into the ileum inhibited small bowel 
transit, indicating that protein induces activation of the ileal brake in humans15. 
However, other authors have reported no effect of intraileal protein-perfusion on 
jejunal motility17, gastric emptying95 or gastric acid secretion27. Although both Spiller 
et al.17 and Welch et al.95 used much lower doses of protein than of fat (to which they 
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were compared), Layer et al. compared equicaloric (60 kcal) ileal perfusions of triolein 
+ sodium-oleate to a protein hydrolysate perfusion, and found that fat, but not the 
protein hydrolysate, reduced spontaneous and stimulated gastric acid secretion27. In 
animals, an isocaloric dose-response study has been conducted, comparing the effects 
of amino acids, oleate, and glucose when infused in the ileum, while gastric emptying 
and proximal small intestinal motility were monitored94. In this study, it was 
demonstrated that protein and fat induce are equipotent activators of the ileal brake 
with regard to small intestinal transit, and gastric emptying94.  
In a study addressing food intake, it was demonstrated that after administration in the 
duodenum, reductions in sham feeding differed between different types of proteins 
administered in the duodenum: L-tryptophane significantly reduced sham feeding, 
whereas L-Alanine had no effect12. However, food intake after ileal administration of 
proteins was not assessed in these dogs. 
Together, the available evidence indicates that ileal protein infusions in both 
humans15 and animals94 activate the ileal brake, although differences may exist 
between different types of protein or amino acids12.  
Carbohydrates 
In humans, ileal perfusion of starch with maltose has been found to inhibit gastric 
emptying, reduce both stimulated and basal gastric acid secretion, small intestinal 
motility and cholinergic-stimulated pancreatic exocrine secretion24,27,37,116. From this, 
we can conclude that the ileal brake is activated by carbohydrates. Welch et al.95 
failed to show an effect of carbohydrate infusions on gastric emptying, but, similarly 
to as discussed above, the dose of carbohydrates used in this study were lower than 
the doses of fat.  
In contrast, Siegle et al. studied gastric emptying and small intestinal motility in dogs, 
and found that ileal glucose inhibited gastric emptying, also at doses lower than 
amino acids and oleate94. This was confirmed by Lin et al., who found a potent effect 
of ileal glucose and of digested starch on gastric emptying of solids in dogs38. Azpiroz 
et al. found that ileal infusion of maltose reduced gastric tone in dogs117. 
Together, these data suggests that ileal administration of carbohydrates activates the 
ileal brake in humans24,27,37,116 and dogs38,94,117. 
Fibre 
Apart from the major dietary macronutrients, other food constituents such as fibres 
can influence activation of the ileal brake. Lin et al. showed in dogs that preventing 
access to the distal gut eliminated the delay in small intestinal transit due to addition 
of water-soluble fibres to an enteral feeding formula118. Soluble fibres may also delay 
the absorption of lipids by thickening the unstirred layer at the luminal surface, 
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resulting in transport of larger amounts of nutrients to the ileum and/or spreading of 
nutrient absorption over a larger intestinal luminal surface area, leading to more 
pronounced inhibitory feedback from the distal gut118. Insoluble fibres may also 
activate a more distal braking mechanism, the colonic brake. Insoluble fibres (but also 
soluble fibres) in the colon are fermented by bacteria, producing significant quantities 
of short-chain FA, which are known to trigger the release of PYY43. The potential role 
and applications of fibre in ileal brake activation in humans needs to be further 
elucidated.  
Satiety and food intake 
Evidence from effects of ileal brake activation on satiety and food intake come from 
studies of ileal perfusion of fat and bariatric surgical procedures that result in 
increased exposure of the ileum to nutrients. While the nutrient perfusions studies 
mainly focus on acute, short-term stimulation of the ileal brake, the surgical model 
reflects a more chronic and sustained activation.  
Nutrient perfusions 
Animals 
The previous sections describe evidence for activation of ileal brake effects on 
gastrointestinal responses by carbohydrates, protein and fat. However, there are only 
a small number of human studies examining the effects of ileal brake activation on 
eating behaviour. Most of the relevant information is therefore derived from animal 
studies. 
In rats, the inhibitory effect of ileal perfusion of nutrients on food intake has been 
clearly demonstrated in several studies119-121. Glick et al. showed that both duodenal 
and ileal perfusions of glucose resulted in a decreases in food intake approximately 
equal to the caloric content of the infusate121,122. A trend towards lower average food 
intake and reduction in number of meals during the ileal perfusion was observed, but 
did not reach statistical significance. Meyer et al. conducted a number of studies 
focusing on different aspects of intestinal satiety mechanisms12,35,40. They 
demonstrated that infusions of carbohydrates, certain amino acids and fatty acids in 
the mid-intestine reduced food ingestion during sham feeding12. Furthermore, they 
showed that the reduction in food intake was larger when the exposed surface of 
small intestine was larger35,40, confirming results on effects of carbohydrates42, fat41 
and proteins33 on gastrointestinal motility. Meyer et al. also demonstrated that 
infusions of dodecanoate, oleate-monolein, maltose and phenylalanine-tryptophane 
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in the coecum reduced food intake significantly. Furthermore, in the same paper, they 
demonstrate that the anorectic effect of dodecanoate infusions increased from 
duodenum- to coecum: in the duodenum, intake was reduced by 11.3%, in the ileum 
by 21.4% and in the coecum 40%12. These data demonstrate that the colon in rats 
does reduce food intake, and contributes to the satiating effect of ileal brake 
activation12.  
 
Evidence for a normal physiologic role of the ileum in eating behaviour is derived from 
experiments assessing effects of resection of the ileum. Meyer et al.12 measured 
suppression of food intake in rats who underwent an ileum resection or sham surgery. 
intraduodenal infusion of nutrients. They found that suppression of food intake by an 
intra- duodenal nutrient infusion was larger in the sham-operated group compared to 
the ileum-resection group, although this was significant only for the oleate perfusion; 
in this group resection attenuated the reduction in food intake from 33% to 12.5% 
after the 0.48 mmoles/h perfusion, and from 80% to 57.25% in the 0.96 mmoles/h 
perfusion12. These results show that the ileum and probably the colon contribute to 
the satiating effects of intestinal nutrients loads, and that this effect increases when 
the speed of absorption of a nutrient is lower. 
 
Furthermore, Meyer et al.12 determined reduction ratios (reduction in energy 
consumed relative to the energy load perfused) of perfusions of different nutrients in 
different amounts in either duodenum or ileum. When the infusate was limited to the 
duodenum/jejunum or to the ileum/colon, reduction ratios were higher after ileal 
perfusions. This can taken to be a demonstration of the greater relative potency of 
ileal perfusions to reduce intake12.  
 
Woltman et al. compared duodenal versus terminal ileal perfusions (14 cm from the 
ileocecal valve) of different amounts of glucose or oleic acid on meal size and number 
of meals in rats120. Ileal glucose was more potent than duodenal glucose for reducing 
cumulative food intake, whereas duodenal oleic acid had a stronger inhibitory effect 
on food intake than ileal oleic acid. The glucose experiments demonstrate that the 
anorectic effect of ileal glucose exposure is more potent than duodenal glucose 
exposure, confirming the higher potency of the ileal brake to reduce food intake. 
Furthermore, the colon may have added to the anorectic effect of the ileal infusion, as 
demonstrated by Meyer et al.12. The experiments with oleic acid seem to contradict 
this. Nevertheless, since absorption of glucose is about nine-fold faster than 
absorption of oleic acid40, oleic acid, but not glucose, will contact the entire small 
intestinal length during duodenal infusions of higher doses; whereas during these ileal 
perfusions, only 14 cm of ileum and colon were contacted, resulting in a shorter 
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segment of intestine. This may explain the larger effect on food intake of oleic acid 
administration in the duodenum compared to the ileum. 
The pattern by which food intake was reduced differed between the site of delivery 
and types of nutrient: In the duodenum, both glucose and oleic acid inhibited feeding 
by decreasing meal frequency, while delivery of nutrients to the ileum reduced both 
meal size and frequency. As the glucose and the oleic acid perfusions were not 
equicaloric, no direct conclusion can be made regarding their relative potency. The 
differing patterns of effects on feeding behaviour led the authors to suggest that ileal 
oleic acid and glucose inhibit food intake by different mechanisms120. 
 
There is also evidence that the appetite suppression induced by nutrients delivered to 
the distal small intestine retains its effects over sustained periods. Cox et al. found 
that prolonged daily jejunal fat perfusion, 7 hours/day for 21 consecutive days, 
induced a net reduction in food intake, without compensation for the suppression of 
intake occurring during the perfusion123. Whether this also applies to the ileum is not 
known. 
Human studies 
Studies on the effect of ileal brake activation on food intake and satiety in humans are 
scarce. Welch et al. performed two studies in which they evaluated the effect of ileal 
fat on food intake and satiety10,11. They perfused a 50% corn oil (370 kcal) emulsion 
(vs. saline control) into the ileum for 90 min and measured satiety-scores and food 
intake by an ad libitum meal 30 minutes after the start of the perfusion. In both 
studies, the ileal nutrients induced reductions (200 kcal and 279 kcal) in food intake 
above the infused amount of calories, when compared with control. No effect on 
satiety before the start of the ad libitum meal was observed in either study in 
response to the ileal perfusions. However, after the start of the ad libitum meal, 
fullness increased significantly during both ileal fat perfusions compared to saline. In a 
further series of experiments, ileal perfusion of corn oil emulsions delayed gastric 
emptying compared with ileal perfusions of albumen and saline10. When they 
compared ileal and jejunal perfusions of fat on satiety and food intake, the inhibition 
of food intake was larger after the jejunal perfusion11. However, because the rate of 
perfusion in the jejunum was supraphysiological, it is very likely that some of the fat 
infused into the jejunum spilled into the ileum. However, some of the fat infused in 
the ileum will have spilled over into the colon. This would result in a larger intestinal 
surface being exposed to fat after the jejunal experiment, which has been found to 
result in an enhanced reduction in food intake in rats40. Welch's observations after 
jejunal v ileal infusions in humans parallel exactly the relative effects of jejunal v. ileal 
infusions of oleic acid later observed in rats35. 
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In both of the experiments described above, ileal fat perfusions did not suppress 
appetite before the meal, but significantly increased fullness during the meal10,11. 
From this, the authors concluded that the effect of ileal brake activation on satiety 
might be explained by an indirect action, i.e. the earlier attainment of a critical level of 
gastric distension due to the delay in gastric emptying, as opposed to a direct action 
of ileal fat on the satiety centres in the brain. This would suggest that inhibition of 
food intake by ileal brake activation could be enhanced when it coincides with an 
intragastric volume load.  
Our group has demonstrated a satiating effect of ileal fat perfusion without a 
preceding meal62. In this randomised crossover study, 14 healthy volunteers received 
either an intraileal perfusion of Intralipid® (a 20% fat emulsion) at 2 kcal/min, or a 
control saline perfusion. Satiety scores increased significantly in response to the ileal 
fat perfusion without a preceding meal, confirming the results of Meyer et al.12, who 
demonstrated similar reductions of food intakes after ileal infusions in rats with or 
without a gastric distension (sham vs natural feeding). These studies demonstrate that 
the satiating effect of the ileal brake is not exclusively mediated by the earlier 
attainment of a critical level of gastric distension, as suggested by Welch et al.10, but 
that a direct effect on satiety centres is very likely.  
Chronic ileal brake activation: surgical models 
Apart from ileal brake activation by perfusion of nutrients in the ileum, bariatric 
surgical procedures provide models in which (a part of) the ileum is exposed to an 
increased amount of nutrients: 1) the jejuno-ileal bypass (JIB), in which the proximal 
jejunum is anastomosed to the distal ileum, and 2) the ileal transposition (IT), in which 
a part of the ileum is transposed into the duodenum or jejunum.  
The JIB was pioneered by Payne and De Wind in 1969, as treatment for gross 
obesity124,125. The observed weight loss was at first thought to result from 
malabsorption, but as the loss in body weight was larger than could be accounted for 
by fecal losses, other mechanisms had to be involved125-127. Condon et al. 
demonstrated that only 21% of the weight loss observed was attributable to 
malabsorption126, while both Naslund et al. and Bray et al. demonstrated that JIB 
induced an decrease in food intake127,128. Bray et al. reported that daily energy intakes 
at 1 and 12 months post-surgery were reduced to 20% and 45%, respectively, of pre-
surgery levels, thereby showing an impressive and sustained reduction in energy 
intake128. Naslund et al. found that nine months after surgery, food intake was 13% 
lower during a test meal compared to the pre-surgery intake127. Psychological factors, 
such as the negative reinforcement of diarrhea after meals, have been considered 
explain these reductions in food intake, but they do not fully account for the sustained 
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differences in intake and preferences because the malabsorption decreases with time 
after JIB129.   
Roentgenological studies have demonstrated that JIB leads to a rapid exposure of the 
ileum to nutrients130. Furthermore, JIB leads to higher concentrations of distal 
intestinal hormones as PYY and GLP-1 compared to pre-surgical levels131. From this it 
follows that the increased exposure of the ileum to nutrients leads to an increased 
activation of the ileal brake, and this suggests that ileal brake-activation is involved in 
the decrease in food intake seen after JIB. However, due to severe complications, the 
JIB is no longer used in clinical practice, and these complications may also have 
influenced the food intake negatively132. 
 
The surgical procedure of ileal transposition is another model to evaluate the effects 
of chronic ileal exposure to nutrients. In this procedure, a 10-20 cm segment of distal 
ileum is prepared and resected with preservation of vasculature and innervation. The 
segment is placed into the duodenum or proximal jejunum133, thereby eliciting early 
and enhanced activity of the ileal brake in response to regular feeding. Koopmans et 
al. compared rats with transpositions of 10 cm (8% of total length of ileum) and 20 cm 
of ileum into the duodenum to a JIB group and a control group in which the resected 
segment was reattached without transposition134. Relative to controls, food intake in 
the 10 and 20 cm transposition groups and the JIB group were reduced by 22%, 44% 
and 44% respectively. These reductions in food intake led to a loss in body weight 
relative to control at five days after surgery: 25% in the 10 cm transposition group, 
33% in the 20 cm group, and by 45% in the JIB group. As food intake was similar 
between the 20 cm ileal transposition group and the JIB group, this difference in 
weight loss is probably due to malabsorption. The results for the ileal transposition 
have been confirmed in a study by Strader et al., where ileal transposition reduced 
food intake and body weight compared to control group, and was associated with 
increased secretion of PYY and GLP-1 133. Furthermore, this study indicates that 
adaptation to the reduction in food intake does not occur133. These results from 
animal studies provide evidence that greatly increased exposure of the ileum to 
nutrients induces a reduction in food intake with subsequent reduction in body 
weight133,135. This has also been confirmed in humans. 
De Paula et al. studied the effect of sleeve gastrectomy, a surgical procedure which 
results in a smaller gastric volume, in combination with ileal transposition (named the 
neuroendocrine brake) on weight loss in 19 obese patients136. All patients lost weight, 
a mean of 9.3% after 1 month, 23% after 6 months and 42.4% after 16 months. 
Together, these and other data suggest that chronic ileal brake activation results in 
weight loss in both animals and humans, with no (or at best incomplete) chronic 
adaptation to the anorexic effects. 
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In the context of the current search for more effective preventive and treatment 
approaches for obesity, these data provide evidence for the potential value of ileal 
brake activation in the control of food intake and satiety. Different studies have 
shown that satiety scores correlate to ad libitum energy intake137,138, and changes 
satiety scores are associated with weight loss138. 
Furthermore, perceived hunger has been shown to be a significant predictor of failure 
to lose weight in clinical trials139, and reduction of hunger is a mode of action of one of 
the major current drug treatments for obesity140. Our group has repeatedly 
demonstrated an increase in satiety-levels after activation of the ileal brake19,62,113, 
and the different surgical models both in humans127,128 and in animals119,135,141,142 have 
demonstrated a large anorectic effect, with concomitant weight loss142.   
Obesity usually reflects a long-term accumulation of relatively small average daily 
excesses in energy intake relative to expenditure143. Technologies to help consumers 
make small but consistent reductions in energy intake, to bring it more closely into 
line with expenditure, should therefore help in obesity prevention. Given the powerful 
reduction observed after ileal brake activation, food products that trigger the ileal 
brake could contribute toward this goal. 
Glycaemic control  
Bariatric surgery can reduce a number of obesity-associated health risks, such as 
hyperglycaemia. For example, in the ileal transposition study of De Paula et al.136, all 
five type 2 diabetes patients (three taking oral hypoglycaemic agents, two using 
insulin) achieved normal blood glucose concentrations without medication within 
three weeks after surgery. Interestingly, the improvements in glucose regulation seen 
after bariatric surgery were achieved before any significant weight loss had 
occurred144. Thus, mechanisms distinct from effects of weight loss itself are involved 
in the improvement of glucose regulation144,145. A recent study in which non-obese 
type 2 diabetes rats underwent an ileal transposition, demonstrated improved fasting 
plasma glucose levels, insulin and glucose tolerance compared to sham-operated rats, 
without alterations in food intake or body weight146. The ileal transposition also 
induced a significant increase in plasma GLP-1 concentrations.  
The beneficial effect of GLP-1 on insulin sensitivity has been shown in humans and in 
animal studies147. GLP-1 is released after exposure of the distal small intestine to 
nutrients27,148, especially carbohydrates and lipids27. Therefore, the improvement of 
glycaemic control after bariatric procedures, such as the ileal transposition and the 
Roux-en-Y gastric bypass is considered to be at least partly the consequence of 
increased distal small intestinal exposure to nutrients145,149,150. However, there are 
also other theories about the causes of improved glycaemic control after bariatric 
surgery144. 
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Conclusions 
Apart from the role the ileal brake plays in the regulation of gastrointestinal motor 
and secretory function, activation of the ileal brake leads to a reduction in hunger and 
in food intake. Activation occurs after exposure of the ileum to fat, carbohydrates and 
protein. Suggested mediators include PYY, GLP-1 and vagal nerve stimulation. The 
inhibitory effect of ileal brake activation on satiety has been repeatedly 
demonstrated, but it is uncertain whether this effect results from direct stimulation of 
central satiety centres in the brain, or if the ileal brake effect on hunger and satiety is 
achieved indirectly via the delay in gastric emptying. It is most likely that, after 
activation of the ileal brake, the enhanced gastric distension from delayed gastric 
emptying interacts with a direct stimulation of central satiety centres by hormonal 
and neural signals, to reduce hunger and energy intake. This reduction in food intake 
occurs when the ileum is exposed to infused nutrients, or when changes in gut 
anatomy after bariatric surgery induce greater exposure of the ileum to nutrients.  
The chronically increased ileal brake activation seen after bariatric surgery 
demonstrates that an appetite-reducing effect of ileal brake activation is sustained. 
This suggests that activation of the ileal brake may serve as an excellent target to 
achieve long-term reductions in food intake. However, the idea of ileal stimulation to 
therapeutically control body weight is provocative but a long way from established. 
The increased glycaemic control as demonstrated in ileal transposition studies 
provides an additional health benefit. The availability of a specific GLP-1 receptor 
antagonist enables new studies investigating the role of GLP-1 in ileal-brake-
dependent reductions in food intake, and functional MRI techniques showing brain 
activation may be applied to study possible direct effects of ileal brake activation on 
CNS satiety centres.  
All in all, the ileal brake appears to be a sensible food target for appetite control that 
merits further research to explore its potential, understand the underlying 
mechanisms, and identify how it can be applied in practice. 
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Abstract  
Objective 
The ileal brake is a feedback mechanism activated by nutrients, especially fat, with marked effects on 
satiety. The effects of low doses of ileal fat on satiety are largely unknown. We therefore studied the effect 
of ileal vs. oral delivery of low doses of fat on satiety and gut peptide secretion. 
 
Design 
Randomized, single-blind crossover design 
 
Subjects 
Sixteen healthy, normal weight volunteers (6 male; mean age 26 yr, mean BMI 22.4).   
 
Intervention 
Subjects were intubated with a 290 cm long nasoileal tube and consumed, on three consecutive days, 
either a liquid breakfast with 3 g fat followed by an ileal placebo infusion at t=105-150 min (treatment C) or 
a fat-free liquid breakfast followed by an ileal infusion of either an emulsion of 3 g (treatment I3g) or 9 g 
(treatment I9g) safflower oil. 
 
Measurements 
Satiety parameters by visual analogue scales and plasma concentrations of CCK and PYY. 
 
Results 
C significantly increased satiety and CCK secretion compared to the fat-free breakfast. Ileal fat perfusion of 
both 3 g and 9 g (I3g and I9g) significantly increased satiety during and after fat perfusion, without 
differences in satiety between I3g and I9g. During ileal fat infusion, CCK increased dose-dependently, 
whereas PYY-concentrations increased significantly only after 9 g of fat. Secretion of CCK but not of PYY 
correlated to satiety levels. 
 
Conclusion 
Postprandial satiety following a liquid breakfast can be effectively and significantly increased by small 
amounts (as little as 3 g) of fat perfused into the ileum. Ileal fat dose-dependently increased CCK but not 
PYY secretion. The satiating effect of ileal fat may be partly mediated by CCK. 
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Introduction 
Satiety feelings on a meal-to-meal basis are to a large extent determined by gastro-
intestinal signals1. An option to prolong satiety and to reduce food intake is by 
delaying gastric emptying and/or small intestinal transit time2-4. This may be achieved 
by activation of the ileal brake5. The ileal brake is the primary inhibitory distal to 
proximal located feedback mechanism that controls meal transit through the 
gastrointestinal tract and is thought to regulate and optimize nutrient digestion and 
absorption5. Several studies have shown that direct delivery of lipids into the ileum 
delays gastric emptying6, prolongs small intestinal transit time7 and induces satiety8. 
Long chain fatty acids (LCFA) are potent triggers of the ileal brake5,7, and several 
studies have demonstrated that the  ileal brake is already activated by small amounts 
of fat or free fatty acids9-11.  
However, it is not known whether these small amounts of fat are able to induce 
satiety and influence food intake. Evidence for a direct effect of the ileal brake on 
satiety and food intake in humans is limited to two publications from the same 
research group8,12. An ileal infusion of 370 kcal of lipids resulted in a significant 
reduction in hunger with a net decrease in caloric intake of 711 kcal. It should be 
noted that the amounts of fat used in these studies were high (41 g), and no studies 
have been performed on the satiating effect of ileal brake activation by very small 
amounts of fat.  
Our aim was to explore whether delivery of small amounts of lipids into the ileum will 
further increase postprandial satiety and whether this effect is dose dependent. A 
second aim was to evaluate the effect of ileal lipid administration on gut peptide 
secretion, more specifically, on CCK, as a more proximal gut peptide with well known 
satiety effects13 and peptide YY, as a distal gut peptide and proposed biomarker for 
the activation of the ileal brake10. 
We constructed the following hypotheses: Compared to oral ingestion of 3 g of lipid 
added to a liquid meal, delivery of the same amount of lipid through postprandial 
(after ingestion of the fat-free breakfast) perfusion into the ileum will 1) lead to an 
increase in postprandial satiety, 2) be dose-dependent (9 g vs. 3 g in the ileum) and 3) 
lead to distal gut hormone secretion. 
Method 
Subjects 
Healthy volunteers were recruited by public advertisement. Sixteen volunteers were 
seen for screening. This included a questionnaire (Dutch Eating Behavior 
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Questionnaire) to exclude restrained eaters, blood tests and physical examination. 
Signed informed consent was obtained from each individual. None had a history of 
gastro-intestinal disease or abdominal surgery, and none were using any medication. 
After providing their written informed consent, sixteen healthy individuals (mean age 
26 yrs, range, 18–60 yrs, mean BMI 22.4 kg/m2 range 18.7-28.6 kg/m2) participated in 
this study.  
Naso-ileal catheter 
Subjects were intubated with a 9-lumen 290 cm naso-ileal cathether (8 infusion ports, 
1 balloon inflation channel, Dentsleeve International Ltd., Mississauga Canada). 
Through an anaesthetized nostril, the catheter was introduced into the stomach, and 
allowed to pass through the pylorus to the ileum by peristalsis. After passing the 
ligament of Treitz, a small balloon at the tip was inflated to facilitate passage of the 
catheter to the ileum. The tip was placed in the ileum (at least 120 cm catheter length 
distal from the pylorus-the catheters were fitted with radiopaque markers that 
enabled assessment of the length of catheter), so that three infusion ports were 
available in the ileum, and at least one infusion port in the duodenum. After this, the 
subjects were instructed to inflate and deflate the balloon during the evening, and 
inflate the balloon upon waking up, in order to advance further passage of the tube. 
During the positioning and before and directly after every test-day, the position of the 
catheter was checked fluoroscopically. The fluoroscopy techniques used do not 
enable assessment of the position of the tube compared to the ileocecal valve. 
However, on fluoroscopy, it was shown that the catheter made multiple loops within 
the small intestine. Furthermore, in two cases, contrast fluid was used to visualize the 
exact position of the catheter. After infusion of the contrast fluid, the contrast 
appeared in the colon within a few minutes, and a short segment of small bowel was 
visible (30-60 cm). 
Experimental design 
In this single-blind randomized controlled crossover design, each subject participated 
in three experiments on three consecutive days in random order. In treatment C (oral 
fat, 3 g), subjects received a liquid meal with 3 g of fat (breakfast X, BX) and an ileal 
placebo infusion (emulsion A). In treatment I3g (ileal fat, 3 g), subjects received a fat-
free liquid meal (breakfast Y, BY) and an ileal infusion with an emulsion with 3 g of fat 
(emulsion B). In treatment I9g (ileal fat, 9 g), subjects received fat-free breakfast (BY) 
and an ileal infusion with an emulsion with 9 g of fat (emulsion C). 
 
On each study day (Figure 4.1), the subject arrived at the laboratory at 8:00 AM 
following an overnight fast. After checking the correct position of the catheter by 
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fluoroscopy, a venous catheter was placed in a forearm-vein for collection of blood 
samples. At 9:00 a basal blood sample and a basal VAS score were taken. Immediately 
thereafter, the liquid meal was consumed. The ileal infusion was scheduled from 
t=105-150 min after meal ingestion, at a rate of 1 ml/min. This resulted in an infusion 
rate of 0.6 kcal/min for the I3 g treatment, and 1.35 kcal/min for the I9g treatment. 
For this experiment, the follow-up ended at t=240 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Study outline for the three experiments. Order of treatments was randomized. Each test day 
started with consumption of breakfast. Each subject consumed either a breakfast with 3 g fat 
followed by an ileal saline infusion at t=105-150 min (treatment C) or a fat-free breakfast 
followed at t=105 min by an ileal infusion of either an emulsion of 3 g (treatment I3g) or 9 g 
(treatment I9g) safflower oil. * denotes drawing blood sample & satiety questionnaire.  
 
 
This study was designed as a proof-of-principle study to evaluate dose-dependent 
effects of the ileal brake on satiety. The timing of the ileal fat perfusions is crucial and 
should represent the physiological postprandial conditions. We chose the infusion 
period at t=105-150 min, as we thought this would best represent the physiological 
moment of arrival of the bulk of the fat14. Furthermore, Goebell et al.15 demonstrated 
that delivery of a meal marker to the ileum was the highest at 2-2.75 hours after 
ingestion of the meal. In this study, we tried to resemble to physiologic postprandial 
situation. 
Liquid meals and emulsions 
The liquid breakfasts and the fat emulsions (+ placebo) for ileal perfusion were 
produced by Unilever Research & Development, Vlaardingen, the Netherlands. Two 
325 ml breakfast drinks were produced: BX (220 kcal) consisting of 99.1% Slim·Fast 
French Vanilla US (fat-free) and 0.9% safflower oil, and BY (193 kcal) consisting of 
100% Slim·Fast French Vanilla US (fat-free). Three emulsions were produced: placebo 
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(named emulsion A – strictly speaking this is not an emulsion as it does not contain 
any oil) consisted of 1.0% sodium caseinate, 0.1% skim milk powder, 0.1% Guar gum, 
0.9% sodium chloride in demineralized water. Oil emulsion B was composed of 1.0% 
sodium caseinate, 0.1% skim milk powder, 0.1% Guar gum, 0.9% sodium chloride and 
6.0% safflower oil in demineralized water. Oil emulsion C was identical to emulsion B 
except that the oil concentration was 18% and NaCl was 0.66%.  
Satiety scores 
The volunteers rated their feelings of hunger and satiety (and appetite for a meal, 
fullness, appetite for a snack and satiety)  by means of a mark on 64-mm line scales 
using a EVAS (Electronic Visual Analogue Scale, iPAQ)16. This scale was anchored at the 
low end with the most negative or lowest intensity feelings (e.g., "extremely 
unpleasant", "not at all"), and with opposing terms at the high end (e.g., "extremely 
pleasant", "very high", "extreme") as described by Flint et al.17.  
Measurements were taken during the test day every 30 min from t=0-240 min, and 
every 15 min during infusion of emulsion (t=105-150 min). 
Gastrointestinal disturbances were scored using forms (4-point scale: “none”, “a 
little”, “some”, “substantial”) at regular intervals (t=-5, 105, 150, 235, 345, 390, 435 
min). The following gastrointestinal symptoms were scored: nausea, heartburn, 
belching, abdominal bloating, abdominal pain, borborygmi, flatulence, and urge to 
defecate. The following general symptoms were also scored: headache, malaise, 
dizziness, and fatigue. 
Hormone assays 
Blood samples were drawn at t=0 (start meal ingestion), t=30, t=60, t=105 (start ileal 
infusion), t=125, t=150 (end ileal infusion), t=195, t=240 min. 
Total plasma PYY was measured by radioimmunoassay. PYY antiserum was generated 
in rabbits by intracutaneous injections of synthetic human PYY (BACHEM Biochemica 
GmbH, Switzerland). PYY was labeled with 125Iodine with chloramine T. The assay is 
highly specific. There is no cross-reactivity with PP or VIP. The detection limit is 
10 pmol/l. Both PYY(1-36) and PYY(3-36) bind to the antibody in dilutions up to 250000. 
The intra-assay variation ranges from 1.8 to 15.6% and the inter-assay variation from 
9.5 to 27.8% 18. 
Plasma CCK concentrations were measured by a RIA, as described previously19. The 
detection limit of the assay is 0.3pM. The intra-assay variation ranges from 4.6 to 
11.5% and the inter-assay variation from 11.3 to 26.1% 20.  
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Statistical analysis 
Results are expressed as least square means with standard error (SE), unless 
otherwise specified. Satiety and hunger measurements were calculated as absolute 
ratings. 
Satiety scores were expressed as percentages of the maximal score (0 mm equaled 0% 
and 64 mm equaled 100%) and as incremental cumulative areas under the curve 
(iAUC). The AUC was calculated, using the trapezoid rule, for different periods and 
corrected for level at the start of that period (incremental AUC). All parameters were 
analyzed using analysis of variance with subjects as blocks and the three treatments 
as factor. Differences between treatment groups were established using Fisher’s least 
significance difference (two-tailed). A p-value of 0.05 was considered significant. To 
establish possible relationships between plasma hormones and satiety ratings, 
Pearson’s R correlations between plasma CCK and PYY levels and the corresponding 
VAS scores for satiety and hunger were calculated. For this correlation AUC for all time 
periods and changes in absolute levels in time were used. 
Gastrointestinal disturbances were analysed using frequency of occurrence per time 
point and a standard ANOVA with the personal scores corrected for each subject's 
overall mean score.  
Statement of Ethics 
We certify that all applicable institutional and governmental regulations concerning 
the ethical use of human volunteers were followed during this research. The study 
protocol was approved by the Ethical Committee of the Leiden University Medical 
Centre.  
Results 
Satiety scores 
Since all satiety parameters gave similar type results, we will only show scores for 
satiety and hunger. VAS scores for satiety are given in Figure 4.2 and for hunger in 
Figure 4.3. Fasting scores for hunger and satiety did not differ between the three 
treatments. Consumption of the meal increased satiety and decreased hunger feelings 
in all three treatments compared to baseline. At t=30 min, suppression of hunger 
levels was significantly more pronounced after the fat containing compared to the fat 
free breakfast, and scores remained lower till the start of the ileal infusion (sign. for 
hunger and satiety at t=105 min). At t=150 min, scores for satiety were significantly 
higher after treatments I3 g and I9 g compared to C. Incremental AUCs (iAUCs) for 
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hunger and satiety for the different time periods are given in Table 4.1. From meal 
ingestion up to the start of the infusion, no significant differences were observed 
between the different treatments. However, from the start of the infusion till the end 
of the study day, iAUC for satiety was sign. higher after I3 g compared to C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Subjective EVAS scores for satiety. * denotes p<0.05 for C vs. I3g and I9g, †denotes p<0.05 for 
I3g and I9g vs. C and ‡ denotes p<0.05 for I9g vs. C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Subjective EVAS scores for hunger.  
 *denotes p<0.05 for C vs. I3g, † denotes p<0.05 for C vs. I9g. 
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Table 4.1 Incremental AUCs satiety scores 
Parameter C 
(%.min) 
I3g 
(%.min) 
I9g 
(%.min) 
SE 
Satiety 
    0-105 min 17.4 19.0 13.9 2.5 
    105-240 min   0.6   11.8*   8.2 3.8 
    0-240 min   8.1 15.0 10.8 2.9 
Hunger 
    0-105 min -19.6 -15.7 -15.3 3.0 
    105-240 min   -1.4   -6.3   -7.9 4.0 
    0-240 min   -9.5 -10.5 -11.2 1.7 
*denotes p<0.05 vs. C 
 
CCK 
Plasma CCK-concentrations are given in Figure 4.4. Baseline plasma CCK 
concentrations did not differ between study days. At t=30 and t=60 min, plasma CCK-
concentrations were significantly higher after treatment C compared to I3g and I9g.  
The ileal infusions caused a rapid and significant increase in plasma CCK 
concentrations, resulting in significantly higher plasma concentrations for I9g and for 
I3g compared to C. With regard to iAUCs (Table 4.2), CCK release was significantly 
larger after C compared to I3g and I9g in the period from meal ingestion till the start 
of the infusion. IAUCs for I3g and I9g were significantly higher compared to C for the 
period between the start of the infusion period and the end of the test period.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Plasma CCK concentrations. * denotes p<0.05 for C vs. I3g and I9g, †denotes p<0.05 for I9g vs. 
C and ‡ denotes p<0.05 for I9g vs. C and I3g, and for I3g vs. C. 
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Table 4.2 Incremental AUCs gut peptides. 
Parameter C 
(pM.min) 
I3g 
(pM.min) 
I9g 
(pM.min) 
SE 
CCK     
    0-105 min 37   15*     3*   6.2 
    105-240 min -1   35*   62* 10.9 
    0-240 min 37 50 65 13.8 
PYY     
    0-105 min 366     -6*                 147   91 
    105-240 min -50 74 1171** 170 
    0-240 min 316 68 1318** 228 
*denotes p<0.05 vs. C; ** denotes p<0.05 vs. C and I3 g 
 
PYY 
Plasma PYY-concentrations are given in Figure 4.5. Baseline plasma PYY 
concentrations did not differ between study days. The fat containing liquid meal 
induced a significantly larger postprandial (t=0-105min) increase in PYY-concentration 
compared to I3g and I9g (Table 4.2). 
The ileal infusion significantly increased plasma PYY-concentrations only after 
treatment I9g, whereas no effect on plasma PYY was seen in treatment I3g. After 
treatment I9g, plasma PYY remained significantly increased from t=150-240 min as 
compared to treatments C and I3g. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Plasma PYY concentrations. * denotes p<0.05 for C vs. I3g, †denotes p<0.05 for I9g vs. C. 
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Correlations 
Plasma hormone levels and the corresponding VAS scores for satiety and hunger were 
plotted and correlations were calculated between CCK and PYY and satiety scores. For 
the period starting with the ileal perfusion until noon (105-240 min), significant 
positive correlations (r=0.68, P<0.01) were found between the change in plasma CCK 
secretion and the increase in satiety (Figure 4.6.) No significant correlations between 
PYY concentrations and satiety scores were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Correlation between incremental plasma CCK response and the delta of the satiety scores for 
the period starting with the ileal perfusion until the end of the test day (105-240 min). R=0.68, 
p<0.01 
 
Discussion 
We are the first to demonstrate in humans that postprandial infusion of a small 
amount of fat into the ileum reduces hunger and increases satiety. This satiating 
effect was not different between 3 and 9 g ileal fat, and correlates with CCK secretion. 
Surprisingly, the release of PYY did not parallel the activation of the ileal brake 
triggered by ileal fat, as only the high dose (9 g) increased plasma PYY concentrations. 
Nutrients administered into the ileum inhibit gastric emptying6, slow intestinal 
motility and transit7,21, decrease exocrine pancreatic secretion9 and reduce food 
intake8. These effects have been attributed to activation of the ileal brake 
mechanism5. Until recently, it was assumed that undigested nutrients reach the distal 
small intestine only under conditions of malabsorption or maldigestion. A more recent 
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study in dogs has clearly shown that even under physiological circumstances 
unabsorbed fat reaches the distal small intestine and activates the ileal brake-
mechanism22. A role for the ileal brake in the physiologic regulation of gastrointestinal 
motility and secretion has been proposed23.  
The effect of lipids administered into the small intestine on satiety and food intake in 
humans has been studied previously by Welch et al. 8,12. These authors demonstrated 
that infusion of fat in the ileum caused a reduction in food intake in healthy 
volunteers.  
In our experiments, we perfused the ileum with only small amounts of lipid (3 and 9 g 
of lipid in total, perfused over a 45 min period). This results in a delivery of calories to 
the ileum of 0.6 kcal/min and 1.8 kcal/min for the 3 and the 9 g of oil in total 
respectively, both being much lower than the 4.9 kcal/min in the studies by Welch et 
al.8,12.  
The 3 g ileal fat resulted in a reduction in appetite and an increase in satiety. This 
effect was comparable to that induced by the 9 g of ileal fat. Therefore, the satiating 
effect of ileal fat infusion was not dose-dependent. In humans, Pironi et al. were the 
first to show a significant correlation between the dose of lipids administered to the 
ileum and the ileal brake-effect on gastric emptying10. Similarly, Keller et al.9 
demonstrated that the ileal brake induced a dose-dependent inhibition of pancreatic 
and biliary secretion. No dose-response studies with regard to the ileal brake and 
satiety have been performed in humans. With respect to the duodenum, a relation 
between fat load and satiating effect has previously been demonstrated24. 
It is not apparent why no dose-dependent effects of ileal fat on satiety were observed. 
Several factors may be involved. First, triacylglycerols need to be hydrolyzed to fatty 
acids in order to be able to reduce satiety and food intake25. It is well known that the 
lipolytic capacity in the ileum is smaller compared to the duodenum26. A lack of lipase 
in the ileum may have limited the hydrolysis of the high fat dose. However, as plasma 
CCK-concentrations did increase dose-dependently, this is unlikely.  Second, after the 
distal ileal perfusion, fat might directly spill over into the colon, from where no further 
satiety signals will arise. However, in humans, the satiety response to colonic lipids 
containing long chain fatty acids has not been studied in detail.  
This study shows two important findings regarding gut peptides: (1) CCK, generally 
considered a “proximal” gut hormone was released in a dose-dependent fashion 
during distal small intestinal administration of the oil emulsion and CCK secretion 
correlated significantly with changes in satiety. (2) PYY, a distal gut peptide thought to 
represent activation of the ileal brake, did increase after ileal infusion of 9g of fat, but 
not after 3 g of fat and did not correlate with the changes in satiety. 
As the dose of ileal oil was increased to 9 g, a significant increase in CCK secretion was 
observed and correlated significantly with the increase in satiety. We and other have 
previously reported on the satiating effects of CCK13,19,27-29. There is consensus that 
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CCK suppresses food intake on the short term. Our study confirms the correlation 
between satiety scores and plasma CCK secretion.  
It is remarkable that secretion of a so-called “proximal” gut peptide is activated upon 
ileal delivery of fat. However, Sjolund et al.30 demonstrated that CCK-producing cells 
are present in the ileum, confirming observations by Capella et al.31. The number of 
CCK-secreting cells in the distal ileum was lower compared to the duodenum or 
jejunum, but not absent, as in the large intestine30. The presence of these I-cells can 
explain the increase in plasma CCK concentrations observed after infusion of fat in the 
ileum.  
To date, release of CCK by ileal fat infusion has previously been shown only by Lin et 
al. in dogs32. In this study by Lin et al., there was no difference in CCK-release between 
the proximal and distal small intestinal infusions32, whereas Konturek et al.33 did not 
find an increase in plasma CCK concentrations. However, in the study by Konturek et 
al.33, all intrinsic enteric nerves between the proximal and distal segments were 
severed whereas in the Lin study, neural fibres remained intact. Thus, a neural 
mechanism connecting the distal and proximal small bowel may be responsible for the 
increase in plasma CCK-concentrations after ileal fat infusion32. Such a mechanism has 
been shown in animals for the release of Apolipoprotein A-IV (Apo A-IV), a peptide 
secreted after intestinal lipid absorption34,35. However, such a neural distal-to-
proximal mechanism involved in the secretion of CCK has never been demonstrated in 
humans. 
 
Pironi et al.10 found an increase in PYY release after ileal infusion of a small amount of 
480 mg of fat (given as FFA). In this study, the amounts of lipids administered 
correlated with release of PYY. Our results are not in line with these findings, as PYY 
release did not increase during the 3 g fat experiment but only during the 9 g infusion.  
Recently, Pilichiewicz et al.24 demonstrated that, after duodenal infusion of lipid, a 
threshold infusion rate exists for fat in order to be able to induce PYY-release. They 
demonstrated that a load of 0.25 kcal/min did not increase PYY plasma levels, 
whereas 1.5 kcal/min did24. In our study with 3 g of fat, we infused 0.6 kcal/min 
through three infusion ports, each separated from the other by 15 cm, thus 
0.2 kcal/min per infusion port. Although covering a larger area of the ileum, this 
infusion rate may result in a fat load that is below the sensing-threshold in order to 
induce PYY-release. Furthermore, the combination of a small amount of fat with a 
relatively low lipase activity in the ileum may also have limited the release of PYY after 
the low dose. 
Infusion of PYY has been shown to affect eating behavior in various animal models. A 
recent study by Batterham et al. showed an impressive reduction in food intake after 
infusion of PYY in both lean and obese human subjects36. The anorectic effect of PYY 
has been confirmed by Degen et al.37. However, in that study, the anorectic effect of 
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exogenous PYY infusion was observed only at pharmacological but not at physiological 
plasma concentrations37.  
While both 3 and 9 g of ileal fat increased satiety, PYY secretion was increased only 
during and after the high dose.  
Previous studies have suggested that the activation of the ileal brake is accompanied 
by release of the distal gut hormone PYY9,10,38. PYY is released from L-endocrine cells 
of which the high concentrations in humans are found in the distal small intestine, 
colon and rectum, with progressively more PYY producing cells when going distally in 
the gut. The most powerful stimulants for PYY release is fat, especially (triglycerides 
consisting of) long chain fatty acids, although amino acids and even carbohydrates 
have been shown to be effective. Our results therefore do not fully support the 
hypothesis that PYY is the mediator of the ‘ileal brake’. There is evidence that PYY acts 
as a paracrine agent after release by the L-cell39,a nd this may suggest that plasma 
levels do not reflect the local effects of PYY.  
 
In summary, we have shown that postprandial satiety following a liquid breakfast can 
be effectively and significantly increased by small amounts (as little as 3 g) of oil 
perfused into the ileum. This effect correlated with CCK release, but not with PYY 
release. This satiety effect deserves further evaluation in clinical setting as a factor 
that may contribute to a reduction in caloric intake and weight loss. 
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Abstract  
Introduction 
Fat induces satiety. A reduction in droplet size results in accelerated fat digestion but the effect on appetite, 
especially after ileal fat infusion, is not known. 
 
Objective 
To compare the effects of fat emulsions differing in droplet size (fine versus coarse) infused in either 
duodenum or ileum, on satiety, food intake, gastrointestinal transit and peptide (CCK, PYY) secretion. 
 
Design 
Randomized single-blind crossover study with 15 healthy volunteers (mean age 23 yrs, mean BMI 
21.6 kg/m2) who received, after intubation with a nasoileal tube, 4 different treatments on 4 consecutive 
days. After consumption of a liquid meal at t=0 min, 6 g of Fine or Coarse fat emulsion was infused into 
duodenum (t=30-90 min) or ileum (t=105-165 min). Study parameters were food intake (ad libitum lunch), 
satiety (line scales), gastrointestinal transit (breath tests), gut peptides (RIA) and statistically evaluated 
using ANCOVA with subjects as blocks and location (Duodenum, Ileum) and size (Fine,Coarse) as factors. 
 
Results 
In the duodenum, Fine emulsion significantly reduced hunger and increased fullness versus Coarse, whereas 
in the ileum no such effect was observed. After duodenal infusion, Fine emulsions significantly delayed 
gastric emptying compared to Coarse. Droplet size did not affect gut peptide secretion after duodenal 
infusion, but after ileal infusion, Fine emulsions increased both CCK and PYY significantly versus Coarse. 
Droplet size did not affect food intake (p=0.06). 
 
Conclusions 
Compared to larger fat droplets, smaller fat droplets significantly affect satiety, gastric emptying and gut 
peptide release, with the effect dependent on the intestinal location of fat delivery. 
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Introduction 
The gastrointestinal tract provides various signals that affect satiety and food intake1. 
These signals are released in response to both mechanical (distension)2,3 and chemical 
(nutrients) stimuli1. The presence of nutrients in the small intestine is sensed by 
receptors in the intestinal mucosa, and activation of these receptors induces 
activation of neural afferents or the release of gut peptides, such as cholecystokinin 
(CCK) and peptide YY (PYY). These neural and hormonal stimuli lead to an increase in 
satiety, a reduction in food intake and multiple effects on gastrointestinal (GI) 
function. 
Upon entry into the small intestine, fat has potent effects on hunger and food intake. 
Recent studies have demonstrated that addition of orlistat, a lipase inhibitor, 
abolishes the effects of fat infusion, indicating that digestion of triacylglycerols (TAG) 
to fatty acids is a crucial step for fat in order to be sensed by the small intestine and to 
influence satiety4-6. Sensing of nutrients results in satiety, reduces food intake, affects 
gut peptide secretion and also gut physiology. An increase in the sensing of fatty acids 
will affect the magnitude of these effects. Evidence for the hypothesis of dose 
dependent satiety effects by fatty acids is provided by a recent study by Armand et 
al.7, who compared the effects of an intragastric fat emulsion with different droplet 
sizes on gastric emptying. Lipase is active on the surface of a fat droplet, and smaller 
droplet size will increase total emulsion surface area, thereby allowing the rate of fat 
hydrolysis to increase (as in a state of lipase abundance in the duodenum surface area 
will become the rate-limiting step) . Indeed, Armand et al. observed that inhibition of 
gastric emptying is more pronounced after smaller droplets compared to larger fat 
droplets, suggesting an increase in fatty acid sensing. Additional evidence is provided 
by Ledeboer et al.8, who showed that reducing emulsion droplet size significantly 
increased secretion of CCK. Taken together, these studies suggest that a reduction in 
fat droplet size may increase the satiating and anorectic effects of a fat load.  
This was recently confirmed by Seimon et al.9, who demonstrated that, after duodenal 
infusion,  fat droplet size affects satiety, peptide secretion and motility. In their study, 
these authors compared a small droplet (0.26 μm) soy bean emulsion (intralipid), 
consisting mainly of di-unsaturated fatty acids, to 2 canola oil emulsions with larger 
droplets (30 μm, 170 μm) consisting mainly of mono-unsaturated fatty acids. After 
duodenal infusion, the smaller droplet-emulsion had larger effects on satiety, motility 
and peptide ecretion compared to the larger droplet-emulsions. 
The duodenum is the most extensively studied location with regard to small intestinal 
satiety mechanisms in response to nutrients. Welch et al. have demonstrated that 
entry of nutrients into the ileum also has potent effects on satiety and food intake 
through activation of the ileal brake10,11. We have previously demonstrated that the 
effects of ileal fat infusion on satiety are larger than these of fat infused into the 
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duodenum12. Furthermore, a satiating effect was already demonstrated after infusion 
of  a small amount of fat13. 
The effect of fat droplet size during ileal fat infusion on satiety and food intake and on 
peptide secretion has never been investigated. Therefore, the present study was 
designed to compare the effect of emulsions differing in droplet size on 1.) satiety and 
food intake and on 2.) GI peptide release and motility when the emulsions are infused 
into the duodenum or ileum. We hypothesize that reducing lipid droplet size will lead 
to 1. an increase in the inhibitory effect on food intake and hunger and 2. an increase 
in gut peptide secretion and gastrointestinal transit, through increased fatty acid 
sensing. 
Materials and methods 
Subjects 
Healthy volunteers aged between 18 and 55 yrs with a BMI between 18 and 32 kg/m2 
were recruited by advertisement. Restrained eaters (as assessed by the Dutch Eating 
Behaviour Questionnaire14) and subjects who reported that they were following either 
a weight-reduction diet or a medically-prescribed diet were excluded from 
participation. Subjects who were taking medication that may have influenced appetite 
and sensory function or who reported metabolic or endocrine disease, gastro-
intestinal disorders or a history of medical or surgical events that may have affected 
study outcome were also excluded. Informed consent was obtained from each 
individual, and the study protocol was approved by the local Medical Ethics 
Committee. Seventeen subjects met the inclusion criteria. Two volunteers dropped 
out during the study: one due to discomfort during catheter positioning and one due 
to failure to position the tip of the catheter beyond the ligament of Treitz (flexura 
duodenojejunalis). Fifteen healthy volunteers (12 female, mean age 23 yrs, mean BMI 
21.6 kg/m2) participated in the study and completed the protocol. 
Study design 
In this single-blind randomized controlled crossover design, 6 g of fine or coarse oil 
emulsion was administrated into the duodenum or into the ileum. The study design is 
shown in Figure 5.1. 
Protocol 
The study protocol consisted of five consecutive days. On Monday, subjects arrived at 
12:00 hr for catheter placement. The catheter for ileal intubation was a 290 cm long 
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rubber silicon 9-channel (8-lumen, 1 balloon inflation channel, diameter 3.5 mm) 
catheter custom-made by Dentsleeve International Ltd (Mississauga, Ontario, 
Canada). The functional length of the catheter was 240 cm, with a additional 50 cm 
connection segment. The catheters contained side-holes at 0, 10, 20, 30, 115, 130, 
145 and 160 cm from the tip and had an inflatable balloon (maximum inflation 
capacity 10 ml) at the distal tip. At least one of the four proximal side-holes (usually at 
145 or 160 cm) was positioned in the duodenum, and was used for the duodenal 
infusion. The three distal side-holes (0, 10, 20 cm) reaching into the ileum were used 
to administer placebo or fat emulsion in the ileum. Through an anaesthetized nostril, 
the catheter was introduced into the stomach, and allowed to pass trough the pylorus 
to the ileum by peristalsis. After passing the ligament of Treitz, a small balloon at the 
tip was inflated to facilitate passage of the catheter to the ileum. During the day, the 
subject was offered sugared tea or coffee to stimulate peristalsis. The tip was placed 
in the ileum (at least 120cm distal from Treitz). During the positioning and before 
every test-day, the position of the catheter was checked by fluoroscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Study outline for the experiment.  
 The study consisted of four treatments. Order of treatments was randomized. Each subject 
started each test day by consuming a 145 kcal fat-free liquid meal. On two of the test days, a 
duodenal fat infusion was scheduled from t=30-90 min, and on the other two test days, an 
ileal fat infusion was scheduled from t=105-165 min. Each fat infusion consisted of 6g of fat, 
and either of small droplets (fine emulsion: 0.65 micron) or large droplets (5.40 micron). 
Throughout the test day, blood was sampled for gut peptide analysis and satiety was 
measured by VAS questionnaires. Gastric emptying was measured during the duodenal 
infusion experiments by the 13C breath test. Small bowel transit time was measured by H2 
breath test. On all test days, an ad libitum meal was consumed at t=240 minutes 
Liquid meal
0 60                  120                 180           240
Duodenum-fine
Duodenum-coarse
Ileum-fine
Ileum-coarse
Lactulose H2 breath test + 13C-actetate breath test
Tr.1
Tr.2
Tr.3
Tr.4
Ad libitum meal
Self-rated satiety scores (EVAS)
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Test day (Figure.1) 
On each of the four consecutive test days, the subject arrived at the laboratory at 8:00 
hr following an overnight fast. First, correct position of the catheter was verified by 
fluoroscopy. Then, a venous catheter was placed in a forearm-vein for collection of 
blood samples. At 8:45 hr (t=-15min), a basal VAS score was taken, and at 9:00 hr a 
basal blood sample. Immediately after this (at t=0 min), the breakfast (fat free 
Slim·Fast Optima Ready To Drink (RTD): 325 ml, 145 Kcal, Unilever, Covington, TN, 
USA) was consumed within fifteen minutes. To this breakfast, 150 mg Sodium [1-C13]-
acetate was added in order to measure gastric emptying half time (T1/2).  
The duodenal infusion started 30 min after the start of the breakfast, and lasted for 60 
minutes till t=90 min. This infusion was given through the infusion port which was 
located just distal from the pylorus. The ileal infusion, which was perfused through the 
most distal infusion ports, started at t=105 min, and lasted till t=165 min. Infusion rate 
in both cases was 1 ml/min or 0.9 kcal/min. Each day either the ileum or the 
duodenum was perfused with an emulsion, consisting either of fine or coarse 
droplets. When the duodenum was perfused with emulsion, the ileum was perfused 
with saline and vice versa. Subjects were unaware of the timing and the nature of the 
infusion. 
Ten min before each fat infusion (at t=20 min for the duodenal fat infusion; at t=95 
min for the ileal fat infusion), 6 g of lactulose (Legendal, Inpharzam, Amersfoort) 
dissolved in 20-30 ml tap water was administered by syringe through the duodenal 
infusion port closest to (but located distally from) the pylorus, to enable measurement 
of the small bowel transit time. 
At 13:00 hr, t=240 min, the ad libitum-lunch was served. At 14:45 hr, the intravenous 
canula was removed, and subjects were allowed to go home. They received an 
evening meal from which they were allowed to consume freely till 22:00 hr.  
The infusion periods (t=30-90 min, t=105-165 min) were chosen to represent the 
physiologic postprandial period of maximum exposure of respectively the duodenum 
and ileum to fat15,16. Goebell et al. demonstrated that delivery of a meal marker to the 
ileum was at it maximum at 120-165 min after the meal16. We performed an 
explorative study on the timing of arrival of the low energy liquid meal (Slim·Fast) in 
the cecum and found a mean arrival time of 110 min after ingestion (data not 
published).  
Satiety  
The volunteers rated their feelings of hunger, satiety, appetite for a meal, fullness, 
appetite for a snack by means of a mark on 64-mm line scales using a EVAS (Electronic 
Visual Analogue Scale, iPAQ)17. This scale was anchored at the low end with the most 
negative or lowest intensity feelings (e.g., "extremely unpleasant", "not at all"), and 
 Fat droplet size, site of infusion and satiety⏐81 
 
with opposing terms at the high end (e.g., "extremely pleasant", "very high", 
"extreme") as described by Flint et al.18. Measurements were taken at regular 
intervals during the test day. 
Gastrointestinal disturbances (nausea, abdominal pain, bloating, heartburn, 
abdominal cramps) and general symptoms (headache, malaise, dizziness, and fatigue) 
were analysed using frequency of occurrence per time point and a standard ANOVA 
with the personal scores corrected for each subject's overall mean score. 
Food intake 
Each test day, an ad libitum-lunch was served to measure food intake. Each lunch was 
offered in excess, and consisted of 15 slices of brown bread with mature cheese. Each 
sandwich was cut in different-sized pieces, so the subject would not be able to assess 
the number of sandwiches eaten. During the ad libitum-lunch, subjects were not 
allowed to watch television, listen to the radio or read, as this could have influenced 
the amount eaten. 
Gastric emptying 
Gastric emptying was measured by 13C stable isotope breath test. The parameters 
used were gastric emptying half time (T1/2) which is the moment at which half of the 
marker has been emptied from the stomach. For this purpose, 150 mg of sodium 
[1-13C]-acetate (99%; Cambridge Isotope laboratories/ ARC Laboratories, Amsterdam) 
was added to the RTD ingested at t=0. One basal breath sample was taken at t=0 
before consuming the RTD, and subsequent samples were taken at 15 min intervals 
for the first two hours, and at 30 min intervals thereafter until t=240 min. Breath 
samples were collected using plasticized aluminium bags, and analysed by InfraRed 
ISotope analysis (IRIS, Wagner Analisen Technik, Bremen, Germany). Half time of 
gastric emptying was calculated after curve fitting using methods described by Braden 
et al.19.  
Small Bowel Transit Time  
Small bowel transit time (SBTT) measurement was performed by lactulose hydrogen 
breath analysis as described by Ledeboer et al.20. Samples of end-expiratory breath 
were taken just before administration of 6 g of lactulose and at regular intervals 
during the test day afternoon. The samples were directly analyzed using a handheld 
hydrogen breath test unit (Gastrolyzer, HoekLoos, The Netherlands). SBTT is defined 
as the time between the administration of lactulose and the onset of a sustained (in 
three consecutive readings) rise in breath H2 concentration of at least 10 parts per 
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million (ppm) above basal level. At our department the mean coefficient of variation 
for SBTT using the lactulose hydrogen breath test with 6 g lactulose is 12 %.  
Hormone assays  
Blood samples were drawn at regular intervals throughout the test day. Total plasma 
PYY was measured by radioimmunoassay as described previously21. The detection limit is 
10 pmol/l. The intra-assay variation ranges from 1.8 to 15.6% and the inter-assay 
variation from 9.5 to 27.8%21. 
Plasma CCK concentrations were measured by a RIA, as described previously22. The 
detection limit of the assay is 0.3pM. The intra-assay variation ranges from 4.6 to 
11.5% and the inter-assay variation from 11.3 to 26.1%13.  
Emulsions 
The emulsions consisted of 10% Canola oil (high oleic rapeseed oil) in water. As 
emulsifier 2.5% K-caseinate was used. A very small amount of xanthan gum (0.1%) and 
guar gum (0.1%) was used as stabiliser. Sodium chloride was added to obtain iso-
osmotic solutions (0.8% NaCl). The emulsions were standardized on a fixed oil/water 
ratio and a fixed amount of emulsifier. The variation in droplet size was obtained 
using high-shear mixers. The volume-weighted mean diameter was 0.88 micrometer 
for the fine emulsion and 15.5 micrometer for the coarse emulsion. The surface-
weighted mean diameter was 0.65 and 5.40, respectively, implying that droplet 
surface was 5.4/0.65=8.3 times larger for the fine emulsion as compared to the coarse 
one. When droplet sizes were measured after two months of storage, no change in 
droplet size was observed. Also osmolarity (262 mOsm/kg), pH (6.8) and viscosity 
(50 cP at 60 rpm at a Brookfield DVII Viscometer) were similar for both emulsions and 
this did not change after two month of storage.  
Statistical analysis 
Results are presented as least squares means with standard error (SE), unless 
otherwise specified. Satiety VAS scores were expressed as percentages of the maximal 
score (0 cm equaled 0% and 64 mm equaled 100%) and as cumulative areas under the 
curve (AUC). The AUC was calculated using the trapezoid rule. 
Where possible, parameters were analyzed using analysis of variance (ANCOVA) with 
subjects as blocks and location (duodenum/ileum) and size (fine/coarse) as factors. A 
p-value of 0.05 was considered significant. 
The timing for the duodenal (t=30-90 min after liquid meal) and ileal infusions (105-
165 min after liquid meal) was chosen as being in the physiologic range of 
postprandial exposure to intraluminal nutrients16. However, as the timing of the 
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duodenal and ileal infusions was different, this precludes a direct comparison 
between the duodenal and ileal infusion. 
Results 
The results are presented per site of fat infusion: first, results from duodenal 
infusions, then results from ileal infusions.  
Duodenum: Food intake 
In the duodenum droplet size did not significantly influence food intake (Fine vs. 
Coarse, 185 vs. 199 g, SE=7, p>0.05).  
Duodenum: Appetite 
Since the appetite parameters gave similar results, only scores for fullness and hunger 
are shown. Fullness and hunger scores for the duodenal infusions are shown in Figure 
5.2, starting from the onset of the duodenal infusions. Fasting scores of fullness and 
hunger did not differ between the two treatments (data not shown).  
During the duo-fine infusion, EVAS scores remained at the same level until at least the 
end of the infusion (t=90 min), whereas during the duo-coarse infusion, fullness scores 
started to decrease and hunger scores started to increase already during the infusion, 
and became significantly different compared to the duodenum-fine at the end of the 
infusion period (fullness t=75, 90 min; hunger: t=105 min, p<0.05).  
As shown in Figure 5.3C-D, the AUC for fullness was significantly increased for duo-
fine vs duo-coarse, whereas the difference for hunger was not statistically significant.  
Duodenum: Gastric emptying 
In the duodenum, a significant difference in gastric emptying half time (Figure 5.3) 
was HP observed between the Fine and Coarse treatment (148 vs. 129 min, SE=5, 
p<0.05).  
Duodenum: SBTT 
In the duodenum (Fine vs. Coarse, 83 vs. 84 min, SE=15, p>0.05) droplet size did not 
influence small bowel transit time.  
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Figure 5.2 Results for Fullness and Hunger after duodenal fat infusions. Duodenal infusion of either the 
fine or the coarse emulsion was scheduled from t=30-90 min. Fullness and Hunger were 
measured by EVAS (Electronic Visual Analogue Scales) and were expressed as percentages of 
the maximal score (0 cm equaled 0% and 64 mm equaled 100%). Data are LSmeans (± SEM), 
n=15, * denotes p<0.05, based on analysis by ANCOVA. 
 A. Results for fullness after the duodenal fat infusions. B. Results for fullness AUC after 
duodenal fat infusions. AUC was calculated by trapezoid rule over t=30-240 min period. C. 
Results for hunger after the duodenal fat infusions. D. Results for hunger AUC after duodenal 
fat infusions. AUC was calculated by trapezoid rule over t=30-240 min period.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Gastric emptying T1/2 in response to the duodenal infusion of either the fine or the coarse 
emulsion (30-90min). Gastric emptying was measured by the 13C acetate breath test. 150mg 
of Sodium [1-13C]-acetate was added to the liquid meal ingested at t=0, and throughout the 
test day, breath samples were collected. 
 Data are LSmeans (± SEM), n=15, * denotes p<0.001, based on analysis by ANCOVA. 
DuoCoarseDuoFine
*
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Duodenum: Gut peptides 
Plasma concentrations and AUC of CCK and PYY are given in Figure 5.4. Fasting 
concentrations of CCK and PYY did not differ between the two treatments (data not 
shown). Both infusions significantly increased plasma concentrations of CCK and PYY, 
but secretion of these peptides was not affected by the droplet size of the emulsions. 
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Figure 5.4 Results for Cholecystokinin (CCK) and peptide YY (PYY) plasma concentrations after duodenal 
fat infusion. Duodenal fat infusion of either the fine or the coarse emulsion was scheduled 
from t=30-90 min. Blood samples were collected at regular intervals throughout the test day, 
and kept on ice. CCK and PYY were measured by RIA. Data are LSmeans (± SEM), n=15. 
 A. Results for plasma CCK concentrations after the duodenal fat infusions. B. Results for CCK 
AUC after duodenal fat infusions. AUC was calculated by trapezoid rule over t=30-240 min 
period. C. Results for plasma PYY concentrations after the duodenal fat infusions. D. Results 
for PYY AUC after duodenal fat infusions. AUC was calculated by trapezoid rule over t=30-240 
min period. 
Ileum: Food intake 
In the ileum, droplet size did not significantly influence food intake (Fine vs. Coarse, 
163 vs. 174 g, SE=7, p>0.05).  
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Ileum: Appetite 
Results for hunger and fullness are given in Figure 5.5. For the ileal infusions, no 
significant differences between the two emulsions were seen for hunger and fullness.  
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Figure 5.5 Results for Fullness and Hunger after ileal fat infusions. Ileal infusion of either the fine or the 
coarse emulsion was scheduled from t=105-165 min. Fullness and Hunger were measured by 
EVAS (Electronic Visual Analogue Scales) and were expressed as percentages of the maximal 
score (0 cm equaled 0% and 64 mm equaled 100%). Data are LSmeans (± SEM), n=15. 
 A. Results for fullness after the ileal fat infusions. B. Results for fullness AUC after ileal fat 
infusions. AUC was calculated by trapezoid rule over t=105-240 min period. C. Results for 
hunger after the ileal fat infusions. D. Results for hunger AUC after ileal fat infusions. AUC was 
calculated by trapezoid rule over t=105-240 min period.  
Ileum: SBTT 
In the ileum, droplet size did not influence small bowel transit time (Fine vs. Coarse, 
133 vs. 126 min, SE=15, p>0.05).  
Ileum: Gut peptide secretion 
Plasma concentrations and AUCs for CCK and PYY are given in Figure 5.6. Fasting 
concentrations and concentrations at t=105 min (the start of infusion period) of CCK 
and PYY did not differ between the two treatments (data not shown). In the ileum, 
both CCK and PYY plasma concentrations were significantly increased during the fine 
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compared to the coarse infusion experiments. This resulted in a significantly higher 
AUC 105-240 min for CCK, whereas no significant difference were observed with 
regard to the AUC for PYY.  
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Figure 5.6 Results for Cholecystokinin (CCK) and peptide YY (PYY) plasma concentrations after ileal fat 
infusion of fine and coarse emulsions. from t=105-165 min. Blood samples were collected at 
regular intervals throughout the test day, and kept on ice. CCK and PYY were measured by 
RIA. Data are LSmeans (± SEM), n=15, * denotes p<0.005, based on analysis by ANCOVA. 
 A. Results for plasma CCK concentrations after the ileal fat infusions. B. Results for CCK AUC 
after ileal fat infusions. AUC was calculated by trapezoid rule over t=105-240 min period. C. 
Results for plasma PYY concentrations after the ileal fat infusions. D. Results for PYY AUC after 
ileal fat infusions. AUC was calculated by trapezoid rule over t=105-240 min period.  
Food intake- Overall effects 
When the data from both locations were pooled, droplet size did not significantly 
influence food intake (Fine vs. Coarse: 174 vs. 187g, SE=7, p=0.061).  
Small Bowel Transit Time- Overall effects 
Combining the data per location or per droplet size, droplet size did not affect SBTT 
(Fine vs. Coarse: 109 vs. 105 min, SE=15). 
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GI symptoms 
Droplet size did not affect gastrointestinal symptoms. 
Discussion  
In order for fat to influence satiety and food intake, gut function and gut peptide 
secretion, degradation of TAG to fatty acids and subsequent sensing of these fatty 
acids by the intestinal mucosa is required4,5. We hypothesized that reducing fat 
droplet size would increase fatty acid sensing, leading to a reduction in hunger and 
food intake. 
 
Duodenal infusion of fat reduces hunger and increases satiety, and the 
physicochemical properties of the fat present in the emulsion influence the 
magnitude of these effects23. We hypothesized that the fine emulsion would increase 
satiety and reduce hunger compared to the coarse emulsion. Indeed, the effects of 
duodenal fat infusion on satiety scores were significantly more pronounced after the 
fine compared to the coarse emulsion. The fine emulsion postponed the increase in 
hunger and the reduction in fullness observed during the coarse treatment. In the 
ileum, hunger was also reduced and fullness increased after the fine vs. coarse 
emulsion, but these differences were not statistically significant.  
 
Perceived hunger is a significant predictor of failure to lose weight24, which may 
suggest that hunger negatively influences compliance to a dieting strategy. Therefore, 
a reduction in hunger could be helpful in increasing adherence to dieting plans. 
 
Reducing fat droplet size increases the effective surface area available for hydrolysis, 
and this may lead to higher amounts of fatty acids present in the small intestine7. 
Droplet size may also influence other physicochemical properties, such as formation 
of mixed micelles or diffusion of lipids through the unstirred water layer. This may in 
turn affect exposure of epithelial receptors (such as GPR120) to fatty acids7. 
 
Neither during the duodenal nor during the ileal infusions was food intake influenced 
by the droplet size of the infused emulsion. We did observe an overall reduction in 
food intake of 7% after the fine vs. the coarse emulsion, but this difference was not 
statistically significant (p=0.061). It is well known that infusion of fat reduces food 
intake11,23, and this effect is influenced by a number of physicochemical properties of 
fat, such as fatty acid chain length25 and degree of saturation23. The lack of a 
significant effect of droplet size on food intake may be related to the interval between 
 Fat droplet size, site of infusion and satiety⏐89 
 
the infusion and the meal (135 min for the duodenal infusions, 75 min for the ileal 
infusions)26. Rolls et al. demonstrated that increasing the interval between a preload 
and the ad libitum test meal by 90 min reduced the effect of a preload on intake of 
the ad libitum meal by 14%. In our study, the longer time interval will have decreased 
the effects of the fat infusions on food intake26. One should realise that the timing of 
the infusion was aimed to represent the physiologic postprandial period of maximum 
exposure of the ileum to meal components. Several studies have demonstrated that 
exposure of the ileum to digestive products of nutrients  peaks at 120-165 min. after  
meal ingestion15,16.  
 
Duodenal infusion of fat increases plasma concentrations of both CCK and PYY. We did 
not observe an effect of droplet size on CCK release in our study when fat was infused 
in the duodenum. This may be due to the fact that at the start of the infusion, plasma 
CCK concentrations were already elevated by ingestion of the breakfast meal. 
However, when infused into the ileum, the fine emulsion significantly increased 
plasma CCK concentrations. An identical pattern was observed for PYY, although the 
integrated PYY secretion did not differ significantly between the fine and coarse 
emulsion. As CCK is considered a proximal gut peptide, release of CCK in response to 
ileal fat might not be expected to occur. However, CCK release after ileal fat infusion 
has previously been shown in humans13 and animals27. Previous work from Sjolund et 
al.28, demonstrating the presence of CCK-secreting cells in the terminal ileum supports 
these findings.  
 
Smaller fat droplet size will result in readier hydrolysis with an increased generation of 
fatty acids. In the duodenum, the amount of intraluminal lipase is abundant relative to 
the ileum. Generation of fatty acids with subsequent release of peptides is not limited 
by lipase activity, in contrast to the ileum. The observed effects after ileal infusions, 
expressed in plasma CCK-response, do suggest that not the total amount of FFA , but 
rather the rate of release of FFA is important.  
A discrepancy seems to exist between the results obtained from the duodenum and 
the ileum infusions. In the duodenum experiments, the fine emulsion increased 
satiety, but did not affect CCK or PYY secretion, whereas in the ileum experiments, no 
differences existed in satiety scores but the fine emulsion significantly increased 
secretion of both CCK and PYY. Opposing results in peptide secretion and satiety 
scores have been described previously29,30. Gut peptides act local as paracrine or 
neurocrine agents, and not only as hormones31,32. Plasma concentrations of peptides 
may therefore not truly reflect the local effects of these peptides1. Moreover, 
nutrients in the small intestine also have a direct, non-peptide-mediated effect on 
neural afferent contributing to satiety33. These intestinal signals interweave with 
signals from the stomach, and are integrated in the satiety centres in the brain34,35. 
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Gastric emptying after duodenal fat infusion was significantly affected by emulsion 
droplet size. The fine emulsion significantly delayed gastric emptying half time 
compared to the coarse emulsion, confirming the results of Armand et al.7.  
At the start of the duodenal infusions (t=30 min), most of the meal still is present in 
the stomach, whereas, at the start of the ileal infusions (t=105 min), the meal will 
have largely emptied from the stomach. A link between gastric emptying and gastric 
distension on the one hand and satiety and eating behaviour on the other has 
repeatedly been demonstrated1,2,30,36. Kissileff et al. have demonstrated that, in the 
presence of elevated plasma CCK-concentrations, additional distension of the 
stomach further reduces food intake3. During the duodenal infusions, gastric emptying 
was more delayed in the fine vs. the coarse infusion, resulting in a more pronounced 
and prolonged gastric distension. We therefore hypothesise that these differences 
have contributed to the observed differences in satiety levels.  
 
We studied the effect of reducing fat droplet size on satiety by direct infusion of 
emulsions into the small intestine. It is, however, uncertain whether these effects will 
remain when the emulsions are added to food products and then ingested orally. The 
gastric environment can affect the stability of emulsions. Marciani et al.37 for instance, 
showed that gastric stable emulsions behave differently than gastric unstable 
emulsions, and this, in turn, can influence the effects on peptide secretion and satiety 
scores38. However, in vitro and in vivo data suggest that the emulsions used in the 
current study are acid stable39, implying that the effects observed after intestinal 
infusion would mimick effects after oral or gastric infusion. However, when these 
emulsions are ingested orally, data from Armand et al. suggest that passage through 
the stomach may influence droplet size. Armand et al. observed an increase in the 
average emulsion droplet size after intragastric administration of an emulsion 
consisting of small droplets. This, however, may be a measurement artifact as it may 
very well be the result of rapid hydrolysis of the smaller fat droplets (and thus 
measurement of the remaining bigger droplets).  
 
In conclusion, we have demonstrated that, compared to larger fat droplets, smaller fat 
droplets significantly affect satiety, gastric emptying and gut peptide release, with the 
effect dependent on the intestinal site of fat delivery. Thus, fat droplet size, through 
influencing fatty acid sensing, is relevant for satiety signalling and regulation of GI 
function and secretion. 
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Abstract  
Background 
Background: Ileal delivery of fat reduces hunger and food intake through activation of the ileal brake. 
Physicochemical properties of fat have been shown to affect satiety and food intake. 
 
Objective 
The objective of this study was to assess the effect of ileal fat emulsions with differing degrees of fatty acid 
saturation on satiety, food intake and gut peptides (CCK, PYY). We hypothesized that long-chain 
triacylglycerols (LCT) with diunsaturated fatty acids would increase satiety and reduce energy intake 
compared to LCT with monounsaturated or saturated fatty acids. 
 
Design 
We performed a double-blind randomized cross-over study in which fifteen healthy subjects (mean age: 24 
yrs, mean BMI 22 kg/m2) were intubated with a naso-ileal catheter and participated in four experiments 
performed in random order on four consecutive days. After consumption of a liquid meal, subjects received 
fat or control infusion in the ileum. Fat emulsions consisted of 6 gram of either C18:0 (Shea oil; mainly 
C18:0), C18:1 (Canola oil; mainly C18:1) or C18:2 oil (Safflower oil; mainly C18:2). Food intake was measured 
during an ad-libitum lunch. Satiety questionnaires (VAS) and blood samples were collected at regular 
intervals. 
 
Results 
Compared to control, only C18:2 and C18:1 significantly increased fullness and reduced hunger. No effect 
on food intake was observed. C18:1 and C18:2 increased CCK secretion significantly compared to control. 
Fatty acid saturation did not affect PYY secretion. 
 
Conclusions 
When infused into the ileum, TAG with unsaturated fatty acids increases satiety compared to control, 
whereas TAG with saturated fatty acids does not. 
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Introduction 
Fat in the gastrointestinal tract reduces hunger and impairs food intake by eliciting 
satiety signals1. These signals are evoked by entry of triacylglycerols (TAG; after 
hydrolysation to fatty acids) or fatty acids (FA) into the small intestine. Duodenal fat 
induces release of CCK and other gastrointestinal peptides, involved in the regulation 
of satiety and food intake1. When infused into the ileum, fat also increases satiety and 
reduces food intake2. Studies in both animals3,4 and humans1,5 suggest that the 
satiating effect of fat from the ileum is even larger compared to the effect of fat from 
the duodenum. Infusion of fat into the ileum activates the ileal brake mechanism6, an 
inhibitory distal to proximal feedback mechanism that regulates the transit and 
handling of a meal through the digestive tract in order to optimize nutrient digestion 
and absorption7. 
 
The satiating effect of fat is dependent on its physicochemical properties8,9. For 
instance, reduction of hunger and food intake increases with increasing fatty acid 
chain length8. Feltrin et al.8 demonstrated that reduction in energy intake and in 
hunger was stronger after isocaloric infusion of Lauric acid (C12) versus Decanoic acid 
(C10).  
Apart from FA chain length, another physicochemical property of fat that may affect 
hunger and food intake is the degree of fatty acid saturation. The effect of fatty acid 
saturation on ileal brake mediated satiety is not known, but data are available on oral 
and duodenal administration of fats differing in fatty acid saturation. Lawton et al.10 
demonstrated that oral ingestion of TAG with unsaturated FAs induced a greater 
reduction in food intake than TAG with saturated FAs. However, Flint et al.11 and 
Alfenas and Mattes12 did not find such a difference on food intake or satiety. 
French et al.9 measured food intake and satiety following various intraduodenally 
infused fat emulsions. Emulsions enriched with linoleic acid (c18:2) reduced food 
intake more than oleic (c18:1) or stearic (c18:0) acid without affecting satiety. 
Entry of fat into the small intestine induces release of gut peptides (CCK, PYY), and 
secretion of these peptides is (partly) responsible for the effects of fat on satiety and 
food intake1. 
Aim of the present study was to assess the effect of ileal fat emulsions with differing 
degrees of saturation of fatty acid chains on 1. satiety and food intake and 2. secretion 
of peptides known to affect satiety (CCK, PYY). We hypothesized that long-chain 
triglyceride (LCT) emulsions with di-unsaturated fatty acids will enhance postprandial 
satiety and reduce energy intake compared to LCT emulsions with mono-unsaturated 
or saturated fatty acids. 
98⏐Chapter 6 
 
Materials and method 
Subjects 
Healthy volunteers aged between 18 and 55 yrs with a BMI between 18 and 32 kg/m2 
were recruited by advertisement. Restrained eaters (as assessed by the Dutch eating 
behaviour questionnaire) and subjects who reported that they were following either a 
weight-reduction diet or a medically-prescribed diet were excluded from partici-
pation. Subjects who were taking medication that may have influenced appetite and 
sensory function or who reported metabolic or endocrine disease, gastrointestinal 
disorders or a history of medical or surgical events that may have affected study 
outcome were also excluded. Informed consent was obtained from each individual. 
The study protocol had been approved by the Medical Ethics Committee of the Leiden 
University Medical Centre, and procedures followed were in accordance with the 
ethical standards of the institution on human experimentation. This study has been 
registered (ISRCTN51742545), and subject recruitment started in September 2005. 
Eighteen subjects met the inclusion criteria. Three volunteers dropped out during the 
study: one due to discomfort during catheter positioning and two due to failure to 
position the tip of the catheter beyond the ligament of Treitz (flexura 
duodenojejunalis). Fifteen healthy volunteers (13 female, mean age 24 yrs, mean BMI 
22 kg/m2) participated in the study and completed the protocol.  
Catheters 
The catheter for ileal intubation was a 290 cm long rubber silicon 9-channel (8-lumen, 
1 balloon inflation channel, diameter 3.5 mm) catheter custom-made by Dentsleeve 
International Ltd (Mississauga, Ontario, Canada). The functional length of the catheter 
was 240 cm; there was a 50 cm connection segment. The catheters contained side-
holes at 80, 95, 110, 125, 210, 220, 230 and 240 cm from the proximal junction and 
had an inflatable balloon (maximum inflation capacity 10 ml) at the distal tip. The 
three distal side-holes (220, 230, 240 cm) reaching into the ileum were used to 
administer placebo or fat emulsion.  
Experimental protocol 
In this double blind placebo controlled crossover design, four different perfusions 
were scheduled: 1. saline (control) or a 6 g fat emulsion consisting either of 2. mainly 
unsaturated fats (C18:0), 3. mainly mono-unsaturated fat (C18:1) or 4. mainly di-
unsaturated fat (C18:2) was administered into the ileum. (See Table 6.1. for details on 
fatty acid composition of the different emulsions.)  
 Ileal brake: Fat saturation affects hunger, hormone release⏐99 
 
Table 6.1 Fatty acid composition of the emulsions. 
 Overall fatty acid comp. sn-1,3 fatty acid comp. 
 C18:0 C18:1 C18:2 C18:0 C18:1 C18:2 
Shea 59% 32%   4% 83%   7%   5% 
Canola   2% 76% 12%   2% 77%   7% 
Safflower   2% 12% 76%   3% 12% 72% 
Percentage fatty acid composition for the different emulsions used in this study, specified for all three fatty 
acid positions, and for the sn-1, 3 positions. 
Catheter positioning 
On Monday, subjects arrived at 12:00 hr after a light breakfast (ingested before 09:00 
AM). Through an anaesthetized nostril, the catheter was introduced into the stomach, 
and allowed to pass through the pylorus to the ileum by peristalsis. After passing the 
ligament of Treitz, a small balloon at the tip was inflated to facilitate passage of the 
catheter to the ileum. During the day, the subject was offered small snacks and 
sugared tea or coffee to stimulate peristalsis. The tip was placed in the ileum (at least 
120 cm distal from the pylorus13), so 3 infusion ports were available in the ileum. In 
our study, we perfused the ileum at at least 175-195 cm from the nose. During the 
positioning and before every test-day, the position of the catheter was checked 
fluoroscopically. 
Test day 
On each study day, the subject arrived at the GI unit at 8:00 AM following an overnight 
fast. After checking the position of the catheter, a venous catheter was placed in a 
forearm-vein for collection of blood samples. At 8:45 hr, a basal VAS score and a basal 
blood sample were taken. After this, the experiment was started. At 9:00 hr (t=0 min), 
a fat-free liquid meal was ingested. 
The ileal infusion started at t=105 min. Infusion rate was 1 ml/min (0.9 kcal/min) for 
60 min. Each day the ileum was perfused with a fat emulsion or the fat-free emulsion. 
The three most distal catheter ports were used for this perfusion, so the emulsion was 
spread out over a length of 30 cm. 
At 13:00 hr (t=240 min) the ad libitum lunch was served. At 14:45 hr, the intravenous 
canula was removed, and subjects were allowed to go home. They received an 
evening meal and snackbox from which they were allowed to consume freely till 
22:00 hr. 
Satiety  
Scores for satiety feelings (fullness, hunger, prospective feeding, desire to eat a meal, 
desire to eat a snack) was measured using electronic Visual Analogue Scales (EVAS) 
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anchored at the low end with the most negative or lowest intensity feelings (e.g., 
extremely unpleasant, not at all), and with opposing terms at the high end (e.g., 
extremely pleasant, very high, extreme)14. Volunteers were asked to indicate on a line 
which place on the scale best reflects their feeling at that moment. Measurements 
were taken during the test day every 30 min, and every 15 min during infusion of 
emulsion. 
Food intake 
Each test day, an ad libitum-lunch was served to measure food intake. Each lunch was 
offered in excess, and consisted of 15 equal slices of brown bread with mature cheese 
(48% fat). Each sandwich was cut in different-sized pieces, so the subject would not be 
able to assess to number of sandwiches eaten. During the ad libitum-lunch, subjects 
were not allowed to watch television, listen to the radio or read books as this could 
have influenced the amount eaten.  
Liquid meal 
As breakfast, subjects received a fat-free Slim·Fast Optima drink (Slim-Fast Foods, 
West Palm Beach, FL; 325 ml, 145 kcal). These are vitamin- and mineral-fortified meal 
replacement products, used by consumers primarily in order to aid in weight loss 
and/or prevention of weight gain. 
Emulsions 
The emulsions consisted of 10% oil in water. As an emulsifier 2.5% K-caseinate was 
used. A very small amount of xanthan gum (0.1%) and guar gum (0.1%) was used as a 
stabiliser. Sodium chloride was added to obtain iso-osmotic solutions (0.8% NaCl). See 
Table 6.1. for fatty acid composition of the emulsions. Total infused volume was 
60 ml, containing 6 g fat. Caloric load was 54 kcal. The pH of the emulsions ranged 
from 6.7 till 6.8. 
Hormone assays 
Blood samples were drawn at regular intervals throughout the test day. After 
collection, the blood was kept on ice. PYY (total) and CCK were measured by sensitive 
and specific radioimmunoassays, as described previously15,16. 
Statistical analysis 
Results are presented as least squares means with standard error of the mean (SEM), 
unless otherwise specified. Satiety VAS scores were expressed as percentages of the 
  
maximal score (0 cm equaled 0% and 6,4 cm equaled 100%) and as incremental 
cumulative areas under the curve, with the value at t=105 min, the starting point of 
the infusion, as a covariate. The incremental AUC was calculated, using the trapezoid 
rule, with the beginning of the infusion period, t=105 min, as a covariate. 
All parameters were analyzed using analysis of variance with subjects as blocks and 
treatment as factor. Differences of the treatment groups from the control were 
established using Dunnett least significant difference test (two-tailed). A p-value of 
0.05 was considered significant. When a significant time x treatment interaction was 
present, differences at individual time points are reported. 
Results 
Satiety parameters 
As results from all satiety parameters are similar and consistent, we will only show 
scores for fullness and hunger. Mean VAS scores for hunger are given in Figure 6.1A 
and for fullness in Figure 6.2A. Fasting scores for hunger and fullness did not differ 
between the four treatments. Consumption of the liquid meal led to a decrease in 
hunger feelings and an increase in fullness in all four treatments. 
The AUCs for hunger for the t=105-240 min period for both canola and safflower 
differed significantly from control (Figure 6.1B). Over the test day (0-240 min), both 
canola and safflower resulted in lower AUCs for hunger compared to control. The 
AUCs for fullness for the t=105-240 min period for both canola and safflower differ 
significantly from control (Figure 6.2B). 
Food intake 
Food intake did not differ significantly between treatments (control 180 g, shea 173 g, 
canola 167 g, and safflower 189 g, SE=10).  
CCK 
Plasma CCK-concentrations are shown in Figure 6.3A. Baseline plasma CCK 
concentrations did not differ between study days. The liquid meal induced an increase 
in CCK-concentrations in all four treatments. The infusion significantly increased 
plasma CCK concentrations after canola oil (t=135, t=150 min) and safflower oil 
(t=150, t=165 min) compared to control. For the period t=105-t=240 min, the AUCs 
(Figure 6.3B) for canola and safflower were significantly greater as compared to 
control, whereas no overall difference in CCK AUCs for the entire period (t=0-240 min) 
was observed between treatments.  
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Figure 6.1 Results for hunger in response to the liquid meal and ileal infusion of shea oil (18:0), canola oil 
(18:1) safllower oil (C18:2) or control. The infusion period was scheduled from t=105-165 min. 
Fullness and Hunger was measured by EVAS (Electronic Visual Analogue Scales) and was 
expressed as percentage of the maximal score (0 cm equaled 0% and 64 mm equaled 100%).  
 A. EVAS scores for hunger. † denotes p<0.05 for shea vs. saline, ‡ denotes p<0.05 canola and 
safflower vs.saline. Data are means (± SEM), n=15, based on analysis by Dunnett. B. Area 
under the curve (AUC) for hunger. AUC was calculated by trapezoid rule over t=105-240 min 
period. Data are means (± SEM), n=15, * denotes p<0.05 based on analysis by Dunnett.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Results for fullness in response to the liquid meal and ileal infusion of shea oil (18:0), canola 
oil (18:1) safllower oil (C18:2) or control. The infusion period was scheduled from t=105-165 
min. Fullness and Hunger was measured by EVAS (Electronic Visual Analogue Scales) and was 
expressed as percentage of the maximal score (0 cm equaled 0% and 64 mm equaled 100%). 
 A. EVAS scores for fullness. ‡ denotes p<0.05 canola and safflower vs. saline. Data are means 
(± SEM), n=15, based on analysis by Dunnett.B. Area under the curve (AUC) for fullness. AUC 
was calculated by trapezoid rule over t=105-240 min period. Data are means (± SEM), n=15, * 
denotes p<0.05 based on analysis by Dunnett.  
PYY 
Plasma PYY-concentrations are given in Figure 6.4A. Baseline plasma PYY 
concentrations did not differ between study days. The liquid meal induced a slight 
increase in PYY-concentrations in all 4 treatments. The start of the infusion induced an 
 T=0-240min  T=105-240min 
A                                                                              B 
 T=0-240min  T=105-240min 
A                                                                              B 
  
increase in plasma PYY concentrations after all fat emulsions compared to control. For 
the t=105-t=240 min and t=0-240 min period, AUCs (Figure 6.4B) were statistically 
increased for all fat emulsions compared to control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Plasma concentrations and AUC of Cholecystokinin (CCK) in response to the liquid meal and 
ileal infusion of shea oil (18:0), canola oil (18:1) safllower oil (C18:2) or control. The infusion 
period was scheduled from t=105-165 min. Blood samples were collected at regular intervals 
throughout the test day, and kept on ice. CCK was measured by RIA. A. Plasma concentrations 
of CCK. Data are means (± SEM), n=15, ‡ denotes p<0.05 canola and safflower vs. saline, 
based on analysis by Dunnett. B. Area under the curve (AUC) of CCK. AUC was calculated by 
trapezoid rule over t=105-240 min period. Data are means (± SEM), n=15, * denotes p<0.05 
based on analysis by Dunnett.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Plasma concentrations and AUC of Peptide YY (PYY) in response to the liquid meal and ileal 
infusion of shea oil (18:0), canola oil (18:1) safllower oil (C18:2) or control. The infusion period 
was scheduled from t=105-165 min. Blood samples were collected at regular intervals 
throughout the test day, and kept on ice. PYY  was measured by RIA. A. Plasma concentrations 
of PYY. Data are means (± SEM), n=15, † denotes p<0.05 for shea vs. saline, ‡ denotes p<0.05 
canola vs. saline, a denotes p<0.05 for safflower vs. saline, based on analysis by Dunnett. 
 B. Area under the curve (AUC) of PYY. AUC was calculated by trapezoid rule over t=105-240 
min period. Data are means (± SEM), n=15, * denotes p<0.05 based on analysis by Dunnett.  
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Discussion 
We have demonstrated that the degree of fatty acid saturation of triacylglycerols 
infused into the ileum affects satiety levels and release of CCK but not food intake. 
Neither did the degree of fatty acid saturation affect PYY release. 
 
Intraduodenal infusion of fat reduces hunger and increases satiety17, and 
physicochemical properties of fat (such as chain length) affect its satiating potency8,9. 
Evidence exists that the degree of fatty acid saturation affects the satiating effect of 
fat10, but this has not been consistently demonstrated9,11,12. While it has been shown 
that ileal infusion of fat reduced hunger and food intake2, the effect of differences in 
fatty acid saturation on ileal fat induced satiety has never been tested. In the present 
study, both TAGs with unsaturated fatty acids reduced hunger and increased fullness 
significantly compared to the saline control infusion, whereas shea oil, consisting of 
saturated fatty acids, did not. This clearly demonstrates that ileal brake-mediated 
satiety is most potently stimulated by oils containing high amounts of unsaturated 
fatty acids. 
The anorectic effect of intestinal fat when infused in the duodenum and in the ileum 
has been demonstrated repeatedly and consistently2,9,18. French et al. observed an 
effect of fatty acid saturation on food intake after duodenal fat infusion9. We 
observed that the different fat emulsions affected satiety, but did not affect food 
intake. In the study by French et al.9 and Welch et al.2 the ad libitum meal was 
provided already during the infusion. In our study, the interval between the end of the 
infusion and the start of the ad libitum lunch was 75 minutes. Rolls et al. 
demonstrated that the time-interval between a caloric load and an ad libitum meal 
affects meal intake19. We hypothesise that the longer interval between infusion and 
lunch (75 min) may have affected the results and may explain the lack of effect of the 
treatments (fat infusion) on food intake, and a significant effect on food intake may 
have been present if we had measured food intake at an earlier point in the test day. 
The finding that at t=240 min the significant differences between the treatments in 
satiety scores had disappeared provides evidence to support this hypothesis. When 
studying eating behaviour and satiety scores, a distinction should be made between 
satiation, the processes that lead to the termination of a meal, and satiety, which 
refers to postprandial events that affect the time interval to the next meal. Satiety 
regulates meal frequency and food intake during a next meal, in which learned habits 
also play a role1. In the studies by French et al.9 and by Welch et al.2,18, food intake 
was measured during the infusion and the parameter studied therefore was satiation. 
During our study, we studied the effects between meals, and have focused on satiety.  
 
  
Entry of fat into the small intestine induces release of CCK1. Beardshall et al.20 found 
that ingestion of a meal high in monounsaturated fat resulted in significantly higher 
plasma CCK concentrations compared to a saturated fat meal. In our study, both 
canola and safflower oil significantly increased plasma CCK concentrations compared 
to the saline infusion, whereas shea oil had no significant effect. Release of CCK after 
ileal fat infusion was not anticipated. However, release of CCK in response to ileal fat 
infusions has been described21. In general, secretion of CCK is thought to be confined 
to the duodenum and jejunum. Sjolund et al.22, as well as others23 have demonstrated 
the presence of CCK-secreting I-cells in the (terminal) ileum. However, the number of 
CCK cells was smaller in the ileum compared to the duodenum or jejunum22. In a 
previous study5, we compared secretion of CCK after isocaloric infusion of fat into the 
duodenum and ileum, and found that both infusions increased secretion of CCK, 
although CCK secretion was more potently stimulated after duodenal compared to 
ileal fat infusion.  
We can exclude that incorrect positioning of the catheter has affected CCK-release. 
Both during the positioning of the catheter and each test day at the start and end of 
the procedure, the position of the catheter was checked fluoroscopically to ascertain 
placement of the tip of the catheter in the ileum. A full 22 hours period was used for 
positioning of the catheter. Subjects were routinely instructed to assist passage and 
aboral progression of the catheter at home. Furthermore, in 3 cases, contrast fluid 
was used to ascertain position of the catheter. After infusion of the contrast fluid, the 
contrast appeared in the colon within a few minutes. 
 
TAGs are hydrolyzed in the proximal GI tract to fatty acids and monoacylglycerols24. 
Hydrolysis is necessary in order to induce the effects of fat on gastrointestinal 
function, hormone release and satiety25,26. Fatty acids are incorporated in micelles, 
and transported to the surface of epithelial cells24, where sensing and subsequent 
absorption of fatty acids occurs27. As the ease of micelle formation increases with the 
degree of fat unsaturation28, unsaturated fatty acids are more readily available for 
sensing and absorption, leading to increased satiety and hormone release27. Jones et 
al.29 demonstrated that after oral ingestion of labelled fatty acids, significantly more 
stearic acid (saturated) was found in stool as compared to oleic acid (unsaturated). 
This is probably due to an increased ability of saturated fatty acids to interact with 
calcium, resulting in the formation of insoluble calcium–fatty acid soaps and increased 
faecal excretion30. Both mechanisms (micelle formation, calcium binding) may be 
involved in the differences in satiety and CCK-release observed in our study. However, 
Recent studies demonstrate that the ‘metabolisation’ of saturated and unsaturated 
fats occurs roughly at the same rate, and differences in plasma peaks are caused more 
by the sn-structure, and not by the degree of saturation/unsaturation {486}. 
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In the present study, all fat emulsions induced a significant increase in PYY-secretion 
compared to the saline infusion, without differences between the fat emulsions. With 
respect to GI peptides, both CCK and PYY are considered satiety signals. Infusion of 
CCK reduces food intake during a meal17. The reduction in hunger observed after fat 
infusion can be abolished by a CCK receptor antagonist17, pointing to a role for CCK in 
the physiologic regulation of eating behaviour. Batterham et al.31,32 demonstrated that 
infusion of PYY reduced food intake in both animals and humans. Whether PYY is 
involved in the physiological regulation of food intake is still object of debate33. In 
animals, this debate has been resolved: although many studies failed to confirm the 
results of Batterham et al.33, adequate habituation and acclimatisation of animals 
proved to be essential in these studies, and PYY is considered to be a physiologic 
satiety signal34.  
We have previously performed a study in human subjects in order to examine 
whether the satiating effect of ileal brake activation was mediated by PYY. At plasma 
PYY-concentrations that were similar after intravenous PYY infusion and after ileal fat 
infusion, the effects on satiety after the intestinal fat infusion were much more 
pronounced35. From that study, we concluded that the satiating effect of the ileal 
brake is not solely mediated by PYY. From the current study, as from previous 
studies36, we hypothesise that a role for CCK in ileal brake-mediated satiety should be 
considered. However, other peptides may also be involved. Release of GLP-1, a gut 
peptide released from L-cells that predominate in the distal small intestine and colon 
has been shown to increase after a monounsaturated fat-rich compared to saturated 
fat-rich meal37, and a reduction in both hunger and food intake has been 
demonstrated after GLP-1 infusion1. In animals, Kalogeris et al.38 have demonstrated 
that, compared to saturated fatty acids, unsaturated fatty acids increased  lymphatic 
outflow of Apo A-IV, a chylomicron particle that has been shown to reduce food 
intake in rats39, significantly.  
In conclusion, when infused into the ileum, TAG with unsaturated fatty acids increases 
satiety compared to control whereas TAG with saturated fatty acids does not 
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Abstract  
Objective 
In both the duodenum and ileum, exposure of the luminal wall to nutrients activates a negative feedback 
mechanism. This duodenal and ileal brake are known to reduce appetite and food intake, and to inhibit 
gastric emptying and small bowel transit. In this study we compared the effects of duodenal vs. ileal fat 
infusion on satiety, food intake, gastrointestinal transit and peptide release. Furthermore, we studied 
whether the timing of the infusions relative to a previous meal influences these effects. 
 
Design 
Randomized single-blind cross over study. 
 
Subjects 
15 healthy female volunteers (mean age 23 yrs, mean BMI 22kg/m2). 
 
Intervention 
Subjects were intubated with a 290 cm long nasoileal tube. Through this tube, subjects received an 
infusion of 6g fat either in the Duodenum or in the Ileum. This infusion was given in the Early (30-90 min 
after ingestion of breakfast) or in the Late (105-165 min after breakfast) postprandial phase. 
 
Measurements 
Appetite parameters, food intake, gastric emptying, small bowel transit time and plasma concentrations of 
CCK and PYY. 
 
Results 
Compared to Duo-Early, Ileum-Early significantly reduced appetite and increased fullness, and delayed 
gastric emptying and small bowel transit. Food intake did not differ between treatments. CCK-secretion was 
higher after Duo-Early vs Ileum-Early, whereas PYY was increased after Ileum-Early vs. Duo-Early at one time 
point.  
In the Late postprandial phase, no differences existed between these parameters.  
The effects of ileal fat on appetite were larger in the Early vs. the Late postprandial phase. 
 
Conclusions 
The effects of fat infusion are more potent in the distal compared to the proximal small intestine, 
particularly in the early postprandial phase. 
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Introduction 
The gastrointestinal tract is an importance source for signals that influence appetite 
and food intake1,2. Traditionally, appetite signals arising from the stomach are 
triggered by mechanical stimuli3-5, whereas signals from the intestine are evoked by 
chemical or nutritional stimuli5. After ingestion of a meal, these gastric and intestinal 
signals interact to terminate food intake (satiation) and influence between-meal 
satiety2. This interaction was demonstrated by Oesch et al., who showed that infusion 
of nutrients into the duodenum lowered the threshold at which a gastric distension 
reduces hunger6, confirming earlier results by Matzinger et al.7. In animals, a 
synergistic effect of gastric and intestinal stimuli on food intake has also been 
reported5.  
 
It has been suggested that within the small intestine, differences may exist in the 
relative potency of  segments of the small intestine to reduce food intake and 
hunger8. Most human studies have focused on the effects of duodenal nutrient 
infusions on satiety and food intake. Evidence for the effects of infusion of nutrients 
into the ileum on satiety and food intake comes from two types of studies. First, 
studies with  ileal perfusion of fat using catheters and second, studies on surgical 
procedures that result in increased exposure of the ileum to nutrients.  
Welch et al. were the first to demonstrate a reduction in food intake after ileal fat 
infusion9. More recent, we compared ileal fat infusion to oral fat ingestion, and 
demonstrated that ileal fat infusion reduced hunger significantly compared to oral 
fat10. In animals, several  studies have been performed comparing the effects of 
duodenal and ileal nutrient infusions on food intake. From these studies it can be 
concluded that 1) infusion of nutrients into the ileum does reduce food intake, 2). the 
surface area over which nutrients are spread plays an important role in the magnitude 
of food intake reduction, and 3). when comparing nutrients that are absorbed rapidly 
(and spread over only a small intestinal segment) the inhibitory effect of ileal 
nutrients is at least equal and presumably larger than the effect of the same nutrients 
infused into the duodenum11-14. 
An interesting model for increased ileal exposure to nutrients is ileal transposition. In 
this surgical procedure, a segment of ileum is resected with preservation of vascular 
and neuronal innervations, and anastomosed to the duodenum or proximal jejunum. 
In rats, Koopmans et al. compared an ileal transposition group to a group of rats in 
which a segment of ileum was resected and reattached in the same location15-17. In 
regular feeding conditions, the ileal transposition group reduced food intake by 20 
and 40%, dependent of the length of the transposed segment. 
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These studies clearly demonstrate that, at least in animals, increased exposure of the 
ileum to nutrients reduces food intake. However, in humans, the relative potency of 
the duodenum and the ileum to reduce food intake has never been compared. 
 
Therefore, the aims of this study were 1. to compare the effects of small amounts of 
fat infused either in the duodenum vs. the ileum on postprandial satiety and on food 
intake, gastrointestinal transit and hormone release, and 2. to test whether timing of 
the infusions relative to a previous meal (early or late) influences these effects. 
Cholecystokinin (CCK) and peptide YY (PYY) were measured as proximal and distal 
regulatory peptides. 
Materials and method 
Subjects 
Healthy volunteers aged between 18 and 55 yrs with a BMI between 18 and 32 kg/m2 
were recruited by advertisement. Restrained eaters (as assessed by the Dutch Eating 
Behaviour Questionnaire18) and subjects who reported that they were following either 
a weight-reduction diet or a medically-prescribed diet were excluded from 
participation. Subjects who were taking medication that may have influenced appetite 
and sensory function or who reported metabolic or endocrine disease, 
gastrointestinal disorders or a history of medical or surgical events that may have 
affected study outcome were also excluded. Informed consent was obtained from 
each individual, and the study protocol was approved by the Medical Ethics 
Committee of the Leiden University Medical Centre. Seventeen subjects met the 
inclusion criteria. Two volunteers dropped out during the study: one due to 
discomfort during catheter positioning and one due to failure to position the tip of the 
catheter beyond the ligament of Treitz (flexura duodenojejunalis). Fifteen healthy 
females (mean age 23yrs, mean BMI 22 kg/m2) participated in the study and 
completed the protocol. 
Study design 
In this single-blind randomized controlled crossover design, 6 g fat was administered 
into the duodenum or into the ileum either in the early or late postprandial phase 
after breakfast. The study design is shown in Figure 7.1. 
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Figure 7.1 Study outline for the four experiments. Order of treatments was randomized. Each subject 
consumed a liquid breakfast at t=0 min. Infusion of 6g of fat was scheduled in the early 
postprandial phase (t=30-90 min) or in the late postprandial phase (t=105-165). The location 
of the infusion was either in the duodenum or in the ileum. Satiety questionnaires and blood 
samples were collected at regular intervals. 
Protocol 
The study protocol consisted of five consecutive days. On Monday, subjects arrived at 
the laboratory at 12:00 hr for catheter placement. The catheter for duodeno-ileal 
intubation was a 290 cm long rubber silicon 9-channel (8-lumen, 1 balloon inflation 
channel, diameter 3.5 mm) catheter custom-made by Dentsleeve International Ltd 
(Mississauga, Ontario, Canada). Through an anaesthetized nostril, the catheter was 
introduced into the stomach and allowed to pass through the pylorus to the ileum by 
peristalsis. After passing the ligament of Treitz, a small balloon at the tip was inflated 
to facilitate passage of the catheter to the ileum. During the day, the subject was 
offered small snacks to stimulate peristalsis. The tip was placed in the ileum (at least 
120cm distal from the pylorus). The catheter was fitted with radiopaque markers, 
which allowed for assessing the position of the catheter during and after the 
positioning procedure by fluoroscopy. Before every test-day, the position of the 
catheter was checked by fluoroscopy. 
Test day (Figure 7.1) 
On each of the four consecutive test days, the subject arrived at the laboratory of the 
Gastroenterology department at 8:00 hr following an overnight fast. First, correct 
position of the catheter was verified by fluoroscopy. Then, a venous catheter was 
placed in a forearm-vein for collection of blood samples. At 8:45 hr (t=-15 min), 
appetite ratings were scored, and at 9:00 hr a basal blood sample was taken. 
Immediately after this (at t=0 min), a breakfast (fat free Slim·Fast Optima Ready To 
Drink meal replacer; Unilever, Vlaardingen, The Netherlands: 325 ml, 145 Kcal) was 
consumed within fifteen minutes. To this breakfast, 150 mg Sodium [1-C13]-acetate 
was added in order to measure gastric emptying half time (T1/2). 
Time (minutes)
0 60 120 180 240
Early 
infusion
Liquid meal          
(180 kcal)
Late  
infusion
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The early infusion started at t=30 min, and lasted for 60 minutes. The late infusion 
started at t=105 min, and lasted till t=165 min. These periods of infusion were chosen 
as they mimic the physiological period of maximum postprandial duodenal and ileal 
nutrient exposure, respectively19,20. Infusion rate in all cases was 1 ml/min or 
0.9 kcal/min. Each day either the ileum (through the most distal infusion port) or the 
duodenum (through the infusion port which was located just distal from the pylorus) 
was perfused with an emulsion. Subjects were unaware of the timing and the location 
of the infusion. 
Ten min before each fat infusion (at t=20 min for the early fat infusion; at t=95 min for 
the late fat infusion), 6 g of lactulose was administered to enable measurement of the 
small bowel transit time. 
At t=240 min, an ad libitum lunch was served. At t=345 min, the intravenous canula 
was removed, and subjects were allowed to go home. They received an evening meal 
from which they were allowed to consume freely till 22:00 hr.  
Fat emulsion 
The emulsions consisted of 10% high oleic rapeseed oil in water. As an emulsifier 2.5% 
K-caseinate was used. A very small amount of xanthan gum (0.1%) and guar gum 
(0.1%) was used as a stabiliser. Sodium chloride (0.8% NaCl) was added to obtain iso-
osmotic solutions. Total emulsion volume infused per test day was 60 ml. 
Appetite ratings  
The volunteers rated their appetite feelings (appetite for a snack, appetite for a meal, 
fullness, hunger, how much do you want to eat) by means of a mark on 64-mm line 
scales using an Electronic Visual Analogue Scale (EVAS) on a hand-held computer 
(iPAQ21). This scale was anchored at the low end with the most negative or lowest 
intensity feelings (e.g., "not at all"), and with opposing terms at the high end 
(e.g.,"very high") as described by Flint et al.22. EVAS scores were collected at t=-15, 0, 
30, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210 and 240 minutes. 
Gastrointestinal symptoms (nausea, abdominal pain, bloating, heartburn, abdominal 
cramps, headache, fatigue) were scored every two hours. The questions were related 
to symptoms that the volunteers possibly experienced during the last hour. Ratings 
were made on 4-point scale (0=not, 1=mild, 2=moderate, 3=severe) on the handheld 
computer. 
Food intake 
Each test day, an ad libitum-lunch was served to measure food intake. The lunch was 
scheduled at t=240 min. The maximum lunch time was set at 30 minutes. Each lunch 
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was offered in excess, and consisted of 1500 g macaroni pasta (per 100 g: 430 kJ, 
5 g protein, 2 g fat, 16 g carbohydrates). During lunch, subjects were alone and were 
not allowed to watch television, listen to the radio or read. 
Gastric emptying 
Gastric emptying half time (T1/2) was measured by 
13C stable isotope breath test. For 
this purpose, 150 mg of sodium [1-13C]-acetate (99%; Cambridge Isotope laboratories/ 
ARC Laboratories, Amsterdam) was added to the breakfast ingested at t=0. Breath 
samples were taken at regular intervals over a 240 min period according to a standard 
protocol and analysed by InfraRed ISotope analysis (IRIS, Wagner Analisen Technik, 
Bremen, Germany). Gastric emptying T1/2 was calculated after curve fitting using 
methods described by Braden et al.23. Gastric emptying T1/2 was assessed only for the 
early infusions, as the late infusions were scheduled too late to influence T1/2. 
Small Bowel Transit Time  
Small bowel transit time (SBTT) measurement was performed by lactulose hydrogen 
breath analysis as described by Ledeboer et al.24. Six grams of lactulose (Legendal, 
Inpharzam, Amersfoort) was dissolved in 20-30 ml tap water. This solution was 
administered by syringe through the duodenal infusion port closest to (but located 
distally from) the pylorus. 
Expiratory breath samples were taken at regular intervals over a 240 min period and 
directly analyzed using a handheld hydrogen breath test unit (Gastrolyzer, Hoekloos, 
The Netherlands). SBTT is defined as the time between the administration of lactulose 
and the onset of a sustained (in three consecutive readings) rise in breath H2 
concentration of at least 10 parts per million (ppm) above basal level. At our 
department the mean coefficient of variation for SBTT using the lactulose hydrogen 
breath test with 6 g lactulose is 12%.  
Hormone assays  
Blood samples were drawn at  t=0, 30, 45, 75, 90, 105, 120, 150, 165, 180, 210 and 
240 min. Total plasma PYY concentrations were measured by a Radio Immuno Assay 
(RIA), as described previously10. There is no cross-reactivity with PP or VIP. The detection 
limit is 10 pmol/l. Both PYY(1-36) and PYY(3-36) bind to the antibody in dilutions up to 
250000. The intra-assay variation ranges from 1.8 to 15.6% and the inter-assay 
variation from 9.5 to 27.8%25. Plasma CCK concentrations were measured by a RIA, as 
described previously26. The detection limit of the assay was 0.2 pmol•l-1. The intra-
assay variation ranges from 3.9 to 9.1% and the inter-assay variation from 10.4 to 
19.9%26. 
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Statistical analysis 
Data was analysed using ANOVA with time and location and test day as factors and 
subjects as blocks. In the hormone and EVAS scores analyses, baseline values were 
used as a covariate. As location and time showed a significant interaction, time x 
location combinations were calculated and  time differences within both locations and 
location differences within both times were tested. Bonferroni correction was applied 
by dividing the calculated probability by a factor 4. A p-value of 0.05 was considered 
significant. 
Results are presented as least squares means with standard error (SE), unless 
otherwise specified. EVAS scores were expressed as percentages of the maximal score 
(0 cm equaled 0% and 6.4 cm equaled 100%) and as cumulative areas under the curve 
(AUC). The AUC was calculated using the trapezoid rule.  
Gastrointestinal symptoms were analysed using frequency of occurrence per time 
point and a standard ANOVA with the personal scores corrected for each subject's 
overall mean score. 
Results 
Results will be presented in order of timing of the intestinal infusions: Early infusion 
(30-90 min after breakfast) and Late infusion (105-165 min after breakfast).  
There was no day-effect observed for any of the parameters measured.  
 
Although there were occasional GI symptoms, most of them were rated “mild” and 
some were rated “moderate” (data not shown). gastrointestinal symptoms did not 
differ significantly between treatments. 
Early infusions: Appetite 
Since the effects of the various treatments showed similar trends for all appetite 
scores, only the data for fullness and appetite will be given. Appetite for a snack 
scores were significantly lower after the Ileum-Early vs. Duo-Early treatment for 
several time points (Figure 7.2A). This difference occurred mainly in the later time 
period, which resulted in a significantly lower AUC for t=30-240min, but not for t=30-
90 min (Figure 7.2B). Fullness was significant larger after Ileum-Early vs. Duo-Early at 
later time points (Figure 7.2C), although this difference was not reflected in a 
significantly larger AUC (Figure 7.2D).  
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Figure 7.2 Subjective EVAS scores (LSmeans ± SE, n=15, in %) and AUCs (LSmeans ± SE, n=15, in %·min) 
for Appetite and Fullness after infusion of 6g fat in duodenum or ileum in the early 
postprandial phase (t=30-90 min). * denotes p<0.05 for Duo-Early vs. Ileum-Early. 
Early infusions: Food intake 
Food intake was not affected by the location of fat infusion (408 vs. 422 g for Duo-
Early vs. Ileum-Early, SE=17; N.S.). 
Early infusions: Peptide secretion 
For the early infusions CCK concentrations were significantly increased after Duo-Early 
vs. Ileum-Early (Figure 7.3A), resulting in a significantly higher AUC (t=30-90 min; 
Figure 7.3B).  
Except for one significant time point PYY secretion was, overall, not significantly 
different between Duo-Early and Ileum-Early (Figure 7.3C and 7.3D). 
Early infusions: Gastrointestinal transit 
The Ileum-Early infusion significantly delayed gastric emptying T1/2 and significantly 
prolonged SBTT compared to the Duo-Early infusion, as shown in Table 7.1. 
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Figure 7.3 Plasma concentrations of CCK and PYY after infusion of 6 g fat in duodenum or ileum in the 
early postprandial phase (t=30-90 min). * denotes p<0.05 for Duo-Early vs. Ileum-Early. 
 
 
Table 7.1 Gastrointestinal transit after infusion of 6g of fat either in the early (t=30-90 min) or in the 
late postprandial phase (t=105-165) in either duodenum or ileum. 
Gastric emptying 
(T1/2; min) 
Duo-Early Duo-Late Ileum-Early Ileum-Late SE 
 138b  206 a  10.3 
SBTT (min)  
 85a 108c 144b,d 151b,d 13.7 
P<0.05 for a vs. b, and for c vs. d 
Late infusions: Satiety 
Results for fullness and appetite after the Late infusions are given in Figure 7.4. No 
significant differences were observed for both appetite and fullness between the 
Ileum-Late and Duo-Late treatment.  
Late infusions: Food intake 
During the late infusions, food intake was not affected by the location of fat infusion 
(407 vs. 425 g for Duo-Late vs. Ileum-Late, SE=17). 
 Site and timing of small intestinal fat infusion⏐119 
 
T=105-240 min T=105-240 min
T=105-240 min
T=105-165 min
T=105-165 min
     A                                                                        B 
 
 
 
 
 
 
 
 
     C                                                                        D 
 
 
 
 
 
 
 
 
 
 
Figure7.4 Subjective EVAS scores and AUCs for Appetite and Fullness after infusion of 6g fat in 
duodenum or ileum in the late postprandial phase (t=105-165 min). 
Late infusions: Peptide secretion 
Results for CCK and PYY secretion are given in Figure 7.5 for the late infusions. Neither 
secretion of CCK nor of PYY did significantly differ between Ileum-Late and Duo-Late. 
Late infusions: Gastrointestinal transit 
The Ileum-Late infusion significantly delayed SBTT compared to the Duo-Late infusion, 
as shown in Table 7.1. 
Satiety: Effect of timing 
For satiety, the overall AUCs are displayed in Table 7.2. 
When the overall AUCs (t=30-240 min) for both appetite and fullness are compared, 
no differences are observed between the duodenal early and late infusions. However, 
appetite was significantly lower after Ileum-Early compared to Ileum-Late.  
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Figure 7.5 Plasma concentrations of CCK and PYY after infusion of 6 g fat in duodenum or ileum in the 
late postprandial phase (t=105-165 min). 
 
Table 7.2 Area Under the curve for Appetite after infusion of 6g of fat either in the 
early (t=30-90 min) or in the late postprandial phase (t=105-165) in either 
duodenum or ileum. 
 Duo-Early Duo-Late Ileum-Early Ileum-Late SE 
Appetite (mm.min)      
30-240 min 49.9a 50.1a 41.6b 53.0a 2.0 
Fullness (mm.min)  
30-240 min  43.0 45.9 47.5 41.3 2.3 
P<0.05 for a vs. b 
Food intake: Effect of timing 
The timing of the infusions did not affect food intake (408 vs. 407 vs. 422 vs. 425 g for 
Duo-Early vs. Duo-Late vs. Ileum-Early vs. Ileum-Late, SE=17). 
Gastrointestinal transit: Effect of timing 
As shown in Table 7.1, the timing of the infusions did not affect SBTT. 
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Peptide secretion: Effect of timing 
As shown in Table 7.3 no differences were present between Duo-Early and Duo-Late 
and Ileum-Early and Ileum-Late with regard to secretion of  CCK and PYY.  
 
Table 7.3 Area under the curve for peptide secretion after infusion of 6g of fat either in the early (t=30-
90 min) or in the late postprandial phase (t=105-165) in either duodenum or ileum. 
 Duo-Early Duo-Late Ileum-Early Ileum-Late SE 
CCK (pM.min)      
30-240 min  0.54 0.59 0.45 0.51 0.06 
PYY (pM.min)  
30-240 min  23.8 23.9 24.4 22.9 0.96 
 
Discussion 
Regional differences are thought to exist between the proximal and the distal small 
intestine with respect to the magnitude of the effects of nutrients on appetite and 
food intake8. 
 
In the present study, we have demonstrated that, when given in the early 
postprandial phase, ileal infusion of fat significantly increased satiety compared to 
duodenal fat infusion. On the other hand, during the late postprandial infusions, no 
significant differences in satiety parameters were observed between the duodenal 
and ileal infusions.  
Few studies in humans have focussed on a comparison of the effects of nutrient 
infusion into different parts of the small intestine on satiety. Recently, Chaikomin et 
al. have compared duodenal to mid-jejunal glucose infusions27. These authors found 
that satiety was more pronounced when glucose was infused into the duodenum 
compared to the jejunum27. Welch et al. infused a large amount of 40g of fat into 
ileum and jejunum and found that both infusions reduced food intake, but only the 
jejunal infusion reduced hunger28. However, from this large amount of fat, a 
significant part of fat will have spilled over into the ileum during the jejunal 
infusion28,29 which may have resulted in an increased small intestinal surface area 
exposed to fat and accordingly to a more pronounced reduction in hunger and food 
intake12,13.  
 
In our study, no differences in food intake were observed between any of the 
treatments.  Our study design was based on a breakfast meal early in the morning (at 
9:00) with a lunch scheduled at 13.00 (t=240 min). This resulted in a time schedule 
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that compares to a regular morning, allowing us to assess whether ileal brake 
activation by fat reduces hunger during the morning and would then be able to 
reduce food intake during a subsequent lunch meal. Rolls et al. demonstrated that  
prolonging the time interval between a preload and the ad libitum test meal by 90 
min reduced the effect of a preload on intake of the ad libitum meal by 14% (30). This 
observation suggests that, in our study, the meal may have been scheduled too late to 
be significantly affected by the intestinal fat infusions. Therefore, we cannot not rule 
out  an effect of fat infusion on food intake would have been present when food 
intake had been evaluated at an earlier moment in the protocol . 
 
Duodenal infusion of fat dose-dependently delays gastric emptying31. Inhibition of 
gastric emptying by ileal fat has also been described previously32. However, the 
magnitude of these effects had not been compared previously in humans.  
Compared to the duodenal infusion, the ileal infusion significantly and profoundly 
delayed gastric empting (half time 206 vs 138 min, p<0.05). A link between gastric 
distension and gastric emptying on the one hand and postprandial satiety on the 
other has been demonstrated previously3,33-35. Geliebter et al. demonstrated that a 
gastric volume load by itself can reduce food intake in humans3. Delaying gastric 
emptying results in prolongation of postprandial gastric distension, and may therefore 
affect satiety. Others have shown that  intestinal fat infusion lowers the threshold at 
which a gastric volume load affects satiety scores and food intake6.  
This may explain the larger effect of the Ileum-Early infusion on appetite, when 
compared with the Duo-Early infusion. The Ileum-Early infusions significantly delayed 
gastric emptying compared to the Duo-Early, which resulted in a larger and more 
prolonged gastric distension. When this larger and more prolonged distension is 
combined with an equally or even more satiating intestinal fat infusion, this will 
probably result in a more pronounced effect on appetite. The absence of a difference 
in satiating effect between duodenum and ileum in the late-postprandial phase is 
possibly related to the absence of an effect of the Ileum-Late perfusion on gastric 
emptying, since these  infusions will have been scheduled too late to effectively delay 
gastric emptying. 
 
The ileal brake has initially been described as the inhibition of jejunal motility in 
response to ileal fat infusion36, resulting in an increase in transit time37. In animals, Lin 
et al. have demonstrated that small intestinal transit was more potently inhibited by 
infusions of nutrients in the distal vs. the proximal small intestine38. In our study, ileal 
infusion of fat, both in the early and in the late postprandial phase delayed small 
bowel transit time. The timing of the infusions did not affect SBTT. 
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In the early postprandial period, secretion of CCK was significantly higher after the 
duodenal compared to the ileal infusions. As CCK is considered a peptide 
predominantly originating from the proximal gut1, this result was anticipated. CCK is 
involved primarily in satiation, or meal termination, and to a lesser extent in between-
meal satiety. It is therefore not surprising that the higher plasma concentrations 
observed after the Duo-Early do not translate into reductions in appetite or increases 
in fullness.  
On the other hand, PYY is thought to play a role in between-meal hunger, and has a 
longer-lasting effect on satiety and food intake39,40. PYY is secreted by 
enteroendocrine L-cells, and the concentration of PYY -secreting cells increases 
aborally.  
Although previous studies have demonstrated that secretion of PYY occurs after both 
distal10 and proximal41 fat infusions, we expected the ileal infusions to increase PYY 
secretion more compared to duodenal fat infusions. However, in our study the 
location of the fat infusion did not affect PYY secretion. 
A number of recent studies indicate that mechanisms other than direct sensing of gut 
content by L-cells may be involved in secretion of PYY. For instance, infusion of fat into 
the human duodenum increased PYY concentrations before the distal gastrointestinal 
tract was reached by the fat42. This suggests the presence of neural or humoral 
mechanisms in modulation of PYY release42. Also, vagal stimulation43 or secretion of 
other gut peptides, such as vasoactive intestinal polypeptide (VIP),  gastrin or CCK may 
play a role in the secretion of PYY. This may explain the lack of any difference in PYY 
secretion between the duodenal and ileal fat infusions.  
 
In conclusion, the effects of intestinal fat infusion on satiety and gastrointestinal 
transit are more pronounced and potent  when fat is administered  in the distal 
compared to the proximal small intestine, when given in the early postprandial phase. 
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Abstract  
The site of intestinal fat delivery affects satiety and may affect food intake in humans. Animal data suggest 
that the length of small intestine exposed to fat is also relevant.  
Aim of our study was to investigate whether increasing the areas of intestinal fat exposure would affect 
satiety parameters and food intake.  
In this single-blind randomized crossover study, 15 volunteers, each intubated with a nasoileal tube, 
received 4 treatments on consecutive days.  
The oral (Control) control was a liquid meal (LM) containing 6 g of fat ingested at t=0 min, with saline 
infusion at t=30-120 min. Experimental treatments were a fat-free LM at t=0 min , with either 6g oil 
delivered sequentially (2g duodenal t=30-60, 2g jejunal t=60-90, 2g ileal t=90-120 min), simultaneously (2g 
each to all sites t=30-120 min), or ileal only (Ileum: 6g t=30-120 min). Satiety parameters (hunger, fullness) 
and CCK, GLP-1, PYY secretion were measured until t=180 min, when ad libitum food intake was assessed. 
Only Ileum reduced food intake significantly over Control. Ileum and Simultaneous significantly reduced 
hunger compared to Control. Compared to control, no differences were observed with regard to PYY, CCK 
and GLP-1 integrated 180 min secretion. 
Ileal fat infusion had the most pronounced effect on food intake and satiety. Increasing the areas of 
intestinal fat exposure only affected hunger when fat was delivered simultaneously to the exposed areas, 
not sequentially. These results demonstrate that  ileal brake activation offers an interesting target for 
regulation of ingestive behavior. 
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Introduction 
The rapidly increasing prevalence of obesity necessitates the development of 
strategies for weight management and control. As the gastrointestinal (GI) tract elicits 
various signals that influences hunger and food intake1, the gut is considered a 
strategic target organ.  
The use of reduced energy-diets, such as low-calorie meal replacers, may result in 
body weight reduction2. However, compliance to these diets is difficult to achieve, 
partly due to hunger pangs, thereby seriously limiting its success. Food-based 
approaches that employ GI mechanisms for an enhanced and prolonged  reduction in 
hunger and food intake may be very helpful in this respect.  
 
It is well known that the satiating effect of nutrients varies between the different 
segments of the intestine where nutrients are delivered3-13. For instance, in animal 
studies, surgical transposition of an ileal segment to a proximal site, results in an 
increase in ileal nutrient exposure and a significant reduction in food intake. 
This has been confirmed in human studies. Infusion of fat in the ileum more potently 
reduces hunger feelings compared to infusion of the same dose of fat in the 
duodenum14. Welch et al.9 compared infusion of a high dose of fat in ileum versus 
jejunum. The reduction in food intake was larger after jejunal compared to ileal fat 
infusion9. It should be noticed that the doses of fat employed in that study were 
supra-physiological (370 Kcal). Therefore, fat will have spilled over into the ileum after 
the jejunal infusion, expanding the intestinal area exposed to fat in the jejunal 
experiment. These human data appear to confirm results from animal studies that 
increasing the small intestinal surface area exposed to nutrients increases the impact 
on food intake5.  
 
In previous studies we have shown in humans that fat delivery to the ileum via an ileal 
tube results in a significant reduction in hunger score. Targeted delivery of nutrients 
to the ileum is difficult to achieve in daily life non-invasively. However, development 
of substances or capsules that slowly release fat during intestinal transport appears 
technically feasible (e.g. Knutson et al.). The present study was undertaken to explore 
alternative strategies of intestinal fat delivery, in order to compare and eventually 
optimise their effects on hunger and food intake.  
In the present design, oral fat ingestion was taken as the control, and the effects of 
ileal fat infusion were tested in the Ileum- treatment. Gradual fat delivery was 
mimicked by a sequential release of fat (duodenum first, then jejunum, followed by 
ileum). As animal studies have shown that simultaneous exposure of different small 
intestinal segments increases the effects on food intake, a fourth study arm was 
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added where the identical total amount of fat was simultaneously distributed over 
duodenum, jejunum and ileum. 
 
We hypothesized that increasing the intestinal area exposed to a standard dose of fat 
may reproduce effects on hunger and food intake comparable to those observed 
when the same amount of fat is administered to the ileum only. 
Experimental method 
Subjects 
Healthy volunteers aged between 18 and 55 yrs with a BMI between 18 and 29 kg/m2 
were recruited by advertisement. Restrained eaters (as assessed by the Dutch Eating 
Behavior Questionnaire) and subjects on a weight-reduction diet or a medically-
prescribed diet were excluded. Medication influencing appetite or sensory function 
was not allowed. Subjects with metabolic or endocrine disease, gastrointestinal 
disorders or after abdominal surgery were excluded. Informed consent was obtained 
from each individual. The study protocol had been approved by the Medical Ethics 
Committee of the University Hospital Maastricht, and procedures followed were in 
accordance with the ethical standards of the institution on human experimentation. 
Seventeen subjects met the inclusion criteria. Two volunteers dropped out during the 
study: one due to discomfort during catheter positioning and one due to failure to 
position the tip of the catheter beyond the ligament of Treitz (flexura 
duodenojejunalis). Fifteen healthy volunteers completed the protocol. 
Catheter 
The catheter for small intestinal intubation was a 290 cm long rubber silicon 9-channel 
(8-lumen, 1 balloon inflation channel, diameter 3.5 mm) catheter custom-made by 
Dentsleeve International Ltd (Mississauga, Ontario, Canada). The functional length 
was 240 cm with a 50 cm connection segment. The catheter contains side-holes at 80, 
95, 110, 125, 210, 220, 230 and 240 cm from the proximal junction and had an 
inflatable balloon (maximum inflation capacity 10 ml) at the distal tip. 
Experimental protocol 
The meal replacer we used contains 6g of fat. This meal replacer is expected to reduce 
hunger for a 3-4 hour period, until the next meal. Reducing hunger in the between-
meal period and reducing food intake were specific goals in our design. The 60 
minutes period between the end of the infusion and the ad-libitum lunch was 
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scheduled to assess how the study treatments affect between-meal hunger compared 
to a regular meal replacer. As these meal replacers contain 6 g of fat, this is the 
amount we tested in this study. Amounts as low as 3g have been shown to affect 
ingestive behaviour when delivered to the ileum15. 
 
The experimental protocol is shown in Figure 8.1. In this single blind placebo-
controlled crossover study, four treatments were scheduled. Each test day, a liquid 
meal replacer (for details see below) was ingested at t=0 min, followed by an 
intestinal infusion from t=30 to t=120 min in all treatments. During the control 
treatment, a liquid meal replacer containing 6g of fat was ingested at t=0 min, 
followed by a saline infusion. In the other three treatments, a fat-free liquid meal 
replacer was ingested at t=0 min , followed by intestinal infusions with variations in 
location, but all with delivery of 6 g fat. As positive control, 6 g of fat was given in the 
ileum : ‘Ileum”. In the sequential treatment , representing slow release intestinal 
delivery , 2 g of fat was given in the duodenum (t=30-60 min), followed by 2 g in the 
jejunum (t=60-90 min), followed by 2g in the ileum (t=90-120 min): ‘Sequential’. The 
“Simultaneous” treatment was given to optimize the surface area exposed to 
nutrients Here, 2 g of fat was given in the duodenum, 2 g in the jejunum and 2g in the 
ileum continuously, for 90 minutes, that is from 30 to 120 min. . 
Catheter positioning 
On Monday, subjects arrived at 12:00 hr after a light breakfast (ingested before 09:00 
hr). Through an anaesthetized nostril, the catheter was introduced into the stomach, 
and allowed to pass through the pylorus to the ileum by peristalsis. After passing the 
ligament of Treitz, a small balloon at the tip was inflated to facilitate passage of the 
catheter to the ileum. During the day, the subject was offered small snacks and 
sugared tea or coffee to stimulate peristalsis. The tip was placed in the ileum (at least 
120 cm distal from the pylorus16), so three infusion ports were available in the ileum. 
The most distal port was used for infusion. In this study, we perfused the ileum at at 
least 175-195 cm from the nose. During the positioning and before every test-day, the 
position of the catheter was checked fluoroscopically. 
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Figure 8.1 Study outline for the experiment.  
 The study consisted of four treatments. Order of treatments was randomized. Each subject 
started each test day by consuming a breakfast at t=0 min. In the Control treatment, this was 
a fat-containing drink (199 kcal). This breakfast meal was then followed by a saline infusion 
from t=30-120 min.   
 On the treatment days, a fat-free breakfast (145 kcal) was ingested at t=0 min, followed by an 
intestinal infusion of 6g of fat from t=30-120 min. In the Simultaneous treatment, 2 g of fat 
was given in the duodenum, 2 g in the jejunum and 2g in the ileum continuously for 90 
minutes. During the Ileum treatment, 6 g of fat was given in the ileum only.  Finally, in the 
Sequential treatment, 2 g of fat was given in the duodenum (t=30-60 min), followed by 2 g in 
the jejunum (t=60-90 min), followed by 2g in the ileum (t-90-120 min).  
 Throughout the test day, blood was sampled for gut peptide analysis and satiety was 
measured by VAS questionnaires. Gastric emptying was measured by the 13C stable isotope 
breath test. On all test days, an ad libitum meal was consumed at t=180 minutes.  
 
Test day 
On each study day (Tuesday till Friday), the subject arrived at the gastrointestinal 
research laboratory unit at 8:00 hr following an overnight fast. After checking the 
position of the ileal catheter, a venous catheter was placed in a forearm-vein for 
collection of blood samples. At 8:45 hr, a basal VAS scores for hunger feelings and a 
basal blood sample were collected. After this, the experiment was started. At 9:00 hr 
(t=0 min), the liquid meal was ingested. The infusions started at t=30 min. Infusion 
rate was 0.67 ml/min (0.6 kcal/min) for 90 min for all treatments. At 12:00 hr (t=180 
min) the ad libitum lunch was served. At 12:30 hr, the intravenous canula was 
removed, and subjects were allowed to go home. They received an evening meal and 
snackbox from which they were allowed to consume freely till 22:00 hr. 
6 g fat
0 g fat
g fat
Time (min)
0               30             60                  90              120 180
0g fat
2 g fat duodenum, 2 g jejunum, 2 g ileum
6 g fat in ileum
VAS Scores: satiety               
Control
BreakfastTreatment Infusion
Simultaneous
Ileum
Sequential 0 g fat 2 g fat-duo 2 g fat-jej 2 g- ileum
Ad libitum Lunch
13C-acetate: Gastric emptying               
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Hunger 
Scores for hunger feelings (fullness, hunger, desire to eat a meal, desire to eat a 
snack) was measured using electronic Visual Analogue Scales (EVAS) anchored at the 
low end with the most negative or lowest intensity feelings (e.g., extremely, not at 
all), and with opposing terms at the high end (e.g., not at all, very high)17. Volunteers 
were asked to indicate on a 64 mm line on the iPAQ which place on the scale best 
reflects their feeling at that moment. Measurements were taken during the test day 
every 30 min, and every 15 min during infusion of emulsion. 
Food intake 
Each test day, an ad libitum-lunch was served to measure food intake. Each lunch was 
offered in excess, and consisted of a pasta meal (per 100 g: 430 kJ, 5 g protein, 2 g fat, 
16g carbohydrates). During the ad libitum-lunch, subjects were not allowed to watch 
television, listen to the radio or read as this could have influenced the amount eaten. 
Liquid meal 
A liquid meal replacer with or without fat was administered. The regular, fat-
containing drink, which was given during the control treatment, was a liquid meal 
replacer (Slim·Fast Optima, Unilever, Vlaardingen, Netherlands; 325 ml, 199 kcal) 
containing 6 g of high-oleic rapeseed oil. The fat-free version of the same drink 
(325 ml, 145 kcal) was given during the other treatments. These are vitamin- and 
mineral-fortified meal replacement products, used by consumers primarily in order to 
aid in weight loss and/or prevention of weight gain.  
Emulsions 
The emulsions consisted of 10% oil in water. As an emulsifier 2.5% K-caseinate was 
used. A very small amount of xanthan gum (0.1%) and guar gum (0.1%) was used as a 
stabiliser. Sodium chloride was added to obtain iso-osmotic solutions (0.8% NaCl). 
Total infused volume was 60ml, containing 6g fat. Caloric load was 54 kcal. The pH of 
the emulsions ranged from 6.7 till 6.8. As a control infusion, saline was administrated 
to the ileum. 
Chemical analyses 
Blood samples were drawn at regular intervals throughout the test day. After 
collection, the blood was kept on ice. Total PYY (PYYT-66HK, Linco Research, St. 
Charles, Missouri, US), CCK (RB302, Lucron Bioproducts), and GLP-1 (GLP1A-35HK, 
Linco Research, St. Charles, Missouri, US) were measured by sensitive and specific 
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commercially available radioimmunoassays. Blood for GLP-1 analysis was collected in 
ice-chilled tubes, to which DPP-IV inhibitor was added (DPP4, Linco Research St. 
Charles, Missouri, US). All gut peptides were measured in a subset of 9 subjects. 
Statistical analysis 
Results are presented as least squares means with standard error of the mean (SE), 
unless otherwise specified. Satiety VAS scores were expressed as percentages of the 
maximal score (0 cm equaled 0% and 6.4 cm equaled 100%) and as incremental 
cumulative areas under the curve, with the value at t=0 min as a covariate. The 
incremental AUC was calculated using the trapezoid rule.  
An n=9 subject subset was used for evaluation of gut peptide secretion. This group 
size (n) of nine was based on a power calculation with a predicted difference in 
peptide release of at least 20%, a power of 0.8, and an overall α of 0.05 (taking into 
account multiple comparisons, 2-sided), this resulted in a group size (n) of 9. 
All parameters were analyzed using analysis of variance with subjects as blocks and 
treatment as factor. A Dunnett test was used to compare each treatment to control. A 
p-value of 0.05 was considered significant. 
Results 
Food intake 
Food intake (Figure 8.2) was significantly reduced after Ileum vs. Control (422g vs. 
499g, SE=40, p<0.01), whereas no significant differences were observed after 
Simultaneous and Sequential (458g for Simultaneous and 480g for Sequential, SE=40). 
Hunger 
We measured Hunger, Fullness, Appetite for a meal and Appetite for a snack. As 
hunger, appetite for a meal and appetite for a snack produced identical results, we 
only show hunger scores.  
Over the period t=-15-180 min, hunger AUC (Figure 8.3a) was significantly reduced 
after both Simultaneous and Ileum vs. Control, but not after sequential. No significant 
differences between the four experiments were observed for AUC fullness (Figure 
8.3c). 
At the start of each test day, hunger (Figure 8.3b) and fullness (Figure 8.3d) scores did 
not differ between the treatments. Hunger was significantly reduced after Ileum vs. 
Control at 150 min . No differences were observed for fullness. 
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Figure 8.2 Results for food intake. * denotes p<0.05. 
 
    A                                                                        B 
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Figure 8.3 Results for Fullness and Hunger.  
 A. Results for hunger AUC. * denotes p<0.05. B. Results for hunger scores. * denotes p<0.05. 
C. Results for fullness AUC.  D. Results for fullness scores. 
*
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Gut peptide secretion 
Fasting plasma concentrations of CCK, GLP-1 and PYY did not differ between the 
treatments. With regard to the 0-180 min AUC integrated secretion (AUC 0-180 min), 
neither for CCK, nor for PYY or GLP-1 were significant differences observed between 
the four treatments (Table 8.1). 
 
Table 8.1 Secretion of gut peptides in response to the different treatments, as measured as AUC (t=0-
180 min) 
Treatment: CCK (pM/min) SE PYY (pM/min) SE GLP-1 (pM/min) SE 
Oral 162 55   96 55 3842 462 
Simultaneous 187 55 101 55 5176 462 
Ileum 142 55   91 55 4243 462 
Sequential 204 55   86 55 4496 462 
CCK (cholecystokinin), PYY (peptide YY), GLP-1 (glucagon-like peptide-1) 
Values are LSmeans. No significant differences were observed. 
Discussion 
In the present study, we have shown that infusion of a low, physiological dose of fat 
into the ileum resulted in a significant and clinically relevant reduction in food intake 
when compared to oral ingestion of the same dose of fat.  
When an equicaloric fat dose was spread sequentially over the small intestine, 
mimicking slow release of fat during intestinal transit, neither hunger scores nor food 
intake were significantly affected. On the other hand, optimalisation of the exposed 
intestinal area to fat with the simultaneous delivery of fat along the whole length of 
small intestine resulted in a significant reduction in hunger scores compared to oral 
fat but had no effect on food intake. The observed differences in satiety and food 
intake were not reflected by changes in serum gut peptide levels. 
 
The concept of the ileal brake has been introduced by Spiller et al.16 and Read was 
initially described as a reduction in small intestinal transit in response to ileal nutrient 
infusions16,18. Additionally, ileal brake effects on satiety and food intake have since 
been demonstrated3.  
Welch et al. were the first to show that ileal infusion of large doses of fat reduced 
food intake when compared to a control saline infusion or to intravenous infusion of 
fat9,19. In a previous study, we compared infusion of fat into the ileum vs duodenum 
on hunger levels and food intake14. The ileal fat infusions significantly increased 
satiety and reduced hunger scores compared to duodenal fat infusion. With respect to 
food intake no differences were observed between the two treatments. We 
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hypothesize that the timing of the ad-libitum meal relative to the end of the infusion 
in that study (150 min vs. 60 min in the present study) may have affected the 
outcome. Rolls et al. demonstrated that the effects of a preload on food intake during 
a subsequent meal diminished as the time between preload administration and meal 
ingestion increased20.  
 
Ileal fat infusion reduced food intake by about 15%, which at first sight may seem to 
be a rather small effect. However, obesity usually reflects a long-term accumulation of 
relatively small daily ‘energy gaps’21. Hill et al. describe that by reducing caloric intake 
by 50 kcal per day, weight gain could be prevented in 90% of the population21. This 
suggests that the 15% reduction in food intake we observed represents a meaningful 
and significant contribution to treating and preventing obesity and overweight. 
 
The ileal brake as a target for food-based strategies to reduce hunger and food intake 
has been proposed previously3,22. However, under physiological conditions, only a 
small percentage of nutrients will reach the (terminal) ileum after intake of a normal 
sized meal.. The percentage reaching the ileum may however increase to almost 30% 
after ingestion of a very large volume, high caloric meal23. Targeted delivery of fat to 
the ileum through ileal intubation is feasible for research purposes but not for clinical 
purposes. Therefore, the question arises whether designing emulsions or 
encapsulates that result in a higher amount of fat delivery to the ileum, is feasible. 
This may be achieved by increasing the resistance of the emulsion to lipolysis in the 
proximal GI tract. This may lead either to a larger surface area exposed to nutrients 
and/or to a higher concentration of fat or fatty acids in the distal small intestine. 
Targeted delivery of nutrients to the ileum is difficult to achieve in daily life non-
invasively. However, development of substances or capsules that slowly release fat 
during intestinal transport and do not necessarily need to reach the ileum solely, 
appears much more feasible22,24,25. 
Animals studies have clearly shown that the effect of a small intestinal nutrient load 
on food intake and small intestinal transit increases when the small intestinal surface 
area exposed to these nutrients increases5,26. Two mechanisms appear to be involved. 
First, as the exposed luminal surface increases, the total number of activated 
receptors involved in satiety signalling increases as well. Second, exposure of the 
distal surface area with fat infusion will lead to activation of distal receptors, which 
may be more potent in their effects on satiety14.  
In the present study, two treatments resulted in an increase in the small intestinal 
surface area that was exposed to fat: the sequential and simultaneous fat delivery. In 
the sequential treatment, a slow-release delivery of fat was mimicked, but without 
any significant effect on food intake or hunger scores. As fourth arm we included the 
condition with optimalisation of intestinal area exposed to the 6 g fat. Here we 
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observed a significant reduction in hunger scores. This finding is in line with those of 
Meyer et al., who stated that simultaneous exposure of the different segments of 
small intestine would potentiate the effects on food intake5. This suggests that 
simultaneous feedback from the different small intestinal segments is pivotal in the 
increased effects on eating behaviour and transit that are observed after increased 
small intestinal exposure. 
 
In the small intestine, the secretion of several gut peptide varies dependent on the 
intestinal segments that are activated27. CCK is predominantly released from the 
proximal small intestine, although CCK-secreting cells have also been demonstrated in 
the terminal ileum28. Peptide YY (PYY)-and glucagon-like peptide-1 (GLP-1) secreting 
L-cells reside predominantly in the distal small intestine and colon27. We hypothesized 
that modulating the distribution of fat over the small intestine would affect peptide 
secretion in line with effects on satiety scores and food intake. However, no 
differences were observed in peptide secretion. It should be taken into consideration 
that only small amounts of fat were administered and that peptides may exert their 
effect by paracrine or neurocrine routes vs. endocrine routes (secretion into 
bloodstream)27.    
 
In conclusion, we confirm that ileal fat infusion significantly reduces food intake 
compared to oral fat ingestion. Further optimising the exposure of the small intestine 
to fat through simultaneous fat delivery did result in a reduction of hunger scores, but 
no effects on food intake were observed. These results point to the ileal brake as most 
potent small intestinal control mechanism for hunger and food intake. The ileal brake 
is therefore an interesting target for food-based strategies in weight management. 
 Enteral fat distribution affects food intake⏐139 
 
References 
1. Badman MK, Flier JS. The Gut and Energy Balance: Visceral Allies in the Obesity Wars. Science 
2005;307:1909. 
2. Truby H, Baic S, deLooy A, Fox KR, Livingstone MB, Logan CM, Macdonald IA, Morgan LM, Taylor MA, 
Millward DJ. Randomised controlled trial of four commercial weight loss programmes in the UK: initial 
findings from the BBC "diet trials". BMJ 2006;332:1309-1314. 
3. Maljaars P.W., Peters H.P., Mela DJ, Masclee A.A. Ileal brake: a sensible food target for appetite 
control. A review. Physiol Behav 2008;95:271-81 
4. Meyer JH, Hlinka M, Tabrizi Y, DiMaso N, Raybould HE. Chemical specificities and intestinal 
distributions of nutrient-driven satiety. Am J Physiol 1998;275:R1293-R1307. 
5. Meyer JH, Tabrizi Y, DiMaso N, Hlinka M, Raybould HE. Length of intestinal contact on nutrient-driven 
satiety. Am J Physiol 1998;275:R1308-R1319. 
6. Meyer JH, Hlinka M, Khatibi A, Raybould HE, Tso P. Role of small intestine in caloric compensations to 
oil premeals in rats. Am J Physiol 1998;275:R1320-R1333. 
7. Meyer JH, Elashoff JD, Doty JE, Gu YG. Disproportionate ileal digestion on canine food consumption. A 
possible model for satiety in pancreatic insufficiency. Dig Dis Sci 1994;39:1014-1024. 
8. Welch IM, Davison PA, Worlding J, Read NW. Effect of ileal infusion of lipid on jejunal motor patterns 
after a nutrient and nonnutrient meal. Am J Physiol 1988;255:G800-G806. 
9. Welch IM, Sepple CP, Read NW. Comparisons of the effects on satiety and eating behaviour of 
infusion of lipid into the different regions of the small intestine. Gut 1988;29:306-311. 
10. Koopmans HS. An integrated organismic response to lower gut stimulation. Scand J Gastroenterol 
Suppl 1983;82:143-153. 
11.  Koopmans HS. The role of the ileum in the control of food intake and intestinal adaptation. Can J 
Physiol Pharmacol 1990;68:650-655. 
12.  Koopmans HS, Ferri GL, Sarson DL, Polak JM, Bloom SR. The effects of ileal transposition and 
jejunoileal bypass on food intake and GI hormone levels in rats. Physiol Behav 1984;33:601-609. 
13.  Strader AD, Vahl TP, Jandacek RJ, Woods SC, D'Alessio DA, Seeley RJ. Weight loss through ileal 
transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol 
Endocrinol Metab 2005;288:E447-E453. 
14.  Maljaars J, Haddeman E, Peters H., Masclee A. Comparison of Ileal and Duodenal brake mechanisms 
on satiety and gastrointestinal transport. Gastroenterology 2007;132:A207 Suppl.2. 
15.  Maljaars PW, Symersky T, Kee BC, Haddeman E, Peters HP, Masclee AA. Effect of ileal fat perfusion on 
satiety and hormone release in healthy volunteers. Int J Obes (Lond) 2008;32:1633-1639 
16.  Spiller RC, Trotman IF, Higgins BE, Ghatei MA, Grimble GK, Lee YC, Bloom SR, Misiewicz JJ, Silk DB. The 
ileal brake--inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984;25:365-374. 
17.  Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in 
assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000; 
24:38-48. 
18.  Read NW, McFarlane A, Kinsman RI, Bates TE, Blackhall NW, Farrar GB, Hall JC, Moss G, Morris AP, 
O'Neill B, et al. Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and 
plasma levels of neurotensin and enteroglucagon. Gastroenterology 1984;86:274-280. 
19.  Welch I, Saunders K, Read NW. Effect of ileal and intravenous infusions of fat emulsions on feeding 
and satiety in human volunteers. Gastroenterology 1985;89:1293-1297. 
20.  Rolls BJ, Kim S, McNelis AL, Fischman MW, Foltin RW, Moran TH. Time course of effects of preloads 
high in fat or carbohydrate on food intake and hunger ratings in humans. Am J Physiol 1991;260: 
R756-R763. 
21.  Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? 
Science 2003;299:853-855. 
22.  Golding M, Wooster TJ. The influence of emulsion structure and stability on lipid digestion. Current 
Opinion in Colloid & Interface Science 2010;15:90-101. 
140⏐Chapter 8 
 
23.  Lin HC, Zhao XT, Wang L. Fat absorption is not complete by midgut but is dependent on load of fat. 
Am J Physiol 1996;271:G62-G67. 
24.  Knutson L, Koenders DJ, Fridblom H, Viberg A, Sein A, Lennernas H. Gastrointestinal metabolism of a 
vegetable-oil emulsion in healthy subjects. Am J Clin Nutr. 2010;92:515-524. 
25.  Maljaars PJ, Keszthelyi D, Masclee AA. An ileal brake-through? Am J Clin Nutr. 2010;92:467-468. 
26.  Lin HC, Doty JE, Reedy TJ, Meyer JH. Inhibition of gastric emptying by sodium oleate depends on 
length of intestine exposed to nutrient. Am J Physiol 1990;259:G1031-G1036. 
27.  Maljaars J, Peters HP, Masclee AM. Review article: The gastrointestinal tract: neuroendocrine 
regulation of satiety and food intake. Aliment Pharmacol Ther 2007;26 Suppl 2:241-250. 
28.  Buffa R, Solcia E, Go VL. Immunohistochemical identification of the cholecystokinin cell in the 
intestinal mucosa. Gastroenterology 1976;70:528-532. 
 
 
  
 
 
 
 
9 
Intragastric layering of lipids delays lipid 
absorption and increases plasma CCK but 
has minor effects on gastric emptying and 
appetite 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foltz M, Maljaars J, Schuring EAH, van der Wal RJP, Boer T, Duchateau GSM,  
Peters HPF, Stellaard F, Masclee AAM 
Am J Physiol Gastrointest Liver Physiol 2009;295:G982-991 
CC h
h aa
pp tt
ee rr
  
141 
142⏐Chapter 9 
 
Abstract  
Intestinal intubation studies have demonstrated that lipids induce satiety, but the contribution of lipid 
processing by the stomach on satiety remains poorly understood. In this explorative, randomized, placebo-
controlled, crossover study we tested whether delayed lipid absorption, increased cholecystokinin (CCK), 
decelerated gastric emptying (GE) and increased satiety can be achieved by controlling lipid distribution in 
the stomach. Six healthy males were intubated nasogastrically. Two treatments were performed and 
repeated in duplicate. Subjects received in the on top treatment (OT) a fat-free liquid meal (LM, 325 ml, 
145 kcal) followed by intragastric infusion of 4 g high oleic acid rapeseed oil (4.6 ml, 36 kcal) labeled with 
77 mg glyceryl-13C-trioleate. In the emulsion treatment (EM, control) 4 g labeled rapeseed oil was 
incorporated into the LM (325 ml, 181 kcal); 4.6 ml saline was infused as a control. In OT and EM a 2nd LM 
was consumed at t=270 min. Plasma 13C-C18:1, CCK and satiety were measured over 480 min. GE was 
determined using the paracetamol absorption test. OT delayed oleic acid absorption shown by an increased 
lag time of absorption (EM: 37±7 min; OT: 75±10 min; P<0.01) and Tmax (EM: 162±18 min; OT: 280±33 min; 
p=0.01). OT released more CCK than EM (P=0.03) including increased CCK after the 2nd meal. OT accelerated 
initial GE until 30 min postprandial. OT showed a tendency (P=0.06) to suppress hunger and increase satiety 
and fullness 120-270 min postprandially. The results demonstrate that low amounts of lipids, when 
separated from the aqueous phase of a meal, delay lipid absorption and increase CCK. An escalating dose 
study should determine whether this could have implications for the development of weight control foods. 
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Introduction 
Long-term dietary interventions using low energy liquid meals (LM) have clearly 
demonstrated effectiveness in achieving and maintaining weight loss in addition to 
improving metabolic biomarkers of comorbid diseases in clinical trials1,2. Despite the 
proven success of LM in clinical trials, it remains a challenge to achieve and maintain 
weight loss in all users because of perceived hunger, which is a significant predictor of 
failure to lose weight3. This suggests that delaying the return of hunger and increasing 
satiety following consumption of LM would help to improve compliance, and would 
aid in achieving weight loss and weight control4. 
Food stimulates satiety and inhibits food intake by complex and interdependent 
mechanisms in which signals arising from the gastrointestinal tract play an important 
role5. Gastrointestinal satiety consists of two interacting components: distention of 
the stomach (mechanical) and release of gastrointestinal peptides by the small 
intestine (nutritive)5. In the intestine, lipids are sensed in the wall of the intestine by 
specialized receptors, induce inter alia release of cholecystokinin (CCK) from 
enteroendocrine cells and activate extrinsic vagal afferent nerve terminals. Together, 
this leads to a multitude of physiological processes amongst which an inhibition of 
gastric emptying (GE) and finally to a reduction in hunger and food intake6,7. 
Underlying mechanisms of satiety signaling are often investigated by using small 
intestinal intubation studies. In these studies, nutrients are infused at constant rates 
into specific small intestinal regions. In general, infusion rates (0.1–2 kcal/min) and 
concentrations (14–80 mmol) which are suggested to mimic the postprandial 
physiological concentrations entering the small intestine after consumption of a 
meal8-10 were used. It has been proven that these mechanism are associated with 
satiety, food intake and satiety-related physiological parameters such as GE11-14 
However, such mechanistic studies neglect that after intake of complex meals, 
nutrients may arrive in non-uniform patterns to the duodenal and jejunal region15 and 
not at constant rates. Furthermore, effects on satiety and physiological parameters 
related to satiety (GE and gut hormone secretion) that are observed after infusion of 
low-lipid doses may be overruled in complex meals by the effects of other meal 
components (proteins and / or carbohydrates)16,17. Therefore, in our view, when 
compared to “real meal”-situations, small intestinal infusion studies neglect the 
effects of A) intragastric distribution of lipids and the subsequent effects on lipid 
delivery to the small intestine and B) complex and interacting effects of 
macronutrients on satiety inducing mechanisms under fed conditions. Support for the 
former hypothesis, i.e. sequential lipid delivery from the gastric lumen to the gut 
originates from early studies using gamma scintigraphy. These studies show that fat 
empties with the meal from the stomach when it is an integral part of the food18. 
However, when the fat is free and liquid, phase separation occurs, i.e. the fat forms a 
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layer on top of the meal (“creaming”), resulting in slower gastric emptying18,19. Recent 
magnetic-resonance imaging (MRI) studies including echo-planar imaging have 
demonstrated that the rate of emptying of lipids from the gastric lumen influences 
emptying rates of the total meal and is dependent on the physical state of the lipid 
(whether the lipid is part of the meal or free), the ingestion order and posture of the 
subject20-26.  
Most processed foods contain lipids in the form of emulsions. By varying the 
emulsifier type and emulsification process these emulsions can be tailored towards 
their stability under gastric conditions; i.e. emulsions which stay intact at low pH 
(gastric-stable) or emulsions which release free lipid due to emulsifier breakdown 
under gastric conditions (gastric-unstable). Lipids in gastric-stable emulsions have 
been shown to empty with the aqueous phase. Compared to gastric-unstable 
emulsions, where the oil forms a layer on top of the aqueous phase, they increased 
the forward and backward antral flow in the stomach, increased CCK secretion and 
increased gallbladder contraction21,25,26. However, in these studies, pure oil in water 
emulsions at very high lipid doses (75-100 g) were used. It is unclear whether gastric-
unstable emulsions will continue to yield the same results when these emulsions, at 
physiological concentrations, are incorporated into a real food matrix. 
Based on previous work on intragastric lipid distribution in the stomach, 
intraduodenal lipid sensing and triggering of mediators of satiety, we questioned 
whether a modulation is also possible under more physiological conditions. The aim of 
this explorative, randomized, placebo-controlled, crossover study was to investigate 
whether it would be possible to modulate release of lipids from the stomach, plasma 
CCK levels and GE in healthy volunteers by using low lipid loads layered in the 
stomach on an orally consumed LM. Possible translation of these changes, if present, 
into concomitant changes in perceptive satiety was measured as additional outcome. 
In healthy males we infused nasogastrically 4 g of high oleic acid rapeseed oil labeled 
with 13C-C18:1 (oleic acid given in the form of a triacylglyceride) on top of an orally 
consumed LM. In the control treatment 4 g labeled rapeseed oil was emulsified in the 
LM, saline was infused as a control. The effect of emptying of lipids from the stomach 
measured by plasma 13C-C18:1 appearance and CCK profiles (primary outcomes) as 
well as GE of the aqueous phase of the LM and satiety perception (secondary 
outcomes) were determined. 
 Gastric lipid layering delays lipid absorption and increases CCK⏐145 
 
Materials and method 
Subjects 
Male subjects aged 18–45 y were recruited from the campus population of the Leiden 
University Medical Center. Subjects were screened to be generally healthy as assessed 
by means of a screening questionnaire, BMI assessment (19–25 kg/m2) and standard 
hematology. Smokers, restrained eaters (assessed with the Dutch Eating Behavior 
Questionnaire27 with a score of restriction >2.5), subjects with hemoglobin 
concentrations <8.4 mmol/l or had donated blood in the last 4 weeks and subjects 
who reported dieting or who were on a medically prescribed diet in the last 6 months 
before the start of the study were excluded from participation. Subjects on 
medication that may influence appetite and sensory functioning or subjects who 
reported a metabolic or endocrine disease, gastrointestinal disorders were not 
included. Six subjects (age 22.0±1.4 y; BMI 23.8±1.1 kg/m2) were included in the study 
and all subjects finished the study. Participants were informed about the study and all 
subjects signed an informed consent form before participation. The Medical Ethics 
Committee of the Leiden University Medical Center (Leiden, The Netherlands) 
approved the study. 
Study design 
The study was an explorative, randomized, double-blind, placebo-controlled, 
crossover study performed at the University of Leiden Medical Center and was 
conducted following GCP guidelines. The study design is presented in Figure 9.1. The 
study used a within and between subject design with two treatments (OT and EM) 
which each subject underwent twice leading to four interventions per subjects. Thus, 
the study consisted of four intervention days separated by washout periods lasting 
one week each. This study design led to six possible sequences in receiving the 
treatments. Each subject was randomly allocated to one of the six possible treatment 
sequences. The study had a staggered start, with two subjects starting per day. The 
study hypothesis was that intragastric lipid layering leads to delayed lipid absorption 
compared to emulsified lipids when incorporated into a LM. The delayed lipid 
absorption in turn enhances postprandial CCK concentrations and modulates GE. 
Primary outcomes of the study were changes in plasma 13C-C18:1 concentrations 
(Cmax, Tmax and Tlag) and CCK concentrations (area under the time-plasma 
concentration curve). Secondary outcomes were changes in GE (gastric emptying half 
time, T50) as well as satiety and hunger perception (area under the time-appetite 
curve). 
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Figure 9.1 Study design and sampling scheme. Subjects underwent two treatments (OT, oil on top; EM, 
emulsion) which each subject underwent twice resulting in four interventions per subject. The 
treatment order is shown exemplarily, as each subject was randomly allocated to one of the 
six possible treatment orders to avoid a treatment order effect. All treatments were preceded 
by a 2d run in period in which subjects refrained from 13C-rich foods and consumed a 
standardised dinner before the test day. Plasma samples were taken for quantification of 
paracetamol (t=-5–240 min), 13C-C18:1 and CCK (t=-5–480 min). Electronic visual analogue 
scales (EVAS) were used at intervals to register satiety, hunger, fullness, and appetite for a 
meal. Nausea was registered at the same time intervals. 
Sample Size Estimate 
The current study was designed as an explorative study as no data on either the 
variance of the difference between treatments nor on the variance within subjects for 
the primary outcome parameters (oleic acid kinetics) was available. Previous studies 
showed significant differences in fat absorption kinetics with 6 – 9 subjects28. Our own 
studies showed a within subject variance in the incremental AUC of CCK of 
0.64 pmol/l/min. Based on an estimated physiological meaningful effect of at least 
10% needed for CCK, ten observations would be sufficient for CCK (2-sided test, power 
0.8, α 0.05). For satiety, we found in earlier studies a within subject variance of about 
85 (area-under-the curve). Based on a 2-sided test, power of 0.8 and α of 0.05, twelve 
observations would be sufficient to detect significant differences in satiety of at least 
12%. Based on the above mentioned, we decided to use in this crossover study six 
subjects, but to repeat each treatment twice in each subject. By repetition of both 
treatments in each individual, the treatment effect could be estimated with the same 
precision as compared to a trial with 12 individuals and 1 observation per treatment. 
The advantage of this design is that it allows for a statistical analysis in which both 
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inter-individual as well as between individual variations are estimated. In crossover 
trials the within individual variation is the most important variation because the 
treatment difference is estimated within each person. Thus, the current design 
improves the precision of the determination of the within subject variation. The 
model used in the ANCOVA analysis (see Data and Statistical Analysis) took the 
repetition of the treatments per individual into account. 
Treatments 
Two treatments were tested. In the “on top” treatment (OT) subjects received orally a 
fat-free LM (325 ml, 145 kcal, 0.4% intrinsic fat) followed by a nasogastric infusion of 
4.06 g high oleic rapeseed oil (4.6 ml, 36 kcal) labeled with 77 mg 13C-Triolein (glyceryl-
trioleate with a uniformly labeled 13C-C18:1 on the sn-1 position, isotopic enrichment 
99%; Buchem BV, The Netherlands). In the second treatment, “emulsion” (EM), 
subjects received orally a LM (325 ml, 181 kcal, 1.6% fat) containing 4.06 g high oleic 
rapeseed oil (4.6 ml) labeled with 77 mg 13C-Triolein as a fine emulsion; 4.6 ml saline 
was infused via the nasogastric tube as a control. All nasogastric infusions were given 
as bolus infusion within 1 min. In both conditions, 1.5 g paracetamol was dissolved in 
the LM immediately and not later than 10 min prior to consumption. 
Experimental Protocol 
Two days prior to the intervention subjects were asked to refrain from foods rich in 
13C (list provided to participants). In every period the day prior to the intervention the 
subjects received the same standardized dinner. After dinner, subjects stayed absent 
from food and caloric beverages and came on each intervention day to the study 
facility in a fasted state. Subjects arrived at the study facility at least 1.5 h before their 
scheduled intervention. Prior to all interventions the subjects were taken to a room 
equipped with a hospital bed, where a nasogastric tube (Flocare Bengmark, Nutricia, 
Zoetermeer, The Netherlands) was inserted. To avoid detection of differences 
between the two types of treatments by the subject as well as investigator the tube 
was obscured with opaque tape. A cannula was inserted into the antecubital vein of 
each subjects forearm, and a fasting blood sample was taken (t=-15 min). Subjects 
then completed a validated electronic visual analog scale (EVAS) questionnaire to 
assess satiety related parameters and nausea (see “Measurements”). Subsequently 
subjects consumed the LM using a straw and were asked to finish the beverage in 5 
min. The moment in which the last gulp was swallowed, was considered to be t=0 
min. Immediately after consumption of the LM, the intragastric infusion (bolus 
infusion within 1 min) of rapeseed oil (condition OT) or saline (condition EM) was 
performed manually using an obscured syringe taking into account the void volume of 
the nasogastric tube. At t=270 min subjects consumed within 5 min a standardized, 
commercially available LM (325 ml, 176 kcal). Blood sampling and EVAS 
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measurements schedules were as outlined in Figure 9.1. At t=480 min, the nasogastric 
tube and the cannula were removed and subjects departed from the clinic after 
receiving a macaroni meal. 
Preparation of test products 
For this study two LM formulations were produced as referred here to in the following 
as “fat-free” and “fat emulsion-containing” LM. Both formulations were processed in 
the pilot plant of Unilever R&D (Vlaardingen, The Netherlands) by Ultra High 
Temperature using a 2-stage homogenization process (100 and 40 bar) on a 
sterilization line connected to an isolator (La Calhene Inc., France) for aseptic filling. 
All ingredients used were food grade. The 13C-labeled high oleic rapeseed oil was 
prepared by homogenously mixing 6 g 13C-Triolein (glyceryl-trioleate, with uniformly 
labeled 13C-C18:1 on sn-1 position) with 317.5 g high oleic rapeseed oil (Clear Valley 
75 High Oleic Canola Oil, Cargill, USA) using a high shear mixer (Silverson L4RT, UK). 
Fifteen aliquots of 10 ml were filled into syringes for later administration via the 
nasogastric tube. The remaining amount was used to produce the fat emulsion-
containing LM. Emulsification of the 13C-labeled oil was achieved during processing. 
The fat-free formulation was processed on the same line in an identical process, but 
without adding high oleic rapeseed oil to the premix. Oleic acid content of both LM 
was confirmed using gas chromatography (GC) coupled to a flame ionization detector 
(FID, see “Analytical measurements”. Both LM formulations were filled into 330 ml 
polyethylene terephthalate (PET) bottles (Amcor PET Packaging N.V; The 
Netherlands). The fat-free and fat emulsion-containing LM were spiked with 
paracetamol (acetaminophen, European pharmaceutical grade, Pharmachemie, 
Haarlem, The Netherlands) at the intervention day by manually dissolving 1.5 g 
paracetamol into 325 ml of LM until homogeneity. The nutritional composition of 
both LM is given in Table 9.1. 
 
Table 9.1 Nutritional composition of the liquid meal (LM)*. 
Nutritional Facts EM OT 
Serving size – 1 bottle (325 ml) 
Amount per serving 
Energy, kcal1 
 
 
181 
 
 
145 
Fat, g 
- Rapeseed Oil, g 
- Glyceryl-trioleate (13C-C18:1 in sn-1), mg 
5.4 
4.06 
77 
1.35 
- 
- 
Carbohydrates, g 
- Fructose 
- Sucrose 
- Fibre 
15.2 
8.1 
7.1 
5.0 
15.2 
8.1 
7.1 
5.0 
Protein, g1 15.6 15.6 
* Values are calculated based on weighted ingredients 
 Gastric lipid layering delays lipid absorption and increases CCK⏐149 
 
Analytical Measurements 
Blood sampling 
Venous blood samples (10 ml) were collected into ice-chilled EDTA-treated tubes 
containing 400 kU aprotinin•ml-1 (Trasylol, Bayer, Germany). Plasma was separated by 
centrifugation at 3200 rpm for 15 min at 4ºC within 30 min after collection and stored 
in aliquots at -70ºC until analyzed. 
Paracetamol absorption test for determining GE of the aqueous phase of the meal 
Postprandial plasma paracetamol concentrations were used as an indirect marker for 
the rate of gastric emptying of the aqueous phase of the LM29. Plasma paracetamol 
(acetaminophen) concentrations were analyzed with a clinical chemistry analyzer 
(Roche Hitachi 911 Chemistry Analyzer, Hitachi, Japan) using a clinical chemistry 
paracetamol test kit (Product No. 03255379, Roche Diagnostics GmbH, Mannheim, 
Germany) according to the suppliers instructions. The limit of quantification was 
1.2 μg•ml-1 and the assay was linear up to a concentration of 600 μg•ml-1 
(7.9-3972 μmol•l1) as determined with a commercially available linearity set (Roche 
Diagnostics GmbH, Mannheim, Germany). 
Plasma CCK concentrations 
Plasma CCK concentrations (pmol•l-1) were determined using an established 
radioimmunoassay as described previously30 with the following modifications. A rabbit 
antibody binding to all circulating CCK peptides, including sulphated cholecystokinin 
octapeptide, but not with gastrin was used. 125Iodine labeling was performed using 
Bolton-Hunter reagent (PerkinElmer Life Sciences, Inc., Wellesley, MA 02481-4078, 
USA) and human sulphated CCK-33 (Bachem Holding AG, Bubendorf, Switzerland). 
Measurement of CCK in plasma requires extraction with ethanol. Separation of bound 
and unbound label was done using decanting suspension anti-rabbit IgG Sac-Cel© (IDS 
Ltd., Boldon, UK). The detection limit of the assay was 0.2 pmol•l-1. The intra-assay 
variation ranges from 3.9 to 9.1% and the inter-assay variation from 10.4 to 19.9%. 
Plasma oleic acid analysis 
Oleic acid plasma concentrations were performed by applying routine techniques 
using GC analysis (Agilent HP6890 GC equipped with a HP7683 autosampler) coupled 
to a FID (Agilent, Amstelveen, The Netherlands). The method used was a modification 
of the boron-trifluoride procedure originally described by Morrison et al.31. Data 
processing was performed using the Totalchrom multi client data system (Perkin 
Elmer, Norwalk, USA). 
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The 13C/12C ratio of oleic acid (C18:1) in plasma was determined using GC–combustion 
isotope ratio mass spectrometry (GC-C-IRMS) with a Delta plus/Agilent 6890 
instrument (Thermo Fisher Scientific, Bremen, Germany) as described previously32 
with the exception that a 60 m x 0.32 mm DB-23 with a film thickness of 0.25 μm 
(J&W Scientific Inc, Folsom, CA, USA) column was used. The GC temperature 
programming conditions were optimized to obtain baseline separation between oleic 
acid methyl ester and other fatty acid methyl esters. C17:0 was added as an internal 
standard for fatty acid quantification and was used to check the variation of 
measurements. Calibration samples consisting of mixtures of 13C-C18:1 and unlabeled 
C18:1 were used to convert measured enrichment values to molar enrichments. The 
molar enrichment was expressed as concentration of 13C-C18:1 by multiplying molar 
percent 13C-C18:1 enrichment by the endogenous C18:1 plasma concentration 
(µmol•l-1) determined by GC-FID. This resulted in the actual 13C-C18:1 concentration 
expressed in µmol•l-1. 
Appetite perception 
Self-assessed ratings of appetite were monitored using a validated questionnaire on 
satiety feelings (appetite for a meal, prospective food consumption, fullness, hunger, 
appetite for a snack, thirst, satiety) immediately prior to and every 30 min after start 
of the intervention till 480 min. Ratings were made on a hand held computer (iPAQ, 
Hewlett Packard), using EVAS33 anchored at the low end with the most negative or 
lowest intensity feelings (e.g., extremely unpleasant, not at all), and with opposing 
terms at the high end (e.g., extremely pleasant, very high, extreme). Volunteers were 
asked to indicate on a line scale what score on the scale best reflects their feeling at 
that moment. 
Data and Statistical Analysis 
Results are graphically and numerically presented for six subjects with the duplicate 
measures per treatment included for paracetamol, CCK and appetite perception data. 
Plasma samples for 13C-C18:1 were analyzed per individual for the first intervention 
per treatment only, i.e. replicate measures per treatment were not available. Thus, 
data for 13C-C18:1 are graphically and numerically presented for six subjects for the 
first intervention per treatment. 
Kinetic analysis 
Individual plasma concentrations versus time data for 13C-C18:1 and paracetamol 
were analyzed in WinNonlin version 5.1 (Pharsight, Mountain View, CA, USA) using 
non compartmental analysis with lag-time included. The following parameters were 
derived from this analysis: lag time (Tlag), maximum concentration (Cmax), time at Cmax 
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(Tmax), area under the time concentration curve (AUC) and mean residence time 
(MRT). Modeling of the paracetamol data using a one or two compartmental model 
was not possible in two of the six subjects, since a high variability was observed for 
the absorption phase of paracetamol. Therefore, in order to determine the half-life of 
absorption (T1/2 absorption) a population based pharmacokinetic analysis using a mixed-
effects model was performed using the software R with the package “nlme” (R core 
team, 2007).  
CCK plasma concentrations were plotted against time and the AUC was calculated 
using the trapezoidal equation. Cmax and Tmax of CCK were directly derived from the 
non-modeled data set. 
Statistical Analysis 
The statistical analysis was performed using SAS (version 9.1, SAS Institute, Cary, USA). 
Descriptive analysis consisting of distribution statistics (number of available 
observations, mean, standard error of the mean and 95% confidence intervals) is 
presented for continuous data. The data were further analyzed using analysis of 
covariance (ANCOVA) with subjects and treatments as main effect. Baseline 
measurements were used as covariate to correct for individual CCK and satiety levels. 
The statistical model used took the repetition of the treatments per individual into 
account. Differences between the treatment group (OT) and the control group (EM) 
were established on the basis of adjusted means using Fisher’s least significance 
difference (two-tailed). We did not adjust for multiplicity due to testing multiple 
(secondary) variables. We expected the secondary analyses to support the primary 
results. A p-value of less than or equal to 0.05 was considered to be statistically 
significant. Descriptive data are expressed as mean ± SEM and group analysis data of 
13C-C18:1, CCK, satiety, and paracetamol are expressed as adjusted means (LSmeans) 
± SEM. 
Results 
Experimental procedures 
The study protocol was well tolerated and completed by all 6 subjects. None of the 
subjects enrolled withdrew from the study. The nasogastric tube was well positioned 
in the proximal stomach as controlled by length and auscultation. 
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Plasma 13C-C18:1 concentration 
13C-C18:1 was quantified in total plasma using GC-C-IRMS. The measured maximum 
enrichments obtained were all <0.1 atom % excess. Time versus 13C-C18:1 plasma 
concentrations for OT and EM are shown in Figure 9.2A (individual data available in 
supplemental Figure 9.1 in the online supporting material). Baseline 13C-C18:1 
concentration in plasma did not differ from zero in both treatments. The lag time (Tlag, 
time between 13C-C18:1 administration and the time point where 13C18:1 
concentrations significantly increased above baseline concentration) differed 37 ± 12 
min between EM and OT and was significantly longer (p=0.01) in OT (Figure 9.2B and 
Table 9.2). Tmax was delayed in OT with a mean difference of 118 ± 38 min between 
EM and OT (p=0.01). No significant differences in Cmax and AUC0-480 values were 
detected between EM and OT. The mean residence time (MRT) was increased by 
approximately 40 min after OT (p=0.003) (Table 9.2). Plasma concentrations of 13C-
C18:1 did not return to baseline in both treatments 8 h after the label was ingested 
(Figure 9.2A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 9.2 Plasma 13C-C18:1 kinetics in 6 healthy subjects. (A) Time versus plasma 13C-C18:1 concentration 
after nasogastric application of 4 g 13C-labelled rapeseed oil on top of 325 ml of a liquid meal 
(OT, filled circles) and after consumption of the same meal containing the labeled rapeseed as 
an emulsion (EM, open circles). Values are expressed as mean ± SEM. (B) Mean and individual 
shift in lag time (Tlag) in OT (filled circles) and EM (open circles) of absorption of 
13C-C18:1.  
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Table 9.2 13C-C18:1 kinetic parameters in healthy male subjects after consumption of a liquid meal (LM) 
containing 4 g rapeseed oil as an emulsion (EM) and after consumption of a fat-free LM and 
nasogastric application of 4 g rapeseed oil (OT).* 
 Treatment 
 EM OT P value 
TLag, min 37±7 (16-62) 75±10 (53-112) 0.01 
Tmax, min 163±18 (105-240) 280±34 (180-360 0.01 
Cmax, pmol·l
-1 1.97±24 (1.34-2.81) 2.12±0.20 (1.51-2.88 0.5 
AUC0-480, µmol·min·l
-1 572±53 (431-697) 494±65 (304-703) 0.2 
MRT, min 266±9 (244-298) 304±13 (261-349) 0.003 
* Values are expressed as means ± SEM (range) 
Plasma CCK concentrations 
Baseline plasma CCK concentrations were not significantly different between both 
treatments (EM: 0.25±0.08 pmol•l-1, OT: 0.40±0.13 pmol•L-1; p>0.05). Baseline 
concentrations had no significant effect on the AUC for plasma CCK concentrations 
(p>0.05). CCK concentrations increased very rapidly and peaked ~15 min after intake 
of the LM (Figure 9.3A) with no difference in Cmax-1 and Tmax between EM and OT 
(Table 9.3). CCK plasma concentrations were numerically higher in OT in comparison 
to EM between t=50 and 480 min after ingestion of the LM and were significantly 
(p<0.05) elevated at the time points t=50 and t=300 min. The total integrated area 
under the CCK curve (AUC0-480) was significantly higher for OT than for EM (P=0.03), in 
particular this effect was more pronounced when integrated for the area AUC240-480 
(p=0.01) (Table 9.3). Plasma CCK levels returned to baseline within 60 to 90 min after 
consumption of the LM. CCK concentrations increased after intake of the 2nd LM with 
a significant difference in Cmax-2 between EM and OT (Figure 9.3A and Table 9.3). 
 
Table 9.3 CCK plasma concentrations in healthy male subjects after consumption of a liquid meal (LM) 
containing 4 g rapeseed oil as an emulsion (EM) and after consumption of a fat-free LM and 
nasogastric application of 4 g rapeseed oil (OT).* 
 Treatment 
 EM OT P value 
Cmax-1, pmol·l
-1 1.56±0.40 (0.5-3.2) 1.35±0.32 (0.6-2.6) 0.5 
Tmax-1, min 12±2 (5-20) 11±2 (5-15) 0.7 
Cmax-2, pmol·l
-1 0.87±0.16 (0.5-1.4) 1.28±0.26 (0.6-2.3) 0.03 
AUC0-480, pmol⋅min⋅l-1 402±114 519±114 0.03 
AUC240-480, pmol⋅min⋅l-1 232±61 314±61 0.01 
AUC0-240, pmol⋅min⋅l-1 173±51 203±51 0.3 
AUC0-120, pmol⋅min⋅l-1 136±35 143±35 0.6 
AUC0-45, pmol⋅min⋅l-1 84±17 67±17 0.07 
* Values are expressed as means ± SEM (range) for Cmax and Tmax; AUC values are given as LSmeans ± SEM. 
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Figure 9.3 Mean (±SEM) plasma concentration of postprandial CCK (A) and the cumulative fraction 
paracetamol absorbed over time (B) in male subjects following ingestion of a liquid meal 
(325 ml, 145 kcal) and nasogastric infusion of 4 g rapeseed oil (OT, filled circles) and after 
ingestion of a liquid meal (325 ml, 181 kcal) containing the rapeseed oil as an emulsion (EM, 
open circles). In OT and EM the LM was labelled with 1.5 g paracetamol. In both treatments a 
commercially available LM (325 ml, 181 kcal) was ingested at t=270 min. Values are expressed 
as mean ± SEM. 
 
Gastric Emptying 
Gastric emptying of the aqueous phase was estimated using the paracetamol 
absorption test; pharmacokinetic parameters were modeled by non-compartmental 
analysis of the individual data and using a population based model. In EM and OT, 
plasma paracetamol concentrations increased very rapidly (Figure 9.3B) with no 
significant difference in Cmax (Table 9.4). Tmax was significantly (P=0.003) delayed in EM 
(Table 9.4). There was no difference in the effect of the treatments on other 
pharmacokinetic parameters such as T1/2 elimination, AUC0-240 and MRT for plasma 
paracetamol concentrations (Table 9.4). Total gastric emptying, determined as GE half 
time were not significantly different between EM and OT as derived from the 
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cumulative fraction paracetamol absorbed (data not shown). Modeling of the 
paracetamol concentrations in a population-based analysis revealed that the 
treatment affected only T1/2 absorption. The effect of OT on T1/2 absorption was significant 
compared to EM (p=0.001) resulting in a 2.1 times faster absorption of paracetamol in 
OT (T1/2 absorption, OT: 6 ± 4 min; EM: 12 ± 7 min) in the absorption phase, i.e. 30 min 
postprandial. 
 
Table 9.4 Paracetamol kinetic measurements in healthy male subjects after consumption of a liquid 
meal (LM) containing 4 g rapeseed oil as an emulsion (EM) and after consumption of a fat-free 
LM and nasogastric administration of 4 g rapeseed oil (OT).* 
 Treatment  
 EM OT P value 
dose paracetamol  g 1.5 1.5  
Cmax, µmol·l
-1 117±9 (59-171) 118±8 (77-169) 1.0 
Tmax, min 52±8 (20-120) 30±4 (10-60) 0.003 
T1/2 elimination, min 119±5 (92-144) 121±9 (73-176) 0.8 
MRT, min 108±3 (94-122) 103±3 (78-119) 0.2 
AUC0-240, µmol⋅min⋅l-1 12±2 (5-20) 11±2 (5-15) 0.7 
T1/2 absorption, min 12±7 6±4 0.001 
* Cmax, Tmax, T1/2, MRT and AUC were calculated using a non-compartment model (WinNonLin version 5.1). 
Values are expressed as means ± SEM (range). The T1/2 of absorption was determined with the software R 
with the package nlme (R core team, 2007) using a population based model. 
Appetite Perceptions 
Overall, the effects of the treatments on appetite scores were minor (Figure 9.4 and 
9.5). Satiety was significantly decreased (p=0.01) in OT when integrated over the 
whole day (AUC0–480) and in particular in the time period after receiving the 2
nd LM 
(AUC300-480) (Figure 9.5). Self-rated scores of hunger and fullness were not different 
between OT and EM when integrated over the whole day and the period after the 2nd 
meal. Although not statistically significant, in the period AUC150-270 there was a trend 
for increased perception of satiety (p=0.08) and fullness (p=0.07), and lower 
perceptive hunger (p=0.06) in OT compared to EM. 
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Figure 9.4 Postprandial satiety curves for nasogastrically administered rapeseed oil on top of a liquid 
meal (LM) (OT, filled circles) and rapeseed oil emulsified in a LM (EM, open circles). In both OT 
and EM a 2nd LM was ingested at t=270 min. The graphs show self-rated scores for satiety (A), 
hunger (B) and fullness (C). Values are Lsmeans ± SEM. 
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Figure 9.5 Mean weighted satiety scores calculated for various time intervals for OT (filled bars) and EM 
(open bars) using the data presented in Figure 9.4. P-values for differences between OT and 
EM were established on the basis of adjusted means using Fisher’s least significance 
difference (two-tailed). 
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Discussion 
Structuring of emulsions has been suggested to be useful for weight management 
purposes25,26,34. Postprandial sequential release of lipids from the stomach into the 
small intestine achieved by food structuring could modulate secretion of 
gastrointestinal peptides, resulting in an increase in satiety on a calorie-to-calorie 
basis. We hypothesized that layering of lipids on the aqueous phase of a meal, 
significantly alters lipid release from the stomach. This will induce changes in CCK, GE 
and potentially in satiety. The present study demonstrates that very low lipid loads as 
an integral part of a meal have indeed measurable effects on physiological relevant 
parameters linked to satiety. The use of markers for determination of lipid absorption 
and GE of the aqueous phase of the meal in combination with nasogastric intubation 
to mimic intragastric lipid layering, demonstrated that 4 g of intragastric layered 
rapeseed oil affected gastrointestinal physiology. We observed 1) delayed absorption 
of lipids, 2) initial faster GE of the aqueous phase of the LM and 3) increased 
postprandial CCK levels. However, the perception of satiety, hunger and fullness was 
not consistently related to the changes in lipid absorption and CCK throughout the 
day. 
Compared with an equicaloric dose of high oleic rapeseed oil (labeled with 13C-C18:1) 
emulsified in a LM (treatment EM), 4 g of oil when administered via a nasogastric tube 
on top of a fat-free LM (treatment OT) markedly delayed lipid absorption. The latter 
was exhibited by a 2-fold increase in Tlag in OT compared to EM. Moreover, also the 
pulse-time, i.e. the difference between Tmax and Tlag was significantly shorter in EM 
indicating that the bulk of 13C-C18:1 reached plasma faster than in the OT group. In 
addition, the mean time of all 13C-C18:1 absorbed residing in plasma (mean residence 
time, MRT) was in line with the shift in Tlag of about 40 min. This indicates that 
intestinal delivery and/or absorption of oleic acid occurred in OT at slower rates as 
compared to EM. The consistently delayed absorption kinetics of oleic acid in OT 
suggests that the rapeseed oil indeed layered in the stomach and was not mixed with 
the aqueous phase of the LM by antral grinding, pyloric shearing or low shear in the 
small intestine. Furthermore, our test conditions would not have favored spontaneous 
emulsification. At low gastric pH, the protein of the LM will precipitate and not be 
available for emulsification processes. All in all this suggests that nasogastric infused 
lipids stayed as a layer on top of the LM, although very sensitive radiotracer studies 
combined with scintigraphy would be needed to confirm this.  
In our study we achieved layering of the lipid by nasogastric intubation. The question 
is whether such a separation of lipid from the aqueous phase of the meal can be 
achieved using food-based approaches. Recent MRI studies point out that a layering 
effect indeed occurs in vivo after ingestion of high-fat liquid meals. In these studies it 
was visualized that the lipid forms a layer on top of the aqueous phase. The lipid layer 
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markedly accelerated the GE rate as in these studies pure oil in water emulsions were 
used22,24. However, from these studies it is unclear whether the lipid layer consists of 
layered, but still intact small emulsified lipid droplets (i.e. “creamed droplets or of 
coalescesed emulsion particles creating larger particles or even a single oil layer. It 
was also reported in a very recent publication that an in vitro validated, gastric 
unstable fat emulsion behaved in vivo only partly as an unstable emulsion. A 
significant part of the oil fraction stayed emulsified in the oil-water meal26 suggesting 
that the creamed oil fraction would at least partly consists of still intact emulsion 
particles. This is important with respect to the fact that the effect of lipids on 
inhibition of GE depends on lipid hydrolysis35. The degree of gastric lipolysis, which is 
responsible for up to 25% of lipid hydrolysis during meal ingestion36,37, is strongly 
dependent on lipid droplet size and micellization . Thus, the inhibition of GE by lipids is 
most likely not determined only by the rate of emptying of lipid from the stomach but 
also by the rate and degree of gastric hydrolysis of the lipids. In addition, lingual lipase 
has been discussed to commence gastric lipid hydrolysis; however, the contribution to 
overall lipolysis seems to be negligible in humans38-40. Taken together this highlights 
that the effect of nasogastric infusion of rapeseed oil represents an extreme situation 
of intragastric layering of lipids which most likely can not be achieved in vivo by using 
gastric unstable emulsions. 
Monitoring the intestinal fate of such small amounts of lipids as used in the current 
study is not possible using the various state-of-the-art MRI technologies. We have 
therefore chosen to examine emptying of lipids from the stomach indirectly by 
following plasma concentrations of 13C-labeled oleic acid derived from glyceryl-13C-
triolein marked rapeseed oil. The observed increase in Tlag, Tmax and MRT in the OT 
treatment could have been caused by 1) a delayed emptying from the stomach, 2) 
delayed hydrolysis in the gastric and intestinal lumen, 3) prolonged storage in the 
enterocyte due to delayed chylomicron formation or 4) delayed transport by the 
lymph. We hypothesize that the deferred 13C-C18:1 appearance in plasma was most 
likely caused by delayed emptying from the stomach and/or retarded gastric and 
intestinal hydrolysis. This is supported by the faster GE of the LM in the first 30 min 
postprandial and by the increased CCK levels 2 h before ingestion of the second meal 
in treatment OT. CCK and GE are directly influenced by and strongly dependent on the 
amount of lipid delivered from the stomach to the duodenum. Absorption of 
paracetamol was used as a marker of GE of the aqueous phase because of its 
complete and very fast absorption in the duodenum29. The rate constant of 
absorption was 2.1-fold higher in OT than in EM, reflecting greater inhibition of GE in 
EM until 30 min postprandial. This was most likely caused by the higher initial caloric 
outflow induced by the emulsified oil. However, total GE time was not affected by the 
treatment showing that the inhibition of GE was limited to the early postprandial 
phase. In line with this, although not statistically significant (p=0.07), was the greater 
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AUC value of CCK in EM in the first 45 min after treatment. Concomitantly with the 
delayed lipid absorption in OT concentrations of CCK were increased 50–90 min 
postprandial compared to EM. Interestingly, in OT CCK levels were increased after 
ingestion of the second LM and stayed elevated for the remaining intervention period 
(AUC240-480). This suggests, but does not confirm, that the second meal provoked 
hydrolysis of oil retained in the gastrointestinal tract leading to increased CCK 
concentrations via fatty acid sensing in enteroendocrine cells. 
The small, but robust and consistent effect of OT on increased CCK concentrations 
after the 2nd meal is demonstrated by the individual CCK plasma curves (see 
supplemental Figure 9.2 for the individual CCK plasma concentrations). Concurrently 
13C-C18:1 plasma concentrations increased again after the 2nd meal at t=300 min 
(Figure 9.3A), although this effect was mainly observed in two of the six subjects. Early 
triacylglyceride peaks following sequential meals41 have been suggested to be partly 
derived from the previous meal by storage in enterocytes}. In addition, the 
contribution of lipids ingested at the previous meal to increase plasma triacylglyceride 
concentrations after the following meal has been demonstrated recently42. In this 
study lipid ingested at breakfast was partly retained within the stomach/gut and was 
mobilized after lunch ingestion42. Even though it was unclear from these studies 
whether lipid were stored in the gut lumen or in the enterocytes, our data suggest 
that in the current study the increase was due to a gastric “wash-out” via the 
appearance of the 2nd meal causing subsequent increased CCK concentrations. 
Although changes in satiety were not a primary outcome of the study, we tested 
whether changes in biochemical parameters were related to changes in appetite 
scores. The study however, was not powered to pick up small differences in satiety. 
With the current design we would have been able to detect statistical significant 
differences of at least 12% between the treatments. Thus, the small differences as 
observed in the current study must be interpreted with care. Notwithstanding the 
delayed lipid release and concomitantly higher CCK levels, changes in appetite scores 
were minor and mostly not consistent with changes in CCK. Although CCK is the 
prototypical satiety hormone, a number of gastrointestinal signals including the 
peptide hormones PYY and GLP-1 are involved in the regulation of satiety. PYY and 
GLP-1 are released from more distal cells in the small intestine before nutrients have 
reached the predominant sites of production possibly by a neural reflex43. Possibly, in 
treatment OT plasma concentrations of GLP-1 and / or PYY were decreased leading to 
lower satiety as observed over the 8 h period compared to EM. However, as these 
hormones were not assessed and as the mean weighted satiety scores differed only 
by 3 mm on a 100 mm scale this remains speculative. We hypothesize that total 
volume and total energy dominated the satiety perception rather than the intragastric 
lipid distribution. Perception of satiety is in part modulated by the rate of GE and is at 
equicaloric loads mainly volume and not macronutrient dependent44. The initial GE 
 Gastric lipid layering delays lipid absorption and increases CCK⏐161 
 
rate of the bulk of the meal differed between both treatments which was reflected by 
numerical lower satiety scores in OT. The higher CCK levels and the concomitant trend 
for higher satiety in OT between t = 150 and 270 min however, can not be attributed 
to a GE effect as at that time the LM was already emptied23-26,34,44. Overall, the 
marginal effect observed on appetite scores in combination with the slight increase in 
CCK suggests that the amount of lipid infused was too low in order to exhibit a 
significant and consistent effect. An escalating dose study should determine which 
lipid loads are needed in order to achieve physiological meaningful effects on CCK and 
satiety. 
In conclusion, our study demonstrated modest differences in the effects of low, 
equicaloric doses of oil administered nasogastrically and as fine emulsions both in 
combination with a LM. Although delivery of 4 g of oil on top of a LM markedly 
delayed lipid absorption, plasma CCK concentrations were modestly increased 
compared to the same amount of oil incorporated as an emulsion into the LM. 
Intragastric-layered oil, but not emulsified oil, led to an initial increase in GE rate of 
the aqueous phase. This was most likely due to reduced total energy delivery to the 
duodenal-jejunal region in the early postprandial phase in the OT study group. 
Feelings of satiety however were inversely related to lipid absorption and plasma CCK 
concentrations. Although CCK levels were modestly increased after OT delivery, 
overall ratings of satiety were lower compared to the emulsion treatment. Although 
satiety was decreased when integrated over the whole study period ratings of satiety 
and fullness tended to be higher and ratings of hunger to be lower in OT in the 2 h 
before intake of the second meal suggesting that at slightly higher lipid loads the time 
to return to the hunger baseline can be prolonged. Finally, the current study using 
physiological doses of lipids lends support to other studies that showed that 
emulsified lipids behave physically and biochemically different, dependent on the 
emulsifier type used. It remains to be determined whether higher doses of lipids than 
were used in the current study mediate changes in both, primary physiological 
parameters but also in endpoints, i.e. increased CCK and satiety. The present study 
demonstrates the potential importance of structuring of dietary lipid formulations for 
controlling hunger. 
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Background 
The number of persons with overweight and obesity rapidly increases worldwide. This 
has led to an increase in research in developing food-based strategies that aim to 
result in better weight management and weight loss. The most used strategy for 
weight loss is following a caloric restriction diet. However, due to persistent hunger 
feelings, compliance to these diets is small. This limits the successfulness of these 
diets. 
The gastrointestinal (GI) tract generates many so-called satiety signals that play a role 
in the regulation of eating behaviour. The gut is therefore an appealing target for food 
products to induce an satiety and reduce food intake. Gut peptides, such as CCK and 
GLP-1, have consistently been demonstrated to reduce food intake and hunger after 
intravenous administration1-3. Food intake increases when an antagonist to these 
peptides is administrated, pointing towards a physiologic role for these peptides in 
the regulation of eating behaviour4-6. Furthermore, long-term use of a GLP-1 agonist 
has been shown to reduce body weight in obese individuals7. Together, these results 
illustrate the potential of targeting the gastrointestinal tract in weight management 
and weight loss strategies.  
 
In order for the different macronutrients (fat, protein, carbohydrates) to influence 
hunger, food intake and gastrointestinal motor and secretory function, the presence 
of these nutrients in the small intestine has to be detected, or sensed. Concerning fat, 
hydrolysis of triacylglycerols (TAG) to fatty acids (FA) is an essential step in this 
process8. Intraluminal fatty acids are sensed by receptors, such as the g-protein 
coupled receptor-120 (GPR-120), that are present in the intestinal mucosa. Activation 
of these receptors leads to an intracellular signalling cascade which results in the 
secretion of a gut peptide or activation of a vagal afferent.  
 
In the small intestine, differences exist in the potency of the different segments in 
their effects on satiety and food intake. Different studies have suggested that 
exposure of the ileum, by activating the ileal brake, is the most potent in its effects on 
satiety and food intake.  
 
In this thesis, we have therefore examined the role that fat-induced ileal brake 
activation can play in the development of food-based weight management and weight 
loss strategies. We have used a model in which healthy volunteers were intubated 
with a 290 cm long multi lumen naso-ileal catheter. The use of this catheter allowed 
us to specifically infuse nutrients in the different segments of the small intestine. 
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Gastrointestinal satiety signalling 
In Chapters 2 and 3, we reviewed the gastrointestinal mechanisms and peptides that 
contribute to satiety and food intake. In Chapter 2, we describe that satiety and food 
intake are influenced by signals from the stomach and signals from the small intestine. 
Gastric satiety signalling is stimulated by distension of the gastric wall (mechanical 
stimulus)9,10. Previous studies have demonstrated that delaying gastric emptying, by 
prolonging the distension of the stomach, increases satiety and reduces food intake. 
Intestinal signals result from nutrient sensing in the gut (chemical stimulus)9. The 
sensing of nutrients leads to activation of neural and humoral pathways. These 
signals, combined with signals from the stomach, lead to perception of satiety in the 
brain. We also focussed on the effects of ileal brake activation on hunger and food 
intake.  
 
In Chapter 3, we have discussed the ileal brake in more detail. The term ‘ileal brake’ 
was first defined as a “distal to proximal feedback mechanism to control transit of a 
meal through the gastrointestinal tract in order to optimise nutrient digestion and 
absorption”11. Recent studies have pointed to an important role of the ileal brake in 
the physiological regulation of gastrointestinal function. After a regular size meal, 
nutrients reach the ileum12,13 and entry of nutrients into the ileum was associated 
with a transition from a fed to a fasted pattern of gastrointestinal motor and secretory 
function12,14.  
It is not yet certain which mediators regulate the actions of the ileal brake. At first, 
attention focused on enteroglucagon and neurotensin15,16. Recently, the attention has 
bend towards Peptide YY (PYY)17 and Glucagon-like peptide -1 (GLP-1)18. However, a 
direct neural or neurocrine mechanism may also be involved19. Most data on the 
effects of ileal brake on satiety and food intake have been derived from studying 
animal models. These data show that infusion of nutrients into the ileum does result 
in a reduction of food intake20-22 and, that this reduction is larger when the nutrients 
were infused into the ileum compared to infusion in the duodenum23. Surgical models, 
in which a part of the ileum was transposed to the duodenum, demonstrate that 
increasing ileal exposure to nutrients does indeed reduce food intake and results in 
weight loss24-26, and that the effect of ileal brake activation is maintained over time. 
Additionally, these studies have demonstrated an improvement in glucose 
homeostasis after ileal transposition, probably due to GLP-1 secretion25,27. Together, 
these data provide strong evidence that ileal brake activation is an attractive and 
excellent long term target for weight management and weight loss strategies. 
 Summary and general discussion⏐169 
 
Ileal brake and satiety 
Few human data have been published with respect to the effects of ileal brake 
activation on satiety and food intake. In 1985, Welch et al. were the first to 
demonstrate an inhibitory effect on food intake after delivery of fat to the ileum28. In 
their study, they infused 40 g of fat into the ileum, which can be considered to be a 
large dose. Remarkably however, this large dose of fat did not lead to a direct effect 
on satiety.  
Our first aim was therefore to perform a proof-of-principle study to see whether ileal 
brake activation by a very small fat load would also lead to effects on satiety. 
Furthermore, we wished to test whether these effects on satiety were dose-
dependent. Therefore, in the study described in Chapter 4, we compared oral 
ingestion of 3 g of fat to ileal infusion of 3 g and of 10 g of fat and measured satiety 
levels. The infusions were scheduled in the physiological postprandial period of 
maximum ileal exposure to nutrients29. In this study, we found that 3 g of fat did 
indeed significantly influence satiety. However, no significant difference was found 
between 3 g and 10 g. We were therefore not able to demonstrate a dose-dependent 
effect of ileal fat on satiety. With regard to gastric emptying17 and pancreatico-biliary 
secretion30 however, such a dose-dependent effect has previously been 
demonstrated.  
 
The knowledge that a small dose of fat in the ileum indeed did reduce hunger 
prompted us to investigate whether the physico-chemical properties of the fat 
emulsion influences these effects. When fat is infused into the stomach, reducing 
emulsion droplet size increases fat hydrolysis which results in a delay in gastric 
emptying31. As fat hydrolysis is a crucial step in the effects of fat on satiety, food 
intake and gastrointestinal motor and secretory function, this suggests that reducing 
fat droplet size may also affect satiety and food intake. We infused 6 g of fat either in 
the duodenum or in the ileum using two different emulsions (Chapter 5). One 
consisted of small droplets (mean diameter 0.88 micrometer), the other of large 
droplets (average mean diameter 15.5 micrometer). We found that, when 
administered in the duodenum, fat droplet size did affect satiety levels, with a 
stronger reduction in hunger and a further increase in fullness after the smaller 
droplets. When administered in the ileum, fatty acid sensing was increased after the 
smaller droplets, as measured by gut peptide secretion. However, this did not lead to 
an increase in satiety. Droplet size reduced food intake in both the duodenum and in 
the ileum by 7%. This difference did not reach statistical significance (p=0.06).  
 
When fat is infused into the duodenum, triacylglycerol fatty acid saturation influences 
food intake32. Whether the degree of FA saturation also influences ileal brake 
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mediated satiety was unknown. We found (as described in Chapter 6) that compared 
to control, TAG with predominantly unsaturated FAs increased satiety, whereas TAG 
with predominantly saturated FAs did not. No significant effects were observed on 
food intake.  
 
As discussed in Chapter 2 and 3, differences may exist between the proximal and 
distal small intestine with regard to the potency of the effects of nutrients on satiety 
and food intake. These data, however, are mainly derived from animal studies. 
Therefore, we have compared the effects of duodenal and ileal fat infusions on satiety 
and food intake (Chapter 7). Furthermore, we have tested whether the timing of the 
infusion, either in the early or in the late postprandial phase, affected these results. 
We found that, compared to the duodenal fat infusions, the effects of ileal fat on 
satiety were significantly larger. Furthermore, the effects on satiety were significantly 
larger after ileal fat infusion in the early vs. the late postprandial phase. No effects 
were observed on food intake.  
 
From animal studies, we have learned that the effects on a nutrient infusion on food 
intake23,33, but also on gastrointestinal transit34,35, can be potentiated by increasing 
the small intestinal surface area exposed to nutrients. In the study described in 
Chapter 8 we studied whether increasing the small intestinal surface area exposed to 
fat would increase the effects on satiety compared to oral ingestion to fat, and how 
this would relate to ileal fat infusion. In this study, two experiments resulted in an 
increase in exposed small intestinal surface. In one experiment, all three small 
intestinal segments (duodenum, jejunum, and ileum) were exposed to fat 
simultaneously. In the other experiment, the segments were exposed sequentially to 
fat. As we learned from the study described in Chapter 7 that the effects on an ileal 
fat infusion on satiety are larger in the early postprandial period, we scheduled all 
infusions in this study at an earlier time point in the test day. Compared to control, 
both increasing the exposed surface area to fat in all segments simultaneously, and 
infusion of fat directly into the ileum significantly reduced hunger, whereas the 
sequential infusions did not. However, only the ileal fat infusion did significantly 
reduce food intake. 
Gastrointestinal transit 
The ileal brake was initially described as the inhibitory effect of ileal fat infusion on 
small intestinal (jejunal) transit and motility15,36. In the studies described in this thesis, 
we have measured gastric emptying by stable isotopes, with emptying half time (t1/2) 
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as relevant parameter, and small bowel transit time, using the duodenal-coecal transit 
time. A summary of these results is presented in Table 10.1. 
In Chapter 5, we examined the effect of fat emulsion droplet size and found that, in 
the duodenum, a smaller fat emulsion droplet size was able to inhibit gastric emptying 
compared to the larger droplets. Studies in animals have demonstrated that the 
effects of exposure of the distal small intestine on gastrointestinal transit are larger 
than the signals from the proximal small intestine37. In Chapter 7, we compared 
gastric emptying and small bowel transit time after equicaloric duodenal and ileal fat 
infusion. In this study, we observed that inhibition of gastrointestinal transit was more 
potently inhibited by the ileal vs. the duodenal fat infusion, confirming the results by 
Lin et al.37. 
 
 
Table 10.1 Gastrointestinal transit. 
Treatment Gastric emptying Small bowel transit 
duodenum Fine vs. coarse ↓ No effect Droplet size 
ileum n.a. No effect 
Location of infusion Ileum ↓ vs. duodenum Ileum ↓ vs. duodenum 
Timing of infusion n.a. No effect 
Fat distribution (surface area) n.a. n.a. 
n.a.: not applicable; this parameter was not assessed. ↓ denotes extra inhibition of gastric emptying and 
small bowel transit 
 
Gut peptide secretion 
In this thesis, we evaluated gut peptide secretion upon infusion of different types of 
fat, at different sites in the small intestine. We have summarized our results in Table 
10.2. In this section, we will briefly discuss our findings.  
CCK is considered to be a proximal gut peptide. However, in our studies, we found an 
increase in CCK secretion after ileal fat infusion. As we have demonstrated in Chapter 
4, this increase was dose-dependent, and correlated significantly with increases 
observed in satiety after ileal fat infusion. This may suggest that CCK plays a role in 
ileal brake mediated satiety. Although the presence of CCK-secreting cells has been 
demonstrated in the (terminal) ileum38,39, secretion of CCK after ileal fat infusion had 
previously only been demonstrated in animals40, and when intrinsic intestinal nerves 
were severed, CCK-secretion was abolished41. This latter finding suggests that, at least 
in animals, a neural link connecting the distal and proximal small intestine may be 
involved in secretion of CCK 
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Table 10.2 Gut peptide secretion. 
Treatment CCK PYY GLP-1 
Dose-dependency  yes no  
duodenum No effect No effect n.a. Droplet size 
ileum Fine vs. coarse ↑↑ Fine ↑↑ n.a. 
Location of infusion Duo ↑↑, ileum ↑ Duo ↑, ileum↑↑ n.a. 
Timing of infusion n.a. No effect n.a. 
Fat distribution (surface area) No effect vs. (oral) 
control 
No effect vs. (oral) 
control 
No effect vs. (oral) 
control 
n.a.: not applicable; this parameter was not assessed.  ↑ denotes increase in secretion of gut peptide 
 
PYY is considered a candidate mediator peptide for the ileal brake. PYY is a gut 
peptide, secreted by the enteroendocrine L-cells. The density of these cells increases 
along the length of the small intestine, with the highest density in the distal small 
intestine and colon. However, secretion of PYY has repeatedly been demonstrated 
after duodenal or oral fat administration. In the studies presented in this thesis, we 
observed an increase in PYY secretion in response to ileal fat infusion. This increase 
was slightly larger after ileal compared to duodenal fat infusion, and can, after ileal 
infusion, be increased by reducing emulsion droplet size. We did not find an 
association between plasma PYY concentrations and satiety, food intake or other ileal 
brake-related parameters.  
 
Finally, across all studies, the relation between peptide secretion on the one hand and 
satiety on the other hand has not been consistent. In Chapter 4, we observed a 
significant correlation between CCK and satiety, but in Chapter 5, a substantial 
increase in both plasma CCK and PYY was observed without concomitant changes in 
satiety scores. In Chapter 8, an increase in satiety was observed without changes in 
plasma concentrations of GLP-1, CCK and PYY. 
 
Within the gut, multiple satiety signalling mechanisms exist. Of these mechanisms, gut 
peptide secretion into the systemic circulation is the only one that can be directly 
measured in humans. Data from previous studies indicates that gut peptides also act 
local as paracrine or neurocrine agents, and not only as hormone42,43. Plasma 
concentrations of peptides may therefore not truly reflect the local effects of these 
peptides44.  
Furthermore, within the small intestine nutrients also have a direct, non-peptide-
mediated effect on neural afferents that contributes to satiety45. These signals, 
combined with signals from the stomach and gut peptide concentrations are 
integrated in the satiety centres in the brain, which ultimately leads to the perception 
of satiety46,47. In Chapter 7, we observed that inhibition of gastric emptying was much 
larger after ileal compared to duodenal fat infusion. We therefore hypothesise that 
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the significant effects on satiety found in the studies in this thesis may at least partly 
be explained by differences in gastric emptying rate, and therefore in gastric 
distension. 
Future perspectives 
In this thesis, we have examined which factors are able to enhance the effects of fat-
induced ileal brake activation on satiety and food intake. We have shown that the 
effects of ileal fat infusion on satiety, food intake and gastrointestinal transit are 
significantly larger than those of oral fat ingestion or infusion of fat in other small 
intestinal segments. The type of fat (fatty acid saturation) and emulsion droplet size 
can significantly affect these results. Furthermore, the timing of exposure of the ileum 
to fat affects the potency of ileal brake-mediated satiety.  
However, questions still remain with regard to the mechanism behind ileal brake-
mediated satiety and the applicability of ileal brake activation in obese subjects. 
Another interesting field of study  is the potential use of increased ileal brake 
activation in type 2 diabetes.  
 
As demonstrated in previous studies, ileal perfusion of protein hydrolysate and 
carbohydrates also leads to activation of the ileal brake16,48. However, the effects of 
ileal infusion of proteins and carbohydrates on satiety have never been tested in 
humans. As some authors suggest that protein is the macronutrients with the highest 
satiating potency, investigating the effects of especially protein on ileal brake-
mediated satiety may be worthwhile. 
 
Another potentially interesting research project would address the observation that, 
in obese subjects, secretion of both GLP-1 and PYY is reduced compared to healthy 
controls. This finding is not consistent since other investigators failed to demonstrate 
any difference between control and obese groups. It is suggested that the presence or 
absence of reduced insulin sensitivity in obese subjects may play a role in this 
inconsistency. Therefore, patient (sub)groups should be well defined and phenotyped.  
Similarly, as both GLP-1 and PYY may play a role in ileal brake-mediated satiety, an 
eventual reduction in secretion of these peptides may affect the efficacy of ileal brake 
activation in obese and overweight subjects. Performing a proof-of-principle study in 
obese subjects in which the effects of ileal brake activation on eating behaviour is 
tested, is therefore necessary. 
 
The potential of ileal brake activation as a target in the prevention and treatment of 
obesity and related disorders has been most convincingly demonstrated in animal 
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studies employing ileal transposition surgery27. In this procedure, a small segment of 
distal ileum is resected with preservation of innervation and vasculature. This 
segment is transpositioned more proximal with anastomoses between duodenum and 
proximal jejunum. Strader et al. demonstrated that ileal transposition not only 
reduced food intake, but also improved glucose homeostasis27 and similar effects 
have been observed after other bariatric surgical procedures. A potential mechanism 
and explanation for both these effects is an increase in GLP-1 secretion. GLP-1 is 
known to reduce food intake and increase satiety in humans, and is assumed to be an 
important mediator of ileal brake activation. Furthermore, GLP-1 is an incretin that 
contributes to glucose homeostasis. However, other mechanisms are also being 
suggested by other authors49,50.  
A further interesting study object would therefore be to study the effects of ileal 
brake activation on postprandial glucose concentrations in subjects with reduced 
insulin sensitivity and in obese subjects. Our intubation model would allow testing 
different hypotheses (such as increased GLP-1 secretion or duodeno-jejunal exclusion) 
regarding this rapid improvement in glucose homeostasis.  
 
Apart from these intubation studies, an ex-vivo model may assist in identifying 
differences between lean subjects, obese subjects and subjects with reduced insulin 
sensitivity. Furthermore, it may also help in revealing the mechanisms behind these 
differences.  
Ussing chambers, in which a biopsied part of small intestinal mucosa is exposed to 
nutrients, allow for direct measurement of gut peptides secreted by the mucosa. 
Furthermore, examination of the tissue after exposure to nutrients enables 
assessment of processes in these tissues. Exposing the ileal mucosa of lean subjects, 
obese subjects and subjects with reduced insulin sensitivity will demonstrate whether 
mucosal factors play a role in the differences in peptide secretion, and examination of 
mucosal tissue before and after exposure to nutrients may help identify the 
mechanisms behind these differences. 
 
In conclusion, in this thesis we have shown the potential of increased ileal brake 
activation as a food target to reduce hunger and food intake. However, not all 
questions on the mechanism have been resolved. Recent studies have demonstrated 
the impressive results of ileal interposition surgery on food intake, body weight and 
glucose homeostasis. These results encourage further studies on the mechanism 
behind these effects, in order to be able to provide a food-based strategy that can 
mimic these results. 
The use of an intubation model, combined with ex-vivo techniques, can make a 
valuable contribution to elucidating this mechanism. 
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Achtergrond 
Wereldwijd is sprake van een toename van het aantal personen met overgewicht en 
obesitas. Dit heeft geleid tot de een toename van onderzoek naar het ontwikkelen van 
voedsel van verschillende strategieën die behulpzaam zouden kunnen zijn bij 
‘gewichtsmanagement’ en gewichtsverlies. De meest gebruikte behandeling voor 
overgewicht en obesitas is het volgen van een dieet. Echter, door persisterende 
hongergevoelens is de therapietrouw vaak gering, wat het resultaat niet ten goede 
komt. Voedselproducten die meer effect hebben op verzadiging en maaltijdinname 
dan je op grond van de calorische waarde zou verwachten, zouden een belangrijke rol 
kunnen spelen bij het verbeteren van de therapietrouw. 
 
Het maag-darmstelsel is de bron van een groot aantal signalen die invloed hebben op 
hongergevoelens, verzadiging en eetgedrag. Zo leidt intraveneuze toediening van 
darmpeptiden zoals CCK en GLP-1 tot een vermindering van hongergevoelens en 
maaltijdinname1-3. Omgekeerd neemt de maaltijdinname toe als er een antagonist van 
deze stoffen wordt toegediend. Dit suggereert dat voornoemde peptiden een rol 
spelen in de fysiologische regulatie van honger en eetgedrag4-6. Daarnaast is 
aangetoond dat langdurige toediening van een GLP-1 receptor agonist leidt tot 
gewichtsafname bij obese patiënten7. Dit bevestigt de potentiële rol van het maag-
darmstelsel in strategieën gericht op gewichtsmanagement en gewichtsverlies.  
 
Voordat macronutriënten (vet, eiwit en koolhydraten) honger, maaltijdinname 
maar ook maagdarm-motoriek kunnen beïnvloeden, dient de dunne darm de 
aanwezigheid van deze voedingsstoffen waar te nemen. Bij vetten is aangetoond dat 
de afbraak van vetten tot vetzeuren een essentiële stap is in dit proces8. De 
aanwezigheid van vetzuren in het lumen van het maagdarmstelsel wordt waarge-
nomen door receptoren die aanwezig zijn in de intestinale mucosa. Activering van 
deze receptoren leidt tot een intracellulaire signaleringscascade, die uiteindelijk leidt 
tot ofwel de afgifte van een darmpeptide, ofwel tot activering van een afferent van de 
N. Vagus.  
 
De dunne darm bestaat uit meerdere segmenten. Studies in zowel mensen als dieren 
hebben aangetoond dat er verschillen bestaan tussen deze segmenten voor wat 
betreft de mate waarin ze verzadiging en eetgedrag kunnen beïnvloeden. Blootstelling 
van het ileum, het meest distale deel van de dunne darm, aan voedingsstoffen lijkt het 
grootste effect op verzadiging en maaltijdinname te hebben. Dit gebeurt door 
activering van een mechanisme dat de ileal brake wordt genoemd.  
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In de studies beschreven in dit proefschrift hebben we nader onderzoek gedaan naar 
de mogelijke rol van de ileal brake voor de ontwikkeling van voedingsmiddelen die 
kunnen worden ingezet in de strijd tegen obesitas en overgewicht. Daarvoor hebben 
we gebruik gemaakt van een humaan model, waarin bij gezonde vrijwilligers een 
naso-ileale katheter werd geplaatst. De katheter stelde ons in staat om voedings-
stoffen gericht toe te dienen in specifieke segmenten van de dunne darm. 
Verzadigingssignalen uit het maag-darmstelsel 
In Hoofdstuk 2 en 3 beschrijven we de gastrointestinale mechanismen en peptiden die 
een rol spelen bij de regulering van verzadiging en maaltijdinname. In Hoofdstuk 2 
beschrijven we dat verzadiging en hongergevoelens beïnvloed worden door signalen 
uit de maag en uit de dunne darm. Verzadigingssignalen uit de maag worden 
afgegeven als reactie op uitzetting, ofwel distensie, van de maag9,10. Zo is aangetoond 
dat het vertragen van de lediging van de maag, wat ertoe leidt dat de maag langer 
uitgezet blijft, leidt tot een toename van verzadiging en een vermindering van 
maatijdinname. Verzadigingssignalen uit de dunne darm worden afgegeven nadat 
voedingsstoffen worden waargenomen in de dunne darm9. Anders dan in de dunne 
darm, waar sprake is van een chemische stimulus, is in de maag sprake van een 
mechanische stimulus. Het opmerken van voedingsstoffen door receptoren in de 
mucosa van de dunne darm leidt tot activering van een neuraal of humoraal signaal. 
Deze signalen, samen met die uit de maag, worden gecombineerd in de 
verzadigingscentra in het brein, waar dit uiteindelijk resulteert in de perceptie van 
honger en verzadiging. 
 
In Hoofdstuk 3 hebben we ons gericht op de effecten van de ileal brake op verzadiging 
en maaltijdinname. De term ‘ileal brake’ werd in eerste instantie gedefinieerd als een 
“distaal naar proximaal feedback signaal dat de passage van een maaltijd door het 
maagdarmstelsel reguleert, zodat afbraak en opname van voedingsstoffen 
geoptimaliseerd wordt”11. Studies hebben laten zien dat de ileal brake een belangrijke 
rol speelt in de fysiologische regulering van de functie van het maag-darmstelsel. 
Inname van een maaltijd van normale omvang leidt ertoe dat voedingsstoffen het 
ileum bereiken12,13. Bij het bereiken van het ileum wordt het patroon van de 
maagdarm-peristaltiek omgezet van een post-prandiaal patroon in een nuchter 
patroon12,14.  
 
Het is niet zeker welke peptiden of neurale mechanismen verantwoordelijk zijn voor 
activering van de ileal brake na blootstelling van het ileum aan voedingsstoffen. 
Aanvankelijk werd gedacht aan enteroglucagon en neurotensine15,16. Recente studies 
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richten zich evenwel op PYY17 en GLP-1 18. Echter, het is goed mogelijk dat een direct 
neuraal of neuro-endocrien signaal een belangrijke rol speelt19. De meeste gegevens 
over de effecten van ileal brake-activatie op verzadiging en maaltijdinname zijn 
verkregen door dierexperimenten. Deze studies laten zien dat infusie van 
voedingsstoffen in het ileum leidt tot een vermindering van de maaltijdinname20-22. 
Tevens hebben deze studies aangetoond dat deze vermindering groter is na infusie 
van vetten in het ileum dan na infusie van vetten in het duodenum23. Chirurgische 
modellen, waarin een deel van het ileum werd weggenomen en verplaatst naar het 
duodenum laten inderdaad zien dat deze dieren minder gaan eten en gewicht gaan 
verliezen24-26. Tevens wordt gezien dat dit effect ook in de loop van de tijd blijft 
bestaan. Verder hebben deze studies laten zien dat de glucose homeostase 
substantieel verbetert, waarschijnlijk door toename van secretie van glucagon-like 
peptide-1 (GLP-1)25,27. Op basis van deze onderzoeksresultaten concludeerden wij dat 
activering van de ileal brake een aantrekkelijk doelwit is voor het creëren van 
strategieën voor gewichtsmanagement en het bereiken van gewichtsverlies.  
Ileal brake en verzadiging 
Er bestaan weinig gegevens over de effecten van ileal brake-activering op verzadiging 
bij mensen. In 1985 waren Welch et al. de eersten die aantoonden dat infusie van 40 
mg vet in het ileum de maaltijdinname verminderde28. Toediening van deze 
substantiële hoeveelheid vet had geen effect op verzadiging. Ons eerste doel was dan 
ook het verrichten van een 'proof-of-principle'-studie, om na te gaan of infusie van 
een kleine hoeveelheid vet in het ileum invloed zou hebben op verzadigingsscores. 
Tevens wilden we nagaan of de effecten van vet op verzadiging dosisafhankelijk zijn. 
  
In de studie beschreven in Hoofdstuk 4 hebben we het effect op verzadiging van orale 
inname van 3 gram vet vergeleken met infusie van 3 gram en van 10 gram vet in het 
ileum. De infusies werden gepland in de periode waarin de fysiologische blootstelling 
van het ileum aan componenten van een maaltijd maximaal is29. Na infusie van 3 gram 
vet in het ileum nam de verzadiging significant toe, maar een dosis-afhankelijk effect 
werd niet gezien. Dit, terwijl op maaglediging wel een dosisafhankelijk effect is 
aangetoond bij vetinfusie in het ileum17. 
  
Wetende dat een kleine hoeveelheid vet in het ileum inderdaad effect heeft op 
verzadiging, zijn we nagegaan of ook de fysisch-chemische eigenschappen van een 
vetemulsie hierbij een rol spelen. Zo is bijvoorbeeld bekend dat, na infusie in de maag, 
een kleinere druppelgrootte van een vetemulsie leidt tot een versnelling van de 
vetafbraak. Dit leidt op zijn beurt weer tot een vertraging van de maaglediging31. 
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Omdat de gedachte is dat het beïnvloeden van de maaglediging via dezelfde route 
verloopt als de beïnvloeding van hongergevoelens, suggereert dit dat druppelgrootte 
ook van invloed kan zijn als gekeken wordt naar de effecten van een vetemulsie op 
hongergevoelens en maaltijdinname.  
  
In de studie beschreven in Hoofdstuk 5 infundeerden we 6 gram vet in het duodenum 
of in het ileum. We gebruikten twee verschillende emulsies: In de ene bestond de 
vetemulsie uit kleine druppels (gemiddeld 0.88 micrometer), in de andere uit grote 
druppels (gemiddeld 15.5 micrometer). In het duodenum bleek het effect van de 
kleinere druppels op verzadiging sterker dan van de grote druppels. Na infusie in het 
ileum nam de vetzuur-sensing, gemeten met een verhoging van plasmaspiegels van 
darmpeptiden, weliswaar toe , maar dit leidde niet tot een toename van verzadiging. 
  
Na infusie van vet in het duodenum beïnvloedt de mate van verzadiging van 
triacylglycerolen (TAG) de grootte van het effect op de maaltijdinname32. Of 
vetzuurverzadiging ook een rol speelt bij  ileal brake-gemedieerde verzadigings-
effecten was echter onbekend. Uit onze studie (beschreven in Hoofdstuk 6) bleek dat, 
vergeleken met de controlegroep, triacylglycerolen met overwegend onverzadigde 
vetzuren hongergevoelens verminderden, terwijl triacylglycerolen met overwegend 
verzadigde vetzuren dit effect niet hadden. Geen van deze interventies had effect op 
maaltijdinname. 
  
Zoals aangetoond in Hoofdstukken 2 en 3 lijkt er een verschil te bestaan tussen de 
proximale en distale dunne darm voor wat betreft de mate waarin ze de 
maaltijdinname kunnen beïnvloeden. Het probleem is dat deze data voornamelijk 
afkomstig zijn van dierexperimenteel onderzoek. In Hoofdstuk 7 beschrijven we een 
humane studie waarin we de effecten van vet in het duodenum en in het ileum 
op hongergevoelens en maaltijdinname vergelijken. Tevens is geanalyseerd of het 
tijdstip van de vetinfusie ten opzichte van de maaltijd een rol speelt. Vergeleken met 
vet in het duodenum leidde vetinfusie in het ileum tot een significante vermindering 
van hongergevoelens. Daarbij bleek dat de effecten van vetinfusie in het ileum groter 
waren in de vroege dan in de late postprandiale fase. Geen van de interventies had 
een significant effect op de maaltijdinname. 
  
Dierexperimenteel werk heeft aangetoond dat de effecten van een vetinfusie in de 
dunne darm op maaltijdinname23,33 en op maagdarmpassage34,35 vergroot kan worden 
als het dunne darmoppervlak dat blootgesteld wordt aan vet vergroot wordt. In de 
studie beschreven in Hoofdstuk 8 onderzochten we of een vergroting van het aan vet 
blootgestelde dunne darmoppervlak zou leiden tot een vergroting van het effect op 
verzadiging. Daarnaast werd bekeken hoe dit zich verhoudt tot het effect van 
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vetinfusie in het ileum. Twee van de interventies leidden tot een vergroot 
blootgesteld dunne darm-oppervlak: in de ene interventie werden de drie dunne 
darmsegmenten simultaan blootgesteld aan vet, in de andere werden deze dunne 
darmsegmenten sequentieel blootgesteld aan vet. 
Nadat we in hoofdstuk 7 geleerd hadden dat de effecten van een vetinfusie op de 
maaltijdinname groter zijn in de vroege postprandiale fase, werden alle infusies vroeg 
in de testdag gepland. Vergeleken met het controle-experiment leidde zowel de 
ileum-infusie als de simultane infusie tot een toename van verzadiging. Echter, alleen 
de ileum-infusie resulteerde in een significante vermindering van de maaltijdinname. 
Deze afname bedroeg 15%. 
Maag-darmpassage 
De ileal brake werd initieel beschreven als het remmende effect van vetinfusie in het 
ileum op de dunne darmmotoriek en de dunne darm passagetijd15,36. In de studies 
beschreven in dit proefschrift hebben we de maaglediging gemeten door middel van 
stabiele isotopen met de halfledigingstijd als relevante parameter. Daarnaast hebben 
we de dunne darm passagetijd gemeten met behulp van de lactulose H2 ademtest. 
Een samenvatting van deze resultaten wordt gegeven in Tabel 11.1. 
  
Tabel 11.1 Maagdarm passage. 
experiment Maaglediging Dunne darmpassage 
duodenum klein vs. groot ↓ geen effect druppelgrootte  
ileum n.v.t. geen effect 
loactie van infusie Ileum ↓ vs. duodenum Ileum ↓ vs. duodenum 
Timing van infusie n.v.t. geen effect 
vetverdeling (oppervlakte) n.v.t. n.v.t. 
n.v.t.: niet van toepassing; deze parameter is niet getest;   ↓ duidt een extra remming van maaglediging of 
dunne darmpassage aan. 
 
In Hoofdstuk 5 laten we zien dat, na infusie in het duodeum, een kleinere 
druppelgrootte leidt tot een significant langere maag halfledigingstijd vergeleken met 
grotere druppels. Dit is waarschijnlijk het gevolg van het versneld verlopen van de 
vetafbraak doordat een groter emulsieoppervlak beschikbaar is voor hydrolyse. In 
Hoofdstuk 7 tonen we aan dat de effecten van vetinfusie in het ileum op maaglediging 
en dunne darmpassage beduidend groter zijn dan die van vetinfusie in het duodenum. 
Dit bevestigt de resultaten van dierstudies van Lin et al.37.  
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Secretie van darmpeptiden 
In de in dit proefschrift beschreven studies hebben we bestudeerd hoe de secretie van 
darmpeptiden verloopt na infusie van verschillende typen vet in verschillende delen 
van de dunne darm. Onze bevindingen zijn samengevat in Tabel 11.2. 
 
Table 11.2 Secretie van darmpeptiden. 
Experiment CCK PYY GLP-1 
Dosis afhankelijk  ja no  
duodenum geen effect geen effect n.v.t. Druppelgrootte 
ileum klein vs groot ↑↑ klein vs groot↑↑ n.v.t. 
Locatie van infusie duodenum ↑↑, 
ileum↑ 
duodenum ↑, 
ileum↑↑ 
n.v.t. 
Timing van de infusie geen effect geen effect n.v.t. 
Vet verdeling (oppervlak) geen effect vs. 
controle 
geen effect vs. 
controle 
geen effect vs. 
controle 
n.v.t.: niet van toepassing; deze parameter is niet getest;  ↑ staat voor toegenomen secretie van het 
genoemde peptide. 
 
CCK wordt beschouwd als een darmpeptide dat voornamelijk wordt afgegeven door 
de proximale dunne darm. Echter, in onze studies zagen we regelmatig een toename 
van CCK secretie na infusie van vet in het ileum. Zoals aangetoond in Hoofdstuk 4 was 
de toename in secretie zelfs dosisafhankelijk en correleerde zij significant met de 
effecten op verzadiging na vetinfusie in het ileum. Dit suggereert dat CCK mogelijk een 
rol speelt bij ileal brake-gemedieerde verzadiging. Hoewel de aanwezigheid van CCK-
secernerende cellen in het (terminale) ileum is aangetoond38,39 is secretie van CCK na 
vetinfusie in het ileum alleen geobserveerd in dierstudies40. In een soortgelijke studie 
leidde het doornemen van de intrinsieke zenuwvezels in de dunne darm ertoe dat de 
afgifte van CCK verdween41. Dit suggereert dat een neurale verbinding tussen de 
proximale en distale dunne darm een rol zou kunnen spelen bij de secretie van CCK . 
  
PYY is een darmpeptide dat wordt uitgescheiden door enteroendocriene L-cellen, die 
zich met name in het distale deel van de darm bevinden. Echter, secretie van PYY 
wordt ook aangetoond na orale inname of duodenale toediening van vet. In de studies 
in dit proefschrift zien we een toename van PYY-secretie na vetinfusie in de dunne 
darm. De secretie van PYY is iets groter na infusie van vet in het ileum dan na infusie 
van vet in het duodenum. Tevens neemt bij infusie van vet in het ileum de secretie 
van PYY toe wanneer de druppelgrootte van de emulsie verkleind wordt. Een 
correlatie tussen plasma PYY concentraties en verzadiging of maaltijdinname werd 
niet gevonden. 
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Tenslotte kan geconcludeerd worden dat de relatie tussen secretie van darmpeptiden 
aan de ene kant en verzadiging aan de andere kant niet consistent is. In Hoofdstuk 4 is 
een significante correlatie tussen CCK en verzadiging gevonden, terwijl in Hoofdstuk 5 
een significante stijging van CCK en PYY concentraties niet leidt tot een significant 
effect op verzadiging. In Hoofdstuk 8 zien we weliswaar significante effecten op 
verzadiging, maar dit gaat niet gepaard met verschillen in peptidesecretie.  
 
In de darm bestaan verschillende mechanismen die kunnen leiden tot beïnvloeding 
van verzadiging en maaltijdinname42,43. Van deze mechanismen zijn plasma-
concentraties van darmpeptiden de enigen die rechtstreeks te meten zijn in mensen. 
Eerdere studies hebben laten zien dat darmpeptiden ook een lokaal (paracrien of 
neurocrien) effect kunnen hebben. De plasmaconcentraties van deze peptiden zijn 
derhalve mogelijk geen adequate weerspiegeling van de lokale effecten van deze 
peptiden44. Daarnaast hebben voedingsstoffen in de dunne darm ook een direct, niet 
peptide afhankelijk effect op neurale afferenten die een bijdrage kunnen leveren aan 
verzadiging45. Deze signalen, gecombineerd met signalen uit de maag en met lokale of 
plasmaconcentraties van darmpeptiden, worden in de verzadigingscentra in het brein 
gecombineerd en geïntegreerd, en dit leidt uiteindelijk tot de perceptie van 
verzadiging. Onze hypothese is dan ook dat de significante verschillen die gevonden 
zijn in de studies in dit proefschrift in ieder geval gedeeltelijk verklaard kunnen 
worden door verschillen in maaglediging en daarmee in maagdistensie. 
Conclusie 
In dit proefschrift hebben we onderzocht welke factoren van belang zijn om het effect 
van de vet-afhankelijke activering van de ileal brake op verzadiging en maaltijdinname 
te vergroten. We hebben aangetoond dat vetzuurverzadiging een belangrijke rol kan 
spelen, net als de gemiddelde druppelgrootte van een vetemulsie. Daarnaast is 
aangetoond dat het tijdstip van de infusie ten opzichte van de maaltijd een belangrijke 
rol speelt. Bovengenoemde onderzoeksresultaten laten zien dat de ileal brake een 
interessant doelwit is voor het ontwikkelen van voedingsmiddelen die een rol kunnen 
spelen in de strijd tegen obesitas en overgewicht. 
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